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The overarching goal of this dissertation is the development and utilization of 
(ring-opening metathesis polymerization) ROMP-derived high load phosphorus- and 
sulfur-based soluble, silica and magnetic alkylating reagents and scavengers. Chapter one 
begins with a brief introduction of solid phase and solution phase organic synthesis, and 
next describes the advances in soluble-, silica- and magnetic-immobilized reagents, with 
a few applications in flow chemistry. Chapter one also outlines the advances in ROMP 
technology for the synthesis of polymeric soluble, silica and magnetic materials for use as 
reagents, scavengers and catalysts. 
Chapter 2 begins with a brief review of immobilized alkylating reagents and next 
describes the development and utilization of soluble high load ROMP-derived oligomeric 
triazole phosphates (OTPn) for the efficient (triazolyl)methylation of nucleophilic species 
in purification free protocols. Chapter 2 finishes with a description of library efforts using 
a purification-free route that combines MACOS scale-out and ROMP-derived oligomeric 
triazole phosphates (OTPn) for the generation of a 106-member library of triazole-
containing benzothiaoxazepine-1,1-dioxides. 
In Chapter 3, the first section describes the use of ROMP technology to aid in the 
development of high-load hybrid silica oligomeric phosphates based alkylating reagents, 
and their applications for facile benzylation and (triazolyl)methylating of N-, O- and S-
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containing nucleophilic species. The surface initiated ROMP reaction of Nb-tagged silica 
particles and functionalized Nb-tagged monomers efficiently yields high-load, hybrid Si-
ROMP benzylating (Si-OBP) and (triazolyl)methylating (Si-OTP) reagents. The second 
section, describes the application of the developed silica-immobilized alkylating reagents 
in one-pot sequential protocols for diversification of benzothiaoxazepine-1,1-dioxides 
analogues. The last section of Chapter 3 outlines the synthesis of high-load, hybrid silica-
immobilized heterocyclic benzyl phosphate (Si−OHBP) and triazolyl phosphate 
(Si−OHTP) alkylating reagents for efficient hetero-benzylation and hetero-
(triazolyl)methylation and their application in purification-free protocols, which diversify 
various nucleophilic species. 
Chapter 4 describes the development and utilization of recyclable magnetic ROMP-
derived alkylating reagents and scavengers, immobilized on Co/C magnetic nanoparticles 
via surface-initiated ROM polymerization. The first section 4.1 outlines the development 
and application of a high-load magnetic Co/C ROMP-derived oligomeric 
benzenesulfonate ester Co/C-OBSEn, as an efficient methylating reagent for a variety of 
carboxylic acids. In addition, an in situ method of methylation/alkylation was developed 
using Co/C benzenesulfonyl chloride Co/C-OBSCn and corresponding ROH.  The desired 
alkylated products were isolated by simple magnetic decantation and filtration and the 
spent byproduct magnetic benzenesulfonic acid Co/C-OBSAn was successfully recycled 
and re-used up to ten times without considerable loss of magnetic material.  
Section 4.2 details the synthesis and utilization of high-load hybrid magnetic 
oligomeric phosphonyl dichloride Co/C-OPCn as an efficient scavenger of amines. The 
magnetic Co/C-OPCn scavenger is employed in amide formations, sulfonylations and 
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urea formations using a variety of amines (used in excess). The coupling products were 
isolated by simple magnetic decantation and filtrations of reaction mixture. The spent 
magnetic scavenger was easily isolated by external magnetic decantation and its 
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Advances in Immobilized Reagents, Scavengers and Catalysts:  








The development of new green technologies that enable the facile assembly of 
small molecules in an economical and safe manner is a key factor in driving modern 
synthesis and drug discovery and development efforts.1  In particular, development 
and utilization of immobilized technologies for carrying out synthesis in a more 
sustainable manner, which minimize the use of toxic reagents and facilitate recovery 
and recycling of expensive reagents, is an important and continually emerging area of 
modern day synthesis.2 Immobilized platforms have not only enabled automated 
synthesis, but also more recently have had a major impact in flow-through 
technologies.3 A wide range of immobilized reagents and scavengers have been 
developed for the facilitated synthesis of small molecules. Despite these 
advancements, limitations exist, and improvement in load levels, synthetic efficiency, 
recyclability, and cost-effectiveness continues to drive innovation in the field.  
It is the purpose of this introductory chapter to highlight recent advancements 
in the area of polymer-supported technologies, with an emphasis on immobilized 
reagents, including silica and magnetic reagents, scavengers and catalysts.  Chapter 1 
will be concluded with an introduction to ring-opening metathesis (ROMP) 
technologies that are at the heart of this dissertation work.  Chapter 2, 3 and 4 will 
detail work carried out in this dissertation regarding the use of ROM polymerization 
to generate soluble, silica supported and magnetic alkylating agents and scavenging 
agents, respectively. In addition, throughout chapters 1–4, employment of these 
reagents in generating molecular libraries will be discussed. 
 3 
1.1.1 Solid-Phase and Solution Phase Synthesis 
 The introduction of solid-phase synthesis by Bruce Merrifield and coworkers 
in 1963,4 has impacted a number of fields, including organic chemistry, medicinal 
chemistry, and automated technologies.5 This pioneering work of Merrifield not only 
enabled new facilitated approaches in peptide chemistry,6 but also played a significant 
role in the generation of complex natural products7 and new synthetic materials.8  
Conventional solid-phase synthesis offers many benefits, which include:  
(i) enabling use of excess reagents to drive reactions to completion, (ii) elimination of 
chromatographic separations for compound purification via simple filtration, (iii) the 
safer handling of toxic materials through immobilization onto solid supports, and (iv) 
automation of optimized high-utility chemical reactions (Figure 1.1.1).   
  
Figure 1.1.1: (a) Solid Phase Organic Synthesis (b) Polymer-Assisted Solution Phase 
Synthesis 
 In addition to aforementioned advantages, polymer-assisted solution phase 
(PASP) synthesis9 has disclosed a new paradigm shift in drug discovery. Compared to 
solid-phase synthesis, reagent-supported solution-phase synthesis offers benefits that 




















conditions (improved reaction kinetics), reaction monitoring, as well as isolation and 
purification of intermediates and products.10  These attributes allow the expanded use 
of nearly the entire repertoire of organic reactions, and have several ideal features, 
including: (i) ease of reaction monitoring using conventional techniques such as TLC, 
NMR, and LC-MS; (ii) no additional steps are needed to attach and cleave substrate 
from solid support; (iii) overcoming the limitations of non-linear reaction kinetics; 
(iv) commercial availability of immobilized reagents, catalysts, and scavengers;11 (v) 
facilitate cleaner and safer reactions through immobilization of toxic materials;12 (vi) 
possible recovery of the spent reagent; and (vii) enabling of the synthesis of libraries 
of small molecules in desirable quantities.13 Immobilized reagents have been 
extensively used in flow-through processes to perform multistep reactions. 
1.2 Advances in Immobilized Reagents and their Application in Flow Chemistry 
The application of polymer-supported reagents has steadily increased over the 
last several decades and has become persistent to play a key role in facilitated 
synthesis of small-molecules. A variety of platforms have been developed for 
immobilization including, polystyrene resins,14 silicas,15 fluorous-tagged 
compounds,16 monoliths,17 and soluble polyethylene glycol (PEG)18 to remove 
impurities and excess reagents from reaction mixtures. These immobilized reagents 
and scavengers have provided ease of synthesis to eliminate time-consuming 
chromatographic separations and have been used frequently in the arena of facilitated 
synthesis and high-throughput chemistry,19 as well as in the scale-up of advanced 
pharmaceutical intermediates.20 Again, limitations continue to drive improvement, 
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such as: (i) enhancing the load, (ii) increasing the synthetic efficiency and thus 
reducing the reaction time, (iii) removing toxic reagents/metals, (iv) ensuring recycle 
ability of reagents, (v) the cost-effectiveness of the process, and (vi) utilization in 
one-pot processes. 
Polymer-supported reagents are continuing to make a significant impact in 
flow-through technologies, whereby a variety of polymer-supported reagents, 
catalysts, and scavengers have been employed through the use of micro-scale reactors 
for the preparation of small molecules and natural products, and thus become quite 
popular in both academia and the pharmaceutical industry.3 Among several seminal 
players, Ley,21 Kirschning,22 Baxendale,23 Seeberger,24 Kobayashi,25 and Jamison26  
are among the most prolific, and have demonstrated a wide array of polymer-assisted 
solution phase (PASP) based techniques via continuous-flow synthetic methodologies 
as outlined in Figure 1.2.1. A number of beautifully written reviews and thematic 
issues have highlighted the myriad advancements in the field27,3 and five 
representative examples are noted below. 
 
 
Figure 1.2.1 Application of Supported Reagents and Catalyst in Continuous Flow 
Systems. 
 








In 2006, Ley and coworkers reported the use of flow-chemistry in the first 
total synthesis of the neolignan natural product grossamide28 (Scheme 1.2.1).  This 
early synthesis was achieved via amide-bond coupling of ferulic acid with tyramine 
using a pre-packed column of polymer-supported HOBt (PS-HOBt), and the use of 
sulfonic acid resin to scavenge out excess amine. 
Scheme 1.2.1 Flow-through Synthesis of Grossamide. 
 
In 2010, Reiser and coworker reported the first example of immobilized 
magnetic Co/C nanoparticles for the kinetic resolution of racemic 1,2-diphenylethane- 
1,2-diol via asymmetric monobenzoylation.29  The carbon-coated Co/C nanoparticles 
were tagged with azabis(oxazoline)-Cu(II) complexes utilizing a CuI-catalyzed 
azide/alkyne cycloaddition reaction. The semi-heterogeneous catalyst was employed 
under batch conditions as well as in continuous flow processes (Figure 1.2.2). The 
magnetic decantation of nano-beads allowed recycling of magnetic reagent not only 



































Figure 1.2.2 Representation of a Closed Circuit Type Reactor For the Asymmetric 
Monobenzoylation of Racemic Diol. 
 
In 2012, Ley and coworkers developed a novel monolith-supported synthetic 
procedure,30 taking advantage of flow processing, to allow facile access to a useful 
family of 2-aminopyrimidine analogues (Figure 1.2.3). This “Catch-React-Release” 
process has been successfully applied to generate a key precursor en route to the 
kinase inhibitor Imatinib (Ar = 3-pyridyl, R1 = 2-methyl-5-nitrobenzyl, R2 = H). 
 
Figure 1.2.3 Synthesis of 2-aminopyrimidines Using Monolith-Supported Flow 
Systems. 
In 2015, Takeda and coworkers reported an application of polyethylene-g-
polyacrylic acid-immobilized dimethylaminopyridine (g-DMAP) as a catalyst in a 

















example described a convenient and simple esterification using di-tert-butyl 
anhydride (Boc2O) as a coupling reagent in a continuous-flow system, which afforded 
decarboxylative esterification with carboxylic acids and alcohols. The reaction time 
was reduced in this esterification reaction in continuous-flow conditions, because of 
the use of polymer-supported catalyst. 




 In 2016, Organ and coworkers reported continuous flow Negishi cross-
couplings employing silica-supported Pd-PEPPSI–IPr precatalyst (Scheme1.2.3).32 
The prepared triethoxysilyl functionalized Pd-PEPPSI–IPr complex was found to be 
active in Negishi cross-coupling reactions under batch and continuous flow 
conditions. The supported-catalyst afforded moderate to excellent yields of coupled 
product with various functionalized alkyl zinc reagents and aryl halides. The catalyst 
was successfully recycled at least five times with minimal loss in activity. 
Scheme 1.2.3 Negishi Cross Couplings Employing Si-Supported Pd-PEPPSI–IPr 






















































 Overall, flow-technology is very adaptable to integration with various 
immobilized platforms, including, polymer supported reagents, scavengers or 
catalysts for multistep synthesis of scaffolds. This combination is continually 
evolving and enabling the development of fully automated processes with an 
increased efficiency and improved sustainability in many synthetic approaches. The 
utilization of supported components packed into simple columns or reactor cartridges, 
makes it possible to perform multistep organic sequences with the benefit of 
purifications. 
1.3 Advances in Silica-Supported Reagents and Catalysts: 
 Silica-supported technologies for the immobilization of reagents and catalysts 
have also emerged as an attractive source of attachment for the development of 
hybrid silica (SiO2) supported materials.33 The reaction with tris(alkoxy)silanes not 
only provides a practical route to silica-immobilized reagents/scavengers/catalysts, 
but also serves to provide linkers for a variety of desired functional handles.34 A range 
of commercial materials has shown the use of silica as a prominent solid-phase 
support, and impressive progress has been reported regarding silica-supported 
reagents in the last decade.15 Efforts in this area have highlighted a number of 
benefits regarding purification, filtration, easy separation, and stability of supported 
materials. 
In 2008, Li and coworkers demonstrated an efficient and recyclable  
Pd-catalyst hybrid material anchored on a silica surface, and employed this catalyst in 
a Heck coupling reaction (Scheme 1.3.1).35 The corresponding cross-coupling 
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products were achieved in good to excellent yields under phosphine- and amine-free 
reaction conditions. Furthermore, the silica-supported Pd-catalyst was recovered by 
simple filtration of the reaction solution and reused for several consecutive trials 
without considerable loss of its catalytic activity. 
Scheme 1.3.1: Synthesis and Utilization of Silica-Supported Pd-Catalyst. 
 
  
In 2011, Jones and coworkers reported polymer-oxide hybrid materials based 
on nonporous silica-supported sulfonic acid-containing polymer for their application 
in ester hydrolysis.36 The catalysts were evaluated for the hydrolysis of ethyl lactate, 
with the hybrid sulfonic acid materials having the same activity as a homogeneous 
catalyst, p-toluenesulfonic acid, and observed more activity than acidic polymer resin 
(Amberlyst 15). The heterogeneous nature of the catalyst facilitated recovery and 
recycling of the spent reagent (Scheme1.3.2). 
Scheme 1.3.2: Silica-Supported Sulfonic Acid-Containing Polymer 
 
In 2013, Diver and coworkers reported a novel silica gel-supported isocyanide 
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from metathesis reactions (Scheme 1.3.3).37 This isocyanide-grafted silica gel 
successfully reduced the concentration of remaining ruthenium from the reaction 
mixture for several alkene and enyne metathesis reactions, requiring simply filtration, 
in combination with chromatography, to further reduce the levels of residual Ru.  
Scheme 1.3.3: Silica-Supported Isocyanide Ligand. 
 
In 2013, Davies and coworkers demonstrated a silica-supported dirhodium(II) 
tetraprolinate catalyst (Figure 1.3.1) for enantioselective carbenoid reactions.38 This 
catalyst was prepared from L-proline and used for various enantioselective 
transformations of donor/acceptor carbenoids, which include cyclopropenation, 
cyclopropanation, tandem ylide formation [2,3] sigmatropic rearrangement, and C–H 
functionalization reactions. The products were obtained in comparable yields to those 
produced with the homogeneous counterpart, Rh2(S-DOSP)4. In addition, the silica-
immobilized chiral dirhodium Rh2(S-DOSP)4 was successfully recycled. 
  
Figure 1.3.1: Silica-Supported Dirhodium(II) Tetraprolinate Catalyst. 
Si NC







































92% yield, 96% ee
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In 2013, Schrock and coworkers reported, a silica-supported tungsten oxo-
alkylidene complex (Figure 1.3.2) for its application as an alkene metathesis 
catalyst.39 The well-defined oxo-alkylidene surface complex 
[(≡SiO)W(═O)(═CHtBu)OAr] is prepared by surface organometallic chemistry and 
displayed unprecedented activity at room temperature in the metathesis of alkenes. 
This catalyst was found to be the most active heterogeneous metathesis catalysts in 
the self-metathesis of cis-4-nonene and ethyl oleate. 
 
Figure 1.3.2: Silica-Supported Tungsten Oxo Alkylidene Complex. 
 
In 2014, Jones and coworkers reported polymer- and silica-supported iron 
BPMEN-catalysts (Scheme 1.3.4) for C–H bond functionalization reactions.40 These 
catalysts were synthesized and evaluated for catalytic C–H functionalization 
reactions, using cyclohexane, cyclohexene, cyclo-octane, adamantane, benzyl 
alcohol, and cumene in the presence of aqueous hydrogen peroxide. The product 
























Scheme 1.3.4: Silica-Supported Iron BPMEN-Catalysts. 
 
In 2016, Liu and coworkers reported a silica-supported rhodium/diamine 
(Scheme 1.3.5) for controllable reaction switching in enantioselective tandem 
reduction−lactonization of ethyl 2‑acylarylcarboxylates.41 The observation 
demonstrated that the extended form of the polymer coating of this catalyst at 40 °C 
facilitates highly efficient tandem asymmetric catalysis, however the closed form at 
15 °C terminates the reaction. This silica-supported heterogeneous catalyst was easily 
recovered and reused up to eight times without any loss of enantioselectivity. 









































1.4 Advances in Magnetic Reagents and Catalysts: 
Magnetic nanoparticles have recently received considerable attention as an 
attracted source for grafting of functional handles and useful scaffolds, to rapidly 
purify products from reaction mixtures with the aid of an external magnetic filed. In 
particular, there has been increased interest in air-stable core-shell magnetic 
nanoparticles.42 These magnetic materials can combine the useful magnetic properties 
of the core-shell with feasible surface functionalization. In this section, discussion 
will focus on the main attributes of magnetic supports, as well as highlight recent 
advancements in the area of magnetic reagents, scavengers and catalysts. 
Seminal efforts by many in the field reported use of core-shell assemblies 
based on super paramagnetic iron oxide NPs [magnetite (Fe3O4) and maghemite (γ-
Fe2O3)],43 which lack magnetic remanence ("magnetic memory") in the absence of an 
external magnetic field. This property is especially beneficial in order to enhance the 
ability to disperse nanomagnets. However, this advantage is offset by a relatively low 
saturation moment of ferrites (MS, bulk ≤ 92 emu/g), which is further diminished 
through additional use of a protective shell.44  As a consequence, for effective 
magnetic separation, hybrid materials that rely on iron oxide NPs demand a high 
metal content, thus limiting the total load capacity of other functional materials in the 
composite.  Therefore, NPs derived from pure metals have been developed and 
exhibit superior magnetic properties to metal oxides; however, their synthesis has 
been limited.45  
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In 2005, Gao and coworkers examined emulsion polymerization for the 
synthesis of an iron oxide nanoparticle-supported catalyst for Suzuki cross-coupling 
reactions (Scheme 1.4.1).46 In this report, styrene, 4-vinylbenzene chloride and 1,4-
divinylbenzene chloride were copolymerized to allow immobilization of 1-
methylimidazole, which further generated N-heterocyclic carbenes. The coordination 
of Pd with NHCs afforded the desired magnetic iron oxide-Pd complex, which was 
subsequently applied for Suzuki Miyaura coupling reactions of aryl halides with aryl 
boronic acids. Recovery of catalysts was achieved by applying a permanent magnet 
externally and the isolated Pd-catalyst was reused without significant loss in catalytic 
activity. 
Scheme 1.4.1. Synthesis of Polymer-Coated Iron oxide Nanoparticles with Pd-NHC 
Complexes, for Application in Suzuki couplings. 
 
In 2007, Grass-Stark and coworkers reported47 the one-step, large-scale 
production of carbon-coated nano-magnets (Figure 1.4.1) with increased air and 
thermal stabilities in a continuous process using a technique called reducing flame-
spray pyrolysis.48  A key feature of these Co/C nanoparticles is the graphene layer, 
which provides an extremely high level of chemical and thermal stability and 
























the Co-core has no detrimental effect on magnetization (158 emu/g).49 Cobalt-carbon 
magnetic beads display excellent magnetic properties and high stability in air at 
temperatures up to 190 ºC. The core–shell particles were functionalized through the 
use of diazonium chemistry, which afforded Cl-, NO2-, and NH2-functionalized 
magnetic nanoparticles (Scheme 1.4.2). 




Figure 1.4.1. Left: Carbon-Coated Nanomaterial. Right: Transmission Electron 
Microscopic image of Graphene Layers Coating of Metallic Cobalt Core. 
 
 In 2007, Alper and coworkers, reported a magnetic-supported proline ligand50 
1.4.2, which was utilized in CuI-catalyzed Ullmann-type coupling reactions of 
aryl/hetero-aryl bromides with several nitrogen heterocycles to generate the 
corresponding N-aryl products (Scheme 1.4.3). This magnetic proline ligand could be 
readily separated using an external magnet and reused up to four times without any 
significant loss in efficiency of the catalyst. 
Co Co ClH2N Cl+
HCl, NaNO2
RT, 15 min















Scheme 1.4.3. Utilization of Magnetic Nanoparticle Supported Proline Ligand. 
 
In 2010, Lee and coworkers reported a heterogeneous Pd-catalyst for Suzuki, 
Sonogashira, and Stille coupling reactions of unreactive aryl chlorides.51 A silylated 
Pd-complex was immobilized on the surface of Fe3O4 coated with a thin layer of 
silica (SiO2). A range of normally unreactive aryl chlorides afforded coupling 
products under mild conditions (Scheme 1.4.4). This magnetic/SiO2 hybrid Pd-
catalyst was successfully reused and retained its performance without significant loss 
of activity. 
Scheme 1.4.4. Synthesis and Utilization of Magnetic Pd-Catalyst for Suzuki, 
Sonogashira, and Stille Couplings. 
 
 
In 2013, Reiser and coworkers reported a magnetic amine resin, a magnetic 
Wang aldehyde (mWang) as a viable scavenger, and a magnetic borohydride 
exchange resin (Fe/C-mBER) for the reduction of various aldehydes, ketones and 






























































 100 ºC, 12 h
1.4.4
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was prepared by the combination of these magnetic resins. The reductive amination 
of aromatic and aliphatic aldehydes was carried out with a magnetic mBER and the 
excess amine needed to complete the reaction was subsequently scavenged by the 
mWang. Simple magnetic decantation afforded secondary amines in good yields and 
purities. In all cases, the spent magnetic resins were successfully regenerated and 
reused for subsequent runs. 
Scheme 1.4.5 Synthesis and Utilization of Magnetic mBER and mWang. 
 
In 2016, Pericàs and coworkers reported magnetic versions of the second-
generation MacMillan organo-catalyst53 supported on 1% DVB Merrifield resin (0.6 
mmol/g) and iron oxide Fe3O4 MNPs (Scheme 1.4.6). This catalyst was immobilized 
on Fe3O4 magnetic nanoparticles through a copper catalyzed alkyne−azide cyclo-
addition (CuAAC) reaction (0.72 mmol/g). The resulting catalytic materials were 
applied to the asymmetric Friedel-Crafts alkylation of indoles with  




1.5 equiv. mBER 1.4.5M



















Scheme 1.4.6 Synthesis and Utilization for FC-Alkylation of Indoles with Enals 
Mediated by Catalyst A 
 
1.5 ROMP-Derived Oligomeric Reagents, Scavengers and Catalyst: 
A large number of immobilized reagents and scavengers have been developed 
and are commercially available.  Moreover, extensive applications have been shown 
in organic synthesis and the production of combinatorial libraries.2,54 Despite huge 
advances in this area, limitations in non-linear reaction kinetics (heterogeneous 
reactions), low resin-load capacities, means of distributing reagents, and solution-
phase automation technology continue to warrant the development of designer 
polymers for library production.55  These limitations (i.e. non-linear kinetics and load) 
motivated the development of new polymer technologies to address them.  In this 
regard, Buchmeiser,56 Bolm,57 Barrett,58 Hanson,59 and others60 have demonstrated 
significant advancements in area by generating a wide range of ROMPgel (Figure 
1.5.1) materials using ring-opening metathesis polymerization (ROMP) of 































Figure 1.5.1. Polymers Using ROMP of Nb-tagged Monomers. 
 
 ROM polymerization is suitable for strained norbornene or 7-oxanorbornene-
based monomers.56,59 These functionalized, olefin-based cyclic Nb-tagged monomers 
are easily prepared from low-cost commercial starting materials. The synthesis of Nb-
tagged monomers is achieved either by a Diels–Alder reaction between 
cyclopentadiene (or furan) with a suitable dienophile or from a Pd-catalyzed, 
reductive Heck reaction with commercially available norbornadiene (Figure1.5.2). A 
variety of functionalized Nb-tagged monomers can be constructed on large scale 
because of the low cost and commercial availability of starting materials. 
 
Figure 1.5.2. Synthesis of Nb-Tagged Monomers. 
The first- and second-generation Grubbs catalysts (Figure 1.5.3) are more 



















































kinetic studies have been carried out by Grubbs and coworkers with 
(PCy3)2(Cl)2Ru=CHPh (G-I)61 and (ImMesH2)(PCy3)(Cl)2Ru=CHPh (G-II)62 to  
 
Figure 1.5.3. Most Commonly Used Olefin-Metathesis Catalysts for ROMP. 
elaborate on the mechanism of ROM polymerization (Figure 1.5.4). The first step 
involves the dissociation of a phosphine ligand from the pre-catalyst, 1.5.1. The 
resulting 14-electron complex 1.5.2 undergoes a [2+2] cyclo-addition reaction with 
functionalized Nb-tagged monomer 1.5.3 to generate metalla-cyclobutane 
intermediate 1.5.4. The rapid [2+2] cyclo-reversion of intermediate 1.5.4 generates 
ring-opened product 1.5.5. The highly ring-strained Nb-tagged monomers favor the 
ring-opened cycle due to the relief of ring strain. Active intermediate Ru-alkylidene 
1.5.5 goes through repeating cycles until monomer 1.5.3 is consumed. The 
polymerization is quenched by the addition of ethyl vinyl ether (EVE), which 
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Figure 1.5.4. Mechanism of Ring-Opening Metathesis Polymerization (ROMP). 
The authors59d observed that the rate of initiation is similar to the rate of 
propagation. As a result, 10 mol % of catalyst (10:1 monomer:catalyst) 
predominantly generates 10-mers, and 5 mol % of catalyst (20:1 monomer:catalyst) 
mainly produces 20-mers, etc. The chain length of oligomers in this process can be 
conveniently controlled by the amount of catalyst. Higher amounts of catalyst 
generate shorter oligomers, and smaller amounts of catalyst generate longer 
oligomers.59d ROM polymerization reactions can be carried out in round bottom 
flasks, screw-cap vials, and pressure tubes, either inside or outside of a glove box. In 
addition, ROM polymerizations can be conducted from milligram to kilogram scale. 
The length of the ROMP-derived oligomer has considerable effect on its solubility 
profile. The shorter length oligomers show more solubility in common solvents as 
compared to higher chain length oligomers. 
In 2002, Barrett and coworkers synthesized ROM polymers as solid supported 
reagents for their application in in various key transformations and parallel synthesis 
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Catalyst       Polymer Length
  10 mol %          10-mers
  5 mol %            20-mers
  2 mol %            50-mers
  1 mol %           100-mers
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cheap and commercially available starting materials. The major benefit of ROM 
polymerization results in a ROMPgel in which every repeating unit is functionalized 
with the desired reagent functionality. The synthesized ROMP polymers have 
reasonably high loading and variable physical properties, which can be easily tuned 
and optimized. 
In 2003, Janda and coworkers reported the first soluble polymer-supported 
convergent parallel synthesis library63 of a PEG-supported tripeptide aryliodides and 
PEG-supported tripeptide arylboronic acids reacted smoothly in a multi-polymer Pd-
catalyzed Suzuki coupling reaction to generate a library of bisaryl-linked 
hexapeptides (Scheme 1.5.1). This convergent parallel synthesis demonstrated the 
utilization of soluble polymers as supports in library synthesis and illustrated the 
synthesis of an 81-membered library of bisaryl-linked hexapeptides. 
Scheme 1.5.1. Polymer-supported Convergent Approach to the Bisaryl-linked 
hexapeptide Library. 
 
In 2010, Buchmeiser and coworkers reported, an amphiphilic block 
copolymer bearing chelating ligands N,N-dipyrid-2-ylamide via ROMP using a Mo-
based Schrock initiator (Scheme 1.5.2).64 Chelation with Rh(I) afforded a polymer-
bound catalyst that was used for the hydroformylation of 1-octene. From the 

























model catalyst, it becomes clear that the use of a micellar catalyst favors the 
formation of the n-aldehyde by suppressing the isomerization propensity of a catalyst. 
Apparently, the higher concentration of the starting alkene inside the micelle 
effectively prevents β-hydride elimination, an effect that can be further enhanced by 
adding free ligand that again accumulates inside the micelle. Further advantages in 
favor of a micellar setup are the low metal contamination of the products, as well as 
the possibility of reuse. 
Scheme 1.5.2. Hydroformylation Using Polymeric Rh-Catalyst. 
 
 
In 2013, Zhu and coworkers reported the facile synthesis of thiol-
functionalized long-chain highly branched (LCHBPs) ROMP-derived polymers and 
its surface was decorated with gold nanoparticles.65 Synthesis of thiol-functionalized 
long-chain highly branched polymers was achieved via combination of ring-opening 
metathesis polymerization (ROMP) and thiol-Michael addition click reaction. The 
thiol containing ROMP polymer with a terminal acrylate and groups is first prepared 
through, and then subsequent thiol-ene reaction between acrylate and thiol, afforded 
LCHBPs. Further Au nanoparticles were fabricated onto the surface of thiol-













Scheme 1.5.3. Synthesis of Thiol-Functionalized Long-Chain Highly Branched 
ROMP Polymers. 
 
In 2013, Smith and coworkers reported the synthesis and validation of a 
recyclable soluble ROMP-derived polymer supported siloxane transfer agents for use 
in Pd-catalyzed cross coupling reactions (Scheme 1.5.4).66  The soluble nature of this 
polymer allows facile product purification as well as afforded recycling without 
significant loss in cross-coupling activity. In addition, another insoluble polystyrene-
supported siloxane-transfer agent was prepared in 2014, for Pd-catalyzed cross-
coupling reactions, which further simplified product purification and reused with 
various nucleophiles and electrophiles. 
Scheme 1.5.4. Polymer-Supported Siloxane Transfer Agents for Pd-Catalyzed Cross-
Coupling Reactions. 
 
Surface functionalization of nanoparticles67,68 represents a well-established 
method for the generation of polymeric hybrid materials. Hybrid nanomaterials 
integrate the physical properties of the inorganic shell (particle size, pore and shape) 
with the tunable properties of the grafted organic polymer.69 Key reports have 


























for grafting of organic-polymers from inorganic nanoparticles,70 metal surfaces,71 
carbon nanotubes,72 and resins.73  Amongst the many grafted-hybrid materials,74  
Si-polymer hybrids are the most commonly reported in the literature for their 
application as heterogeneous supported catalysts,75 and their utilization in consumer 
industry.76 
In 2010, the Hanson group reported the application of surface-initiated, 
ROMP to generate high-load immobilized silica reagents and scavengers.77 The 
synthesis of three high load Si-ROMP reagents was successfully achieved which 
include (i) Si-immobilized bis-acid chloride (Si-OBAC) as scavenger, (ii) Si-
immobilized dichlorotriazine (Si-ODCT) for amide coupling reactions and (iii) Si-
immobilized triphenylphosphine Si-OTPP. The combination of Nb-tagged silica 
particles with functionalized Nb-tagged monomers using surface-initiated ROM 
polymerization generated these high-load, hybrid Si-ROMP reagents (Scheme 1.5.5). 
Scheme 1.5.5 Synthesis of Silica Oligomeric Bis-Acid Chloride (Si-OBAC) 
 
The hybrid Si-OBAC50 material was utilized for the scavenging of excess 
alcohol efficiently, whereby a variety of alcohols were benzoylated to generate the 
corresponding esters. Additional synthesis of materials Si-ODCT50 and Si-OTPP50 
was successfully achieved via the grafting of the corresponding Nb-tagged 
Silica Oligomeric Bis-Acid Chloride
(Si-OBAC) scavenger
 50 mer = 2.74 mmol/g
 100 mer = 5.26 mmol/g
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dichlorotriazine,59a and Nb-tagged triphenylphosphine59g (Figure 1.5.5) utilizing the 
same protocol. 
 
Figure 1.5.5 Silica-grafted Oligomeric Dichlorotriazine and (Si-ODCT50) and 
Triphenylphosphine  (Si-OTPP50) 
 
 In 2010, Hanson-Reiser reported the utilizing the aforementioned surface-
initiated ROMP, and developed a Co/C-immobilized, recyclable Pd-catalyst 
possessing a load of 0.48 mmol Pd/g (Scheme 1.5.6).78 Initially magnetic Co/C NPs 
1.5.9 are synthesized using Nb-tagged propargylic ether 1.5.10 via “click” attachment 
to the azido Co/C NP 1.5.11. The Nb-tagged triphenylphosphine (Nb-TPP) monomer 
1.5.4 was prepared and immobilized onto highly magnetic Co/C NPs 1.5.9 (0.1 
mmol/g), using second-generation Grubbs catalyst [G-II], followed by the addition of 
the Nb-TPP monomer 1.5.12 (50 equiv.), afforded immobilized ROMP-derived 
Co/C-OTPP 1.5.13 possessing increased load (1.1 mmol/g).  In a single step, the 
Co/C-OTPP ligand was utilized to afford the corresponding Co/C Pd-catalyst 1.5.14 
possessing a load of 0.48 mmol/g.  The Co/C-OTPP-Pd hybrid material was 
successfully employed in the construction of biaryl compounds in a Suzuki-Miyaura 
coupling reaction, where the catalyst was recycled and used 6 times without 
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Scheme 1.5.6 Co/C Oligomeric TPP-Pd Catalyst Utilized in Suzuki-Miyaura Biaryl 
Couplings. 
 
In 2010–2011, Hanson, Reiser and coworkers reported a sequestration 
protocol as a variant of the Mitsunobu reaction utilizing Nb-tagged reagents in 
conjunction with Nb-tagged Co/C NPs to sequester all by-products in the reaction.79  
In this impurity annihilation method,80 termed monomer-on-monomer (MoM) 
Mitsunobu, purification was rapidly achieved by reacting the Nb-tagged Co/C NPs 
1.5.11 via addition of the G-II catalyst in a surface-initiated polymerization process, 
which subsequently sequestered all Nb-tagged entities. To consider the biological 
importance of benzofused thiadiazepine-dioxides, in 2011, Hanson and Reiser 
utilized (MoM) Mitsunobu protocol for the synthesis of variable benzofused 
thiadiazepine-dioxides.81 The intramolecular Mitsunobu reaction has been widely 
applied for the cyclization of various molecules in natural product synthesis.82 In this 
process, facile sequestration of the utilized and excess reagents was achieved by three 
methods such as: (i) free catalyst in solution, (ii) surface-initiated catalyst-armed 
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nanoparticles (Nps) [Scheme 1.5.7]. All three methods were found to work well with 
free catalyst in solution, silica surface-initiated ROMP, or Co/C NP surface-initiated 
ROMP, the latter being the most economical and efficient. 
Scheme 1.5.7. Catalyst-armed Silica- and Co/C Magnetic Nanoparticles 
 
Building on these results, substrate scope for the synthesis of benzofused 
thiadiazepine-dioxides analogues were investigated using all three-sequestration 
purification protocols. Thus, MoM Mitsunobu cyclization’s (Figure 1.5.6) were 
employed to generate benzofused thiadiazepine-dioxides using free cat-B, Nb-tagged 
Co/C magnetic particles and Nb-tagged Silica particles. 
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In 2013, Reiser and coworkers in collaboration with Hanson group reported 
efforts on an operationally simple method for the acylation of amines utilizing 
carbon-coated cobalt (Co/C) and iron (Fe/C) nanobeads as recyclable supports 
(Scheme 1.5.8).83 Magnetic Co/C-NPs 1.5.11 was grafted with Nb-tagged acylated N-
hydroxysuccinimide 1.5.15 monomers through surface initiated ROMP using G-II 
catalyst. The high loading hybrid material 1.5.16 (up to 2.6 mmol/g) was utilized for 
the acylation of various 1º and 2º amines in high yields (86–99%) and excellent 
purities after rapid magnetic decantation and simple evaporation of the solvents.  The 
spent N-hydroxysuccinimide NPs 1.5.17 were successfully re-acylated via acid 
chlorides, anhydrides, and acids and reused for up to five cycles without considerable 
loss of activity. 




 In 2016, Reiser and coworkers, reported synthesis and application of a 
magnetic Noyori-type ruthenium catalysts (Scheme 1.5.9) for an asymmetric transfer 
hydrogenation reactions in water.84 The synthesized polymeric Noyori-type 
G-II (2 mol%), CH2Cl2 




















































ruthenium catalysts were immobilized on carbon-coated cobalt nanoparticles and 
were evaluated for asymmetric transfer hydrogenation of various ketones. The spent 
catalysts were recovered and directly reused without further reactivation treatment in 
10 consecutive runs, using advantage of the magnetic decantation of the polymeric 
material. 
Scheme 1.5.9 Recyclable, Magnetic Co/C hybrid Noyori-type Ruthenium Catalysts. 
 
 
Overall, ROMP-derived oligomers possess unique physical properties, which 
make them a robust and useful approach for immobilization of a variety of soluble, 
silica and magnetic reagents, scavengers, and catalysts. The main advantages of 
ROMP technology include (a) various functional groups (Nb-FG) can be incorporated 
before polymerization, however in case of incompatibility with catalyst, post-
polymerization can be achieved, (b) several attractive synthetic routes to 
functionalized norbornene and oxa-norbornene derivatives, (Nb-FG) are available for 
the generation of inexpensive immobilized reagents, (c) physical properties can be 
finely tuned. Chapter 2, 3 and 4 will detail work carried out in this dissertation 
regarding the use of ROM polymerization to generate soluble, silica and magnetic 
alkylating reagents and scavengers. The soluble ROMP polymers are air stable, high-
load free flowing non-toxic solids, which are easy to handle and purification of 















ROMP derived polymers afforded the desired products via simple filtration. However 
magnetic polymers could be isolated by simple magnetic decantation, which further 
simplified the purification process (Figure1.5.7). 
 
Figure 1.5.7: ROMP-Derived Soluble, Silica and Magnetic reagents. 
1.6 Conclusion 
 
The prime examples in recent years have shown significant developments for 
immobilized soluble, silica and magnetic reagents/scavengers/catalysts. Immobilized 
platforms have not only enabled automated synthesis, but also more recently have had 
a major impact in flow-through technologies. In addition, advances in ROMP-derived 
polymers, brings a robust and convenient approach of immobilization for a variety of 
soluble, silica and magnetic reagents/scavengers and catalyst. The combination of 




























play a key role in facilitating complex reaction processes. Taking the combine 
advantages of polymer-assisted solution phase precipitation, silica-supported filtration 
and magnetic-decantation, the frame of work discussed herein represent the front 
lines for future advancement in natural product synthesis and small-molecule library 
development. Since its discovery, ROMP has advanced as a general and viable means 
of immobilizing reagents/scavengers and catalysts and will undoubtedly continue to 
expand beyond these borders. It is reasonable to expect a variety of more useful 
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Section 2.1 “Click”-Capture, Ring-Opening Metathesis Polymerization (ROMP), 
Release: Facile Triazolation Utilizing ROMP-Derived Oligomeric Phosphates 
 
2.1.1 Introduction 
In Chapter 1, recent advances in the area of immobilized reagents for the 
production of libraries for high-throughput screening (HTS) and automated technologies 
were highlighted. In addition, the end of Chapter 1 summarized advances in ring-opening 
metathesis polymerization (ROMP) technology for immobilization of a variety of 
soluble, silica and magnetic reagents/scavengers and catalysts.  In Chapter 2 (Section 2.1) 
we report the development and utilization of high-load, soluble oligomeric triazole 
phosphates for direct triazolation of N-, O- and S-nucleophilic species in a “Click”-
capture, ROMP, release protocol that exploits the innate properties of phosphate-based 
alkylating agents.  To the best of our knowledge, these reagents represent the first 
phosphate-based oligomeric/polymeric reagents in the literature. 
Alkylations of simple nitrogen, oxygen, and sulfur nucleophiles are highly 
prevalent and significant reactions in organic synthesis, medicinal chemistry and drug 
discovery.1 Moreover, benzylation of amines and alcohols are the most commonly used 
protecting group strategies in organic synthesis, due to the ease of benzyl incorporation 
and cleavage, which can be achieved under a variety of conditions.2 In addition, 
benzylation is a useful diversification reaction in medicinal chemistry, high-throughput 
chemistry, and diversity-oriented synthesis (DOS).3 The most common reagents to attain 
this operation are benzyl bromides, which usually severe lachrymators and present both 
safety and toxicity issues. In this regard, a number of alternative methods for 
alkylation/benzylation4 and polymer-supported5 reagents have been developed. 
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In 1998, Reitz and coworkers reported the first example of solid-supported resin 
bound arylsulfonate esters as an alkylating reagent (Figure 2.1.1).6 In 2004, Hanson and 
coworkers reported the development of high-load, soluble oligomeric sulfonate esters 
(OSCn) as a free-flowing solids using ring-opening metathesis polymerization (ROMP) 
technology and demonstrated their utilization for facile benzylation of a variety of 
amines7 (Figure 2.1.1). Later, in 2007, Hanson and coworkers reported oligomeric 
benzylsulfonium salts, which were generated via ROMP8 (Figure 2.1.1). These 
oligomeric sulfonium salts were utilized for facile benzylations of various nucleophiles 
via simple precipitation/filtration to deliver products in excellent yields and purities. 
 
Figure 2.1.1: Polymer Supported and ROMP-Derived Alkylating Reagents 
During the period 2002–2009, several reports from Linclau and coworkers 
demonstrated the application of polymer supported O-alkylisoureas9 for the alkylation of 
various carboxylic acids. This reagent was prepared from commercially available 
polymer supported carbodiimide (Scheme 2.1.1). The prepared o-methylisourea reagent 
was successfully used for the preparation of methyl esters of the corresponding 
carboxylic acids. In addition, O-alkylisoureas were utilized to transform carboxylic acids 
into the corresponding benzyl, allyl, and p-nitrobenzyl esters in high yields and purities 























Scheme 2.1.1: Synthesis and Utilization of Polymer-Supported O-Alkylisoureas 
 
In 2010, Hanson and coworkers reported soluble ROMP-derived oligomeric 
benzyl phosphates (OBPn) for the application in facile benzylation in purification free 
protocols (Scheme 2.1.2).10 The innate property of phosphate as a leaving group,11,12 
including stability, multiple valency/oxidation states, and variable pKa can be harnessed 
to generate these oligomeric phosphate reagents for the benzylation of N, O and S-
nucleophilic species. The oligomeric benzyl phosphates OBP were synthesized via 
ROMP of Nb-tagged phosphate monomers and were utilized for efficient benzylation of a 
variety of nucleophiles. 
Scheme 2.1.2: ROMP-Derived Oligomeric Benzyl Phosphate (OBP), Benzylation of N-, 
O-, and S-Nucleophiles. 
 
A variety of cyclic and acyclic amines were subjected to benzylation and were 
found to proceed smoothly toward the desired benzylated products. Additional, 
benzylation of N-, O- and S-nucleophiles was achieved successfully in excellent yields 
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using a silica SPE cartridge, followed by the evaporation of solvent afforded the desired 
benzylated products in excellent yields and high purities. In this section, we will discuss 
the development and utilization of a new ROMP-derived oligomeric triazole phosphate 
(OTP) for application as a soluble, efficient triazolating reagent of N-, O- and S-
nucleophilic species. 
2.1.2  Results and Discussion 
Triazoles and their derivatives have demonstrated a wide variety of biological 
profiles, which include antifungal,13 antibacterial14 and anticancer activities.15 Despite this 
activity, the utilization of solution-phase or immobilized reagents to directly triazolate 
nucleophilic species in a one-step protocol has been limited to reports of a two-step, one-
pot propargylation-click protocol which, while very powerful, has limitations in the 
potential storage of sub-libraries which would be comprised of reactive alkynes and 
azides.16 In this chapter, we demonstrate the synthesis of ROMP-derived triazolating 
reagents (OTP) for application in purification free diversifications of nucleophilic species 
using the title method, termed “Click”-Capture, ROMP, Release.17 This method utilizes a 
propargyl-tagged norbornenyl-phosphate to capture an azide in a classical “click” 
reaction, followed by ROM polymerization to generate the desired soluble oligomeric 
triazole reagent (OTP). Subsequent release via SN2 displacement with nucleophilic 
species yields triazolated products along with the spent oligomeric phosphate that is 
readily sequestered via precipitation (Figure 2.1.2). 
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Figure 2.1.2 Utilization of Oligomeric Triazole Phosphate (OTP)n 
The synthesis of the oligomeric triazole phosphate bearing a p-methoxy benzyl 
group OTP 2.1.5, starts with the exo-norbornenyl tagged (Nb-tagged) phosphonyl 
chloride 2.1.3 utilized in the synthesis of previously reported ROMP-derived benzylating 
reagent OBP.10,18 Phosphorylation of propargyl alcohol with Nb-tagged phosphonyl 
chloride 2.1.3, followed by a “Click”-capture event of the corresponding azide, yields the 
desired monomer 2.1.5 in an efficient fashion. ROM polymerization of monomer 2.1.5 
was achieved with RuCl2(PCy3)2=CHPh (G-II), followed by basic workup utilizing the 
Pederson protocol.19,20  Precipitation via dropwise addition into anhydrous Et2O, afforded 
the corresponding oligomeric triazole phosphate (OTP20) 2.1.6 as a free-flowing white 
solid possessing a theoretical load of 2.4 mmol/g (Scheme 2.1.3). 
Scheme 2.1.3. Synthesis of Oligomeric Triazole Phosphate (OTP) 2.1.6 
 
Investigation into the utilization of OTP 2.1.6 as a direct triazolating reagent was 
next studied using reaction conditions reported for the application of OBP (Scheme 
2.1.4). After optimization of reaction conditions for the (triazolyl)methylation of 2,4-
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ABSTRACT
Soluble, high-l ad ring-opening metathesis polymerization (ROMP)-derived oligomeric triazole phosphates (OTP) are reported for application as
efficient triazolating reagents of nucleophilic species. Utilizing a “Click”-capture, ROMP, release protocol, the efficient and purification-free, direct
triazolation of N-,O-, and S-nucleophilic species was successfully achieved. A variety of OTP derivatives were rapidly synthesized as free-flowing
solids on a multigram scale from commercially available materials.
Rapid access to collections of diverse molecules in
desirable quantities and purity f r high-throughput
screening is an important challenge in drug discovery. In
this regard, methods that integrate synthesis and purifica-
tion have become powerful tools in the arena of facilitated
synthesis.1,2 This has been driven in recent years by the
development of an array of polymer-bound reagents and
scavengers for utilization in streamlined protocols to ac-
cess small molecule libraries.2 Despite huge advances
in this area, limitations in nonlinear reaction kinetics
(heterogeneous reactions), low resin-load capacities,
means of distributing reagents, and solution phase auto-
mation technology continue to warrant the development
ofdesignerpolymers for libraryproduction.3To this effect,
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dichlorophenol utilizing OTP 2.1.6a, the corresponding triazole ether 2.1.7a, was isolated 
in excellent yield (98%) and crude purity (>90%) using simple filtration through a Celite® 
SPE (Table 2.1.2). 
Scheme 2.1.4. Utilization of Oligomeric Triazole Phosphate (OTP) 2.1.6a 
 
The application of OTP 2.1.6a as an efficient triazolating reagent was extended to 
a variety of N-, O- and S-nucleophilic species (Table 2.1.1).  Initially, a variety of phenols 
were utilized (Table 2.1.1, entries 1–3) though reduced yields were observed for 
sterically hindered napthalene-1-ol.  In addition to phenols, thiophenols  (Table 2.1.1, 
entry 5) and a variety of amines (Table 2.1.1, entries 6–10) were successfully utilized to 
release the corresponding triazole in >90 % crude purity. 
Table 2.1.1. (Triazolyl)methylation of N-, O-, and S-Nucleophiles Using OTP20 2.1.6a 
Entry Nucleophile Pdt Yield (%) 
1 2,4-dichlorophenol 2.1.7a 98 
2 4-fluorophenol 2.1.7b 92 
3 4-(tert-butyl)phenol 2.1.7c 90 
4 naphthalene-1-ol 2.1.7d 69 
5 4-(methylthio)benzenethiol 2.1.7e 60 
6 Morpholine 2.1.7f 72 
7 Thiomorpholine 2.1.7g 75 
8 1-phenylpiperazine 2.1.7h 95 
9 Indoline 2.1.7i 88 
10 N-ethylnaphthalen-1-amine 2.1.7j 62 
[a] Purities >90% observed for all reactions using both GC and 1H NMR. [b] OTP 2.7a utilized as a 20-mer. 
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Building on the success of OTP 2.1.6a, a variety of additional OTP derivatives 
2.1.6b–i were synthesized as free-flowing powders on gram scale from ROM 
polymerization of their corresponding monomers utilizing the G-II  catalyst  
(Table 2.1.2). 
Table 2.1.2. Synthesis of Various OTPn Analogues 
 
Monomer R1 pdt Yield (%)a 
2.1.5a 4-OMe-C6H4 2.1.6a 82 
2.1.5b 4-Me-C6H4 2.1.6b 88 
2.1.5c 2-Me-C6H4 2.1.6c 77 
2.1.5d 4-Cl-C6H4 2.1.6d 71 
2.1.5e 4-F-C6H4 2.1.6e 74 
2.1.5f 4-CF3-C6H4 2.1.6f 73 
2.1.5g Cylohexyl 2.1.6g 70 
2.1.5h 4-Br-C6H4 2.1.6h 89 
2.1.5i 2-Furyl 2.1.6i 56 
aYields corresponding to metathesis of corresponding monomers. 
With a variety of OTP derivatives in hand, the (triazolyl)methylation of both 
naphthalene-1-ol and N-ethylnaphthalen-1-amine with OTP derivatives 2.1.6a–g was 
investigated (Table 2.1.3).  All reactions proceeded with good yields with >90% crude 
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Table 2.1.3 Triazolyation Utilizing OTP derivatives 2.1.6a–g 
 
entry Nucleophile OTP Pdt Yield (%)a 
1 naphthalene-1-ol 2.1.6a 2.1.8a 72 
2 naphthalene-1-ol 2.1.6b 2.1.8b 90 
3 naphthalene-1-ol 2.1.6c 2.1.8c 55 
4 naphthalene-1-ol 2.1.6d 2.1.8d 68 
5 naphthalene-1-ol 2.1.6e 2.1.8e 70 
6 naphthalene-1-ol 2.1.6f 2.1.8f 65 
7 naphthalene-1-ol 2.1.6g 2.1.8g 49 
8 N-ethylnaphthalen-1-amine 2.1.6a 2.1.8h 62 
9 N-ethylnaphthalen-1-amine 2.1.6b 2.1.8i 52 
10 N-ethylnaphthalen-1-amine 2.1.6c 2.1.8j 63 
11 N-ethylnaphthalen-1-amine 2.1.6d 2.1.8k 51 
12 N-ethylnaphthalen-1-amine 2.1.6e 2.1.8l 50 
13 N-ethylnaphthalen-1-amine 2.1.6f  2.1.8m 60 
14 N-ethylnaphthalen-1-amine 2.1.6g 2.1.8n 66 
[a] Purities >90% observed for all reactions using both GC and 1H NMR. [b] OTP 4a-g utilized as a 20-mer. 
Overall, we have developed and demonstrated the synthesis and utilization of 
oligomeric triazole phosphates for direct (triazolyl)methylation of N-, O- and S-
nucleophilic species in a “Click”-capture, ROMP, release protocol.  These oligomeric 
reagents are readily synthesized on multi-gram scale from commercially available 
materials as soluble, high-load, free-flowing powders. These oligomeric reagents are easy 
to handle, non-toxic, air stable and can be easily stored for long-term at room 
temperature. The application of OTP in the diversification of core scaffolds for the 


























Section: 2.2 Facile (Triazolyl)methylation of MACOS-derived Benzofused Sultams 
Utilizing ROMP-derived OTP Reagents  
 
2.2.1 Introduction 
Enabling technologies that allow for the assembly of diverse small molecule 
collections where synthesis, diversification and purification are integrated into one 
parallel process can play a valuable role in fast paced early drug discovery efforts. 
Classical synthetic approaches to small molecule libraries have suffered from multistep 
processes requiring costly and time-consuming solvent/compound transfer and 
purification at every stage. In addition, issues relating to low yielding or unreliable 
reactions for the preparation of compounds and key intermediates have a negative effect 
on early stage drug discovery.21 In recent years, a variety of enabling technologies have 
been developed to address these limitations, giving rapid access to small molecule HTS 
collections.22  One such technology has been the development and utilization of 
continuous flow syntheis platforms, which can carry out multistep processes, combined 
with inline diversification/purification, utilizing immobilized reagents/scavengers.23  In 
addition to inline purification,24  the ability for automation,25 safe, in situ generation of 
reactive intermediates,26 and rapid reaction optimization and multigram scale-out makes 
this a powerful enabling tools in early stage drug discovery.27 
This section of Chapter 2 describes the utilization of a microwave-assisted, 
continuous flow organic synthesis (MACOS) platform in combination with soluble 
oligomeric triazole phosphates (OTP) reagents derived from ROMP for the rapid, 
purification-free synthesis of a 106-member library of benzothiaoxazepine-1,1-dioxides.28 
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 In the recent years, sultams (cyclic sulfonamide analogues) have emerged in as 
important targets in drug discovery due to their extensive chemical and biological 
profiles.29 A variety of core sultam scaffolds prepared via MACOS30 could be quickly 
diversified in a facile, purification-free process utilizing a suite of ROMP-derived 
reagents.31  A number of synthetic methods have been developed to give access to diverse 
sultam libraries.32 Building on these efforts, the utilization of MACOS in combination 
with ROMP-derived oligomeric reagents for the library synthesis of benzothiaoxazepine-
1,1-dioxides will be described here (Scheme 2.2.1).28 
Scheme 2.2.1. MACOS-“Click”-Capture, ROMP, Release 108-Member Library 
 
2.2.2 Result and Discusion 
The correponding core scafolds benzothiaoxazepine-1,1-dioxide were synthesized 
using a MACOS platform33 in colloboration with Organ and coworkers. In a concerted 
effort, a suite of soluble, high-load ROMP-derived oligomeric triazole phosphates were 
generated in our laboratory for the facile, purification-free diversification of nucleophilic 
small molecules.17 These ROMP-derived OTP reagents were found to be bench stable, 
free flowing solids that are readily soluble in a variety of solvents (CH2Cl2, CHCl3, DMF) 
to generate stock solutions, making them well-suited for parallel synthesis.  With these 
reagents in hand, the (triazolyl)methylation of core benzothiaoxazepine-1,1-dioxide 





































of oligomeric triazole phosphate (OTP) reagents {2.2.11–2.2.24}. Initially a 16-member 
prototype library was investigated for the generation of triazole containing 
benzothiaoxazepine-1,1-dioxides (Table 2.2.1).  
Table 2.2.1. Prototype Library Demonstrating Utilization of Scaffolds 2.2.1–2.2.3, 2.2.5, 
2.2.6, 2.2.8–2.2.10 with OTP20 Oligomers {2.2.11;  2.2.12;  2.2.14; 2.2.19; 2.2.21; 
2.2.22} 
 
entrya	   scaffold	   OTP20 {X}	   yield %	   entrya	   scaffold 	   OTP20 {X}	   yield %	  
1	   2.2.1	   {2.2.21}	   85	   9	   2.2.9	   {2.2.11}	   63	  
 2	   2.2.2	   {2.2.22}	   62	   10	   2.2.9	   {2.2.12}	   89	  
3	   2.2.3	   {2.2.21}	   97	   11	   2.2.9	   {2.2.14}	   82	  
4	   2.2.3	   {2.2.22}	   92	   12	   2.2.9	   {2.2.19}	   79	  
5	   2.2.5	   {2.2.22}	   70	   13	   2.2.10	   {2.2.11}	   68	  
6	   2.2.6	   {2.2.21}	   98	   14	   2.2.10	   {2.2.12}	   75	  
7	   2.2.8	   {2.2.21}	   98	   15	   2.2.10	   {2.2.14}	   72	  
8	   2.2.8	   {2.2.22}	   94	   16	   2.2.10	   {2.2.19}	   75	  
a Reaction conditions: OTP20 (1.5 equiv.), NaI (0.2 equiv.), Cs2CO3 (3 equiv.), dry DMF (0.2 M) 
and sultam 2.2.1–2.2.10 (1 equiv.).  Reaction heated at 90 ºC for 2−14 h (TLC analysis). 
Utilizing reported conditions for the (triazolyl)methylation of a variety of 
nucleophilic species,17 the generation of a 16-member prototype library was successfully 
achieved in good yield and crude purity (85–100%, 1H NMR), demonstrating both 
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member library was designed with benzothiaoxazepine-1,1-dioxide scaffolds 2.2.1–
2.2.10 and OTP20 oligomers {2.2.11–2.2.24}. 
Library Design. A full-matrix library was designed using in silico analysis, literature 
precedence, and observed synthetic results.34 A virtual library incorporating all possible 
building block combinations of sultam scaffolds 2.2.1–2.2.10 (Figure 2.2.2)  with OTP 
reagents {2.2.11–2.2.24} (Figure 2.2.3) was evaluated.  Physicochemical property filters 
were applied, guiding the elimination of undesirable combinations that led to products 
with undesirable in-silico properties. These metric filters included standard Lipinski Rule 
of 5 parameters (molecular weight <500, ClogP <5.0, number of H-acceptors <10, and 
number of H-donors <5), in addition to consideration of the number of rotatable bonds 
(<5) and polar surface area.  Absorption, distribution, metabolism and excretion (ADME) 
properties were calculated along with diversity analysis using standard H-aware 3D 
BCUT descriptors compared against the MLSMR screening set (~7/2010; ~330,000 
unique chemical structures).  Guided by this library design analysis, a 96-member library 
was designed. 
 










































2.2.2 2.2.3 2.2.4 2.2.5




Figure 2.2.3. OTP20 Reagents {2.2.11–2.2.24} for Library Building Blocks. 
Microwave-assisted continuous flow organic synthesis (MACOS) has emerged as 
a powerful technology for libraries production of compounds in a scale suitable for 
biological screening purposes.27 The use of microreactors technology can reduce reaction 
times as well as the quantity of waste produced such as solvens, because the method 
efficiently delivers desired quantities of material that are necessary for early stage 
biological screening. The MACOS approach addresses safety, as the quantities of toxic 
compounds are minimized, and reactions performed using this methodology are cleaner 
and higher yielding as compared to typical solution phase approach.35 The combination of 
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successfully utilized for the library preparation of triazole containing 
benzothiaoxazepine-1,1-dioxides. 
Scheme 2.2.2. Facile Library Generation Utilizing MACOS Scale-out Combined with 
Triazolation and ROMP-derived OTPn 
 
Library Generation.  The proposed 96-member library was prepared in 1-dram vials via 
a mix-and-match approach using stock solutions of scaffold (2.2.1–2.2.10) and OTP20 
reagents {2.2.11–2.2.24}.  Crude purity analysis of the 96-member library demonstrated 
that 66 compounds had crude purities of 80–99%, 16 compounds at 70–80% and 8 
compounds with <70% (Scheme 2.2.2).  Final analysis of this library after purification by 
automated mass-directed LCMS resulted in the successful synthesis of 90 compounds 
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Graph 2.2.1. Final Mass, Purity and Yield Analysis for Benzothiaoxazepine-1,1-dioxide 
Library.  
 In conclusion, a 90-member library of triazole containing benzothiaoxazepine-
1,1-dioxides was successfully prepared combining two enabling technologies, namely 
MACOS platform and ROMP-derived OTP reagents.  Utilization of a suite of soluble 
OTPn reagents {2.2.11–2.2.24}, 10 MACOS-derived sultam scaffolds 2.2.1–2.2.10 were 
successfully diversified in a purification-free parallel process amenable for automation.  
Taken collectively, a total of 106 out of 112 sultams were successfully generated (95% 
success rate) with 100/112 (89% rate) possessing purities >90%.  The compound libraries 
have been submitted to the University of Kansas Center for Chemical Methodologies and 


































Molecule Repository (MLSMR) for distribution and broad screening for biological 
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High Load Hybrid Si-ROMP Alkylating Reagents:  




Section 3.1: Synthesis and Development of Si-OBP and Si-OPT as Alkylating 
Reagents. 
 
3.1.1  Introduction 
The need to rapidly synthesize a wide variety of small molecules in desired 
quantities with high purities and yields is an important challenge facing drug discovery 
and developmental chemistry.1  To help address this need, immobilized reagents2,3  and 
scavengers have been developed to provide ease of synthesis and to eliminate time-
consuming chromatographic separation protocols. In this chapter we describe our efforts 
to expand the family of ROMP-derived oligomeric materials that have been grafted onto 
the surface of silica. A metathesis catalyst-armed surface (CAS)-initiated polymerization 
was key to functionalization of units on the silica particle surface.  In Chapter 3 (Section 
3.1), we report the development and utilization of Silica-immobilized oligomeric benzyl 
phosphate (Si-OBPn) and triazole phosphate (Si-OTPn),4 which we previously discussed 
in Chapter 2 as soluble alkylating reagents for enabling library generation.5 
Silica-immobilized reagents6,7,8 are frequently used for enabling synthesis and 
automated flow through technologies. Some of the more recent advances include, silica-
supported isocyanide ligands for scavenging ruthenium,9 mesocellular silica-supported 
boronic acids as direct amidation catalysts,10 silica-supported rhodium catalysts,11 N-
heterocyclic carbenes,12 iron BPMEN-inspired catalysts,13 sulfonic acid catalysts,14 
tungsten oxo-alkylidene,15 TEMPO,16 Pd-, Mn- and Cu(I)-catalysts,17 peracid,18 
phosphines,19 prolinol, and TADDOLs.20  However, despite significant advantages over 
resin-based systems, silica-based immobilized reagents are often limited by several 
factors, including (i) low load levels (ii) heterogeneous reaction kinetics and non-surface 
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diffusion-controlled processes, (iii) immobilized reagent swelling, and (iv) poor solvent 
tolerance.  Inspired by the seminal work of Buchmeister and coworkers,21 our efforts 
were focused on the synthesis and study of a number of hybrid materials that graft several 
ROMPgel materials onto the surface of silica particles.22  Through this grafting process, 
the resulting immobilized ROMP reagents can be removed from solution by simple 
filtration, thus eliminating the precipitation step.  In this regard, silica-supported 
ROMPgel acid chloride, dichlorotriazine, and triphenylphosphine reagents were 
generated and found to have properties nearly identical to the equivalent soluble 
ROMPgel oligomeric reagents. 
Our lab has previously examined a variety of soluble, high-load, oligomeric 
reagents and scavengers derived through the use of ring-opening metathesis 
polymerization  (ROMP) of functionalized norbornene and 7-oxanorbornene monomers.23  
These materials, known as ROMPgels, are built on the pioneering efforts of Barrett,24 
Buchmeiser,25 Bolm,26 and others;27 and they have effectively been used to mediate a 
number of chemical reactions. Our soluble ROMPgel materials behave equivalently to 
traditional homogeneous reagents and catalysts, and are generally removed from solution 
via precipitation.  However, the need to precipitate can at times limit their use in 
pharmaceutical applications. 
Benzylation and triazolation are useful diversification reactions in medicinal 
chemistry, high-throughput chemistry, and diversity-oriented synthesis (DOS).28  The 
benzylation of amines and alcohols also serves as one of the most utilized protecting 
group strategies in organic synthesis due to its easy incorporation and removal.29  While 
these uses have spurred development of a number of alternative approaches to 
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benzylation30 and triazolation, we believe that the generation of the analogous silica-
oligomeric benzyl phosphate (Si-OBPn) and triazole phosphate (Si-OTPn) reagents could 
find efficient, safe, and cost effective applications in chemical synthesis and library 
production. Key advantages of these reagents include: (i) their stability at room 
temperature, (ii) safety in handling when compared to commercially available benzyl 
bromides or iodides, and (iii) ease of purification via simple filtration. 
3.1.2 Results and Discussion  
 Initial efforts were centered on the synthesis of the silica-grafted oligomeric 
benzyl phosphate reagent, as outlined in Scheme 3.1.1, using a modification of the 
procedure reported by Buchmeiser.31  The activated silica 3.1.1 (60 Å, 20 μm) was tagged 
with commercially available norbornene silyl reagent [(MeO)3Si-(CH2)2-Nb (3.1.2)] 
followed by capping with trimethoxymethylsilane and dimethoxydimethylsilane to afford 
the norbornene-functionalized silica (Si-Nb) 3.1.3.  It was observed that the use of 
(MeO)3Si-(CH2)2-Nb (3.1.2) dramatically increased the norbornene load of Si-Nb (3.1.3) 
compared to 5-(bicycloheptenyl)-triethoxysilane [Nb-Si(OEt)3], which was previously 
used for silica tagging.22 By this optimized method, we prepared norbornene-
functionalized silica 3.1.3 (Si-Nb) on gram scale with 0.4 mmol/g loading (determined by 
a modified bromine titration method).32  With this Si-tagged nanoparticle (3.1.3) in hand, 
a metathesis catalyst-armed surface-initiated polymerization was established using the 
C848 catalyst (Grubbs 2nd generation catalyst, G-II)33 (20 mol%, based on Si-Nb load) in 
CH2Cl2 and toluene as solvents, followed by addition of the Nb-tagged benzyl phosphate 
monomer 3.1.4 to rapidly generate the desired hybrid material (Si-OBPn) 3.1.5a. The 
benzyl phosphate monomer 3.1.4 was easily synthesized in good yield and purity 
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according to previously reported methods.4 Norbornene exo-diol 3.1.6 was reacted with 
POCl3 and Et3N in the presence of catalytic DMAP to generate the Nb-tagged 
monochlorophosphate compound 3.1.7 in moderate yields as a white solid (Scheme 
3.1.1).  This material was then reacted with benzyl alcohol in NMI and CH2Cl2 at room 
temperature to yield 3.1.4.  
Scheme 3.1.1. Synthesis of Silica-supported Oligomeric Benzyl Phosphate (Si-OBPn). 
 
The scale-up synthesis of the monomeric reagent, as well as Si-OBPn, have been 
carried out on gram scale as stable, free-flowing powders.  The scanning electron 
microscopy (SEM) images of Si-OBPn and Si-OTPn silica hybrid materials demonstrate 
the grafting of the corresponding monomer on silica surface and inherent morphology of 
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Figure 3.1.1. SEM images of Si-Nb (left), Si-OBPn (middle) and Si-OTPn (right). 
 The utilization of silica oligomeric benzyl phosphate 3.1.5a (Si-OBPn) for 
benzylation with various N-, O-, and S-nucleophiles, including anilines, amines, phenols, 
thiols, and sulfonamides (Table 3.1.1), was examined.  The reactions were carried out in 
a sealed pressure tube with different nucleophiles (1 equiv.), Si-OBPn (1.5 equiv), Cs2CO3 
(3.0 equiv.), and NaI (0.2 equiv.) in THF at 80 ºC (oil bath temperature) to yield the 
products after simple filtration via Celite® SPE to remove the Si-phosphate byproduct. 
Initially, a variety of amines and phenols (Table 3.1.1, entry 1–4) were utilized, and were 
next extended to thiophenols and sulfonamides (Table 3.1.1, entry 5–8).  The 
corresponding benzylated analogs 3.1.8a–3.1.8h were isolated in excellent purities 
(>90%, determined by LC-MS) and yields (>90%). 
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Table 3.1.1. Benzylation of N-, O- and S-nucleophiles utilizing Si-OBPn. 
 
 With these results in hand, an expanded set of Si-OBPn derivatives was next 
examined (Figure 3.1.2).  These high load reagents (3.1.5b–3.1.5d) were synthesized in 
an analogous fashion to the Si-OBPn reagent and were also obtained on gram scales as 
free-flowing powders.  Utilization of these reagents in substitution reactions with O- and 
S-nucleophiles were next carried out to afford benzylated products (3.1.8i–3.1.8n) in 
good yields (>90%) and excellent purity after Celite® SPE filtration (Table 3.1.2). 
Diversification of the Si-OBPn reagents by using different electron withdrawing and 
electron donating group substituents on the aryl moiety were next examined. In all cases, 
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Figure 3.1.2: Various Silica-supported Oligomeric Benzyl Phosphate (Si-OBPn) analogs. 
 
Table 3.1.2. Benzylation of N-, O- and S-nucleophiles utilizing various Si-OBPn analogs. 
 
 Attention was next placed on the gram-scale generation of silica oligomeric 
triazole phosphate hybrid reagents (Si-OTPn).  Triazoles and their derivatives have 
demonstrated a wide variety of biological activities.34 We previously reported soluble 
oligomeric triazole phosphates to construct a wide array of triazole-containing 
compounds.4 Silica-immobilized oligomeric triazole phosphate 3.1.10a (Si-OTPn) was 
synthesized via grafting of the Nb-tagged benzyl triazole phosphate monomer 3.1.9 onto 
the surface of norbornene-functionalized silica (Si-Nb) 3.1.3. The synthesis was 
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Scheme 3.1.1.  The product, 3.1.10a (Si-OTPn), was isolated as a free flowing solid with 
a high-load value (1.15 mmol/g) (Scheme 3.1.2).  The triazole phosphate monomer 3.1.9 
was synthesized in good yield and purity according to previously reported methods.5 
Phosphorylation of propargyl alcohol with Nb-tagged phosphonyl chloride 3.1.7, 
followed by a “Click”-capture event of the corresponding azide, efficiently yielded the 
desired monomer 3.1.9 (Scheme 3.1.2).  The triazole phosphate monomer and the silica 
oligomeric triazole phosphate reagents (Si-OTPn) were synthesized on gram scale as 
stable, free-flowing solids. 
Scheme 3.1.2. Synthesis of Silica-Supported Oligomeric Triazole Phosphate (Si-OTPn). 
 
 With Si-OTPn 3.1.10a in hand, the hybrid material was evaluated for the ability to 
(triazolyl)methylate a variety of nucleophiles, including amines, phenols, thiophenols and 
sulfonamides, in good yields and high purity with chromatography-free purification.  The 
reaction was carried out overnight in a pressure tube with different nucleophiles  
(1 equiv.), Si-OTPn (1.5 equiv.), Cs2CO3 (3.0 equiv.), and NaI (0.2 equiv.) in DMF at 90 
ºC.  The reaction mixture was diluted with EtOAc and filtered through a pad of Celite to 
furnish the corresponding (triazolyl)methylated products. Optimal results were achieved 
in DMF compared to THF.  A variety of N-, O-, and S-nucleophiles were utilized for 
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nucleophilic substitution reactions with Si-OTPn, which afforded the desired 
(triazolyl)methylated products (3.1.11a–3.1.11g) in excellent yield and high purity 
(>85%, determined by LC-MS) (Table 3.13).  In all cases, similar results were obtained 
as compared to Si-OBPn in THF in Table 3.1.2. 
Table 3.1.3. Triazolation utilizing Si-OTPn with O-, N- and S-nucleophiles. 
 
 Building on these results, the project was expanded to the synthesis of additional 
variants of Si-OTPn hybrid reagents (3.1.10b–3.1.10d, Figure 3.1.3) on gram scales as 
free-flowing powders in an analogous fashion to the Si-OTPn reagent in Scheme 3.1.2.  
These Si-OTPn hybrid reagents were utilized for (triazolyl)methylation of O- and S-
nucleophiles.  In all cases, (triazolyl)methylated products (3.1.11h–3.1.11m) were 
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Figure 3.1.3: Various Silica-Supported Oligomeric Triazole Phosphate (Si-OTPn) 
analogs. 
 
Table 3.1.4. Triazolation of N-, O- and S-nucleophiles utilizing various Si-OTPn analogs. 
 
 Overall, this section demonstrated the synthesis and utilization of silica-
supported, hybrid Si-ROMP benzylating and (triazolyl)methylating reagents.  A 
metathesis catalyst-armed surface (CAS)-initiated polymerization was key to 
functionalization of units off the silica particle surface. With this technology, the 
developed Si-immobilized were synthesized on gram scale as stable, free-flowing 
powders. The resulting Si-immobilized ROMP reagents can be removed by simple 
filtration, thus eliminating the precipitation step. SEM imaging was utilized to 
demonstrate the grafting of the corresponding oligomer and the inherent morphology of 
the hybrid materials.  Utilization of these reagents in one-pot protocols for the synthesis 
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Section: 3.2 Application of Silica-Supported Alkylating Reagents in a One-Pot 
Protocol for the Synthesis of Diverse Benzoxathiazepine 1,1-Dioxides. 
 
3.2.1 Introduction 
The utilization of immobilized reagents in one-pot protocols can further integrate 
synthesis, diversification, and purification into one parallel process to rapidly expand 
efforts in early stage drug discovery.2,35 In this section, we report expanded applications 
of our developed silica-immobilized benzyl phosphate Si-OBPn and triazole phosphate 
Si-OTPn reagents (discussed in section 3.1),4,36 in the establishment of one-pot, sequential 
protocols for facile library synthesis of diverse benzothiaoxazepine-1,1-dioxides  
(Figure 3.2.1).37 
 
Figure 3.2.1. Benzothiaoxazepine-1,1-Dioxides in a One-Pot Protocol. 
 
Multi-component reactions in one-pot processes provide efficient pathways to 
synthesize complex heterocyclic scaffolds from simple building blocks.38  One-pot 
strategies enable the formation of multiple bonds and stereocenters in one synthetic step, 
as well as reducing purification resources, time, and waste.  This process minimizes the 
need of work-up and chromatographic separations of intermediary reactions.  Among 
several literature reports, elegant efficient efforts by Hayashi39 have demonstrated the 
power of consecutive one-pot, sequential procedures to complete multi-step syntheses. 
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Benzothiaoxazepine-1,1-dioxides are unique scaffolds,40 that have shown a broad 
range of bioactivities, including inhibition of a variety of enzymes.41  Substituted 
benzothiaoxazepine-1,1-dioxides have shown activity as antipsychotic agents,42 
modulators of histamine H3-recceptor,43 glucokinase activators,44 modulators of AMPA 
receptors45 and monoacidic inhibitors of KEAP146 (Figure 3.2.2). The current demand is 
to develop step-economical methods to facilitate the synthesis of these biologically 
inspired sultams in a desirable fashion.  In light of our recent approaches for the synthesis 
of scaffolds containing benzothiaoxazepine-1,1-dioxides,47 we herein elaborate the 
importance of 2-difluoroarylsulfonyl chloride (3.2.4) as an attractive building block for 
the generation of these scaffolds. 
 






















































3.2.2 Results and Discussion  
The titled silica phosphate reagents, Si-OBPn and Si-OTPn, were synthesized from 
norbornenyl-functionalized silica (Si-Nb) 3.1.1 and Nb-tagged phosphate monomers 
3.2.2a–3.2.2e using a similar protocol to that described in section 3.1 (Scheme 3.1.1). 
Surface-initiated polymerization of these monomers onto the surface of silica was 
achieved using the Grubbs second-generation catalyst (G-II) in toluene-CH2Cl2.33 
Following the reported procedure, the desired Si-ROMP benzylating Si-OBPn 3.23a–
3.3.3c (n ~ 50) and triazolating Si-OTPn 3.2.3d–3.2.3e (n ~ 50) reagents were furnished 
as free-flowing solids on gram-scale. 
Scheme 3.2.1. Synthesis of Si-Supported Oligomeric Benzyl (Si-OBPn) and Triazole (Si-
OTPn) Phosphates. 
  
 With Si-OBPn reagents 3.2.3a–3.2.3c and (triazolyl)methylating reagents Si-OTPn 
3.2.3d–3.2.3e in hand, we directed our attention to their utilization in the titled one-pot 
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nucleophilic aromatic substitution (IM-SNAr), alkylation (Si-OBPn and Si-OTPn), and 
intermolecular SNAr reactions using the same solvent (DMF) in an overall one-pot 
protocol.  The synthesis started with commercially available 2,4-difluorobenzenesulfonyl 
chloride (3.2.4) and a simple chiral amino alcohol 3.2.5 to achieve sulfonylation at room 
temperature using Et3N in DMF.  The resulting sulfonamide 3.2.6 next underwent facile 
IM-SNAr cyclization using microwave conditions at 140 ºC in the same pot to furnish 
benzothiaoxazepine-1,1-dioxide 3.2.7 (Scheme 3.2.2).  Further diversification of 3.2.7 
was achieved through use of Si-OBPn or Si-OTPn for benzylation and 
(triazolyl)methylation, respectively.  Successful benzylations using Si-OBPn 3.2.3a of the 
corresponding cyclic sulfonamides were achieved in the same pot by heating the reaction 
mixture to 80 ºC for 10–12 hours.  The final intermolecular SNAr reaction (150 ºC under 
microwave irradiation) with a variety of cyclic five- or six-membered secondary/aromatic 
amines afforded diverse benzofused sulfonamides 3.2.10a–3.2.10e in the same pot (Table 
3.2.1, entries 1–5).  









































































In the next stage, different variants of silica-immobilized benzylating reagents 
3b–3c were employed in one-pot procedures, and the desired N-benyzlated 
benzoxathiazepine 1,1-dioxides 10f–10j were achieved after the final intermolecular 
SNAr reactions (DMF, 150 ºC under microwave irradiation), using a variety of cyclic 
five-membered secondary/aromatic amines (Table 3.2.1, entries 6–10). 
Table 3.2.1. One-pot Synthesis of Benzothiaoxazepine-1,1-Dioxides Utilizing Various Si-
OBP Reagents. 
 
 We next studied diversifications via sulfonamide N-(triazolyl)methylation 
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were driven by the biological importance of 1,2,3-triazole-containing scaffolds,34 as well 
as their effective mimicry of trans-amide bonds due to similarities in size, planarity, 
dipole, and H-bonding capabilities.48 




To consider the biological importance of benzoxathiazepine 1,1-dioxides (Figure 
3.2.1), we planned to design a small library of diverse N-(triazolyl)methylated 
benzoxathiazepine 1,1-dioxides derivatives using a similar one-pot protocol as described 
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amines afforded the desired N-(triazolyl)methylated benzoxathiazepine 1,1-dioxides 
3.2.11a–3.2.11e in high yield, 70–92% over four sequential steps, representing average 
yields of 92.5–98% per reaction (av/rxn) (Table 3.2.2).  
 Overall, this section demonstrated the applications of silica-immobilized reagents 
(Si-OBPn and Si-OTPn) reagents in the diversification of core scaffolds to achieve the 
synthesis of a variety of unique benzoxathiazepine 1,1-dioxides in a one-pot, sequential 
protocol.  Efforts to expand the scope of these reagents to various drug-related molecules, 
and improvement in synthesis and scale-up are continued for application in diversity-
oriented synthesis. 
Section 3.3: Synthesis of High-load, Hybrid Silica-immobilized Heterocyclic Benzyl 
Phosphate (Si-OHBP) and Triazolyl Phosphate (Si-OHTP) Alkylating Reagents. 
 
3.3.1 Introduction 
Heterocycles are prevalent in small molecule drugs and natural compounds50 and 
often they are used to manipulate structural and electronic properties of small molecules 
that are key to regulating molecular lipophilicity, polarity, and hydrogen bonding 
capacity. 51  Despite these attributes, introduction of N-heterocyclic functionality into core 
structures can be problematic in subsequent purification stages due to increased polarity 
and basicity in combinatorial synthesis.  Immobilized reagents offer many advantages 
that can potentially circumvent these issues. As noted previously, compared to traditional 
solution-phase synthesis, solid-phase techniques52 have shown advantages in simplifying 
the purification process, especially in flow-through chemistry and automated synthesis.53 
In the previous sections (3.1, 3.2), we reported the development and utilization of silica-
immobilized benzyl phosphate Si-OBPn and triazole phosphate Si-OTPn as efficient 
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alkylating reagents, as well as their applications in one-pot protocols.37 In this section we 
report the development of hybrid silica-immobilized oligomeric hetero-benzyl phosphates 
(Si-OHBPn) and hetero-triazolyl phosphate (Si-OHTPn) as efficient alkylating reagents.54  
We envision that these high load ROMP-derived reagents are highly applicable in 
purification-free protocols to install heterocycles, namely pyridines and pyridine-
substituted triazoles in N-, O-, and S-nucleophilic species, in the synthesis of complex 
molecules.  In addition to these benefits, the titled Si-OHBPn and Si-OHTPn reagents are 
bench stable, environmental friendly, and have ease of purification via simple filtration 
through Celite.  Furthermore, the low cost, commercial availability of the starting 
pyridine methanol derivatives, as compared to their corresponding bromomethyl 
pyridines, is another advantage that inspired us to produce the titled silica-supported 
phosphate analogs. Taken collectively, these examples have showcased the development 
of high-load, ROMP-derived silica-immobilized reagents and their utilization in a variety 
of organic reactions.  
3.3.2 Results and Discussion  
The route to the titled phosphates began with reduction of exo-norbornenyl carbic 
anhydride (readily-derived from commercially available endo-norbornenyl carbic 
anhydride)5 to the corresponding diol using LiAlH4, followed by phosphorylation of the 
norbornenyl (Nb) exo-diol using freshly distilled POCl3 and Et3N, to afford the Nb-
phosphorochloridate 3.1.7 described in section 3.1 (Scheme 3.1.1) as a white solid in 
73% yield.  This reagent was conveniently stored for several months as a solid under 
argon in a desiccator for use in preparing various phosphate monomer analogs.  Addition 
of 3.1.7 into a solution containing hetero-benzyl alcohol, NMI, and CH2Cl2 at room 
 99 
temperature cleanly afforded hetero-benzylic phosphates 3.3.3a–3.3.3b in good yields 
(65–70%).  Similarly, phosphorylation of Nb-tagged phosphorochloridate 3.1.7 with 
propargyl alcohol, followed by a “Click”-capture event of an azidomethyl pyridine, 
afforded the corresponding hetero-benzylic triazole phosphate monomers 3.3.4a–3.3.4b 
in good yields (63–65% over two steps). 
Scheme 3.3.1: Synthesis of Hetero-benzyl and Hetero-triazole Phosphate Monomers. 
 
 Utilizing a similar protocol demostrated in the previous section 3.1,4 (MeO)3Si-
(CH2)2-(Nb) 3.1.1 was synthesized. With these Nb-tagged silica particles in hand, 
surface-initiated polymerization of Nb-tagged phosphate monomers 3.3.3a–3.3.3b and 
3.3.4a–3.3.4b onto the silica surface was achieved using the Grubbs second-generation 
catalyst (G-II), followed by washing with CH2Cl2, to furnish the desired silica-tagged 
heterocyclic phosphates as free-flowing solids possessing experiment loads of 1.1–1.7 
mmol/g (Scheme 3.3.2). 
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Scheme 3.3.2: Synthesis of Silica-Supported Oligomeric Hetero-benzyl (Si-OHBPn) and 
Hetero-triazole  (Si-OHTPn) Phosphates. 
 
 Gram-scale syntheses were next carried out for both Si-ROMP hetero-benzylating 
(Si-OHBPn) and hetero-(triazolyl)methylating (Si-OHTPn) reagents, 3.3.7a–3.3.7b and 
3.3.7c–3.3.7d, respectively. 
I---------------50 µm------------I   I----------------20 µm-----------I  
Figure 3.3.1. SEM images of Si-OHBPn (left) and Si-OHTPn (right). 
The SEM images of Si-OHBPn and Si-OHTPn are shown in Figure 3.3.1 and 
depict grafting of the corresponding monomer onto the silica surface and the inherent 





1. G-II (0.2 equiv.)















2. Tol-CH2Cl2, 45 ºC












































Si-OHBPn and Si-OHTPn 









With the hybrid Si-ROMP materials in hand, efforts were focused on utilization 
of Si-OHBPn 3.37a–3.3.7b as hetero-benzylating reagents.  After investigating various 
reagent stoichiometry ratios, an optimized condition was established. The reactions 
proceeded by using nucleophiles (1 equiv.), Si-OHBPn (1.5 equiv.), Cs2CO3 (3.0 equiv.), 
and NaI (0.2 equiv.) in 0.1 M THF at 80 ºC (oil bath temperature) in a sealed pressure 
tube.  With these optimized conditions, the hetero-benzylation of a variety of N-, O-, and 
S-nucleophiles was achieved using two silica oligomeric hetero-benzyl phosphates (Si-
OHBPn, 3.3.7a, 3.3.7b) (Table 3.3.1).   












































































1) R2–XH (1.0 equiv.) 
   Cs2CO3 (3.0 equiv.) 
   NaI (0.2 equiv.)





R1 = 3-pyridyl (3.3.7a)
























Various phenols and thiophenols, as well as more complex sulfonamides, were 
successfully alkylated to afford the corresponding hetero-benzylated products 3.3.8a–
3.3.8i (Table 3.3.1).  In all cases, simple filtration through a Celite® SPE allowed the 
products to be isolated in good to excellent yields (70–99%) and desired crude purity 
(>90%, calculated by UV area percent from HPLC analysis). 
With the hybrid Si-ROMP materials in hand, efforts were focused on utilization 
of Si-OHBPn 3.37a–3.3.7b as hetero-benzylating reagents.  After investigating various 
reagent stoichiometry ratios, an optimized condition was established. The reactions 
proceeded by using nucleophiles (1 equiv.), Si-OHBPn (1.5 equiv.), Cs2CO3 (3.0 equiv.), 
and NaI (0.2 equiv.) in 0.1 M THF at 80 ºC (oil bath temperature) in a sealed pressure 
tube.  With these optimized conditions, the hetero-benzylation of a variety of N-, O-, and 
S-nucleophiles was achieved using two silica oligomeric hetero-benzyl phosphates (Si-
OHBPn, 3.3.7a, 3.3.7b) (Table 3.3.1).  Various phenols and thiophenols, as well as more 
complex sulfonamides, were successfully alkylated to afford the corresponding hetero-
benzylated products 3.3.8a–3.3.8i (Table 3.3.1).  In all cases, simple filtration through a 
Celite® SPE allowed the products to be isolated in good to excellent yields (70–99%) and 
desired crude purity (>90%, calculated by UV area percent from HPLC analysis). 
In the next step, silica-immobilized triazole phosphate derivatives 3.3.7c–3.3.7d 
were synthesized on gram scale with a load of 1.1–1.3 mmol/g as free-flowing powders.  
Use of these reagents in nucleophilic substitution reactions with N-, O-, and S- 
nucleophiles afforded (triazolyl)methylated products 3.3.9a–3.3.9f in excellent yields 
(81–93%) and purities (>90%, calculated by UV area percent from HPLC analysis) using 
simple filtration through a Celite® SPE (Table 3.3.2). 
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Table 3.3.2: Hetero-(triazolyl)methylation of N-, O- and S-nucleophiles Utilizing Si-
OHTPn 
 
Efforts to expand the scope of these reagents in multicomponent reactions (one-
pot processes) towards drug-related heterocycles, and improvement in scale-up are 
continued for further applications in diversity-oriented synthesis.  These efforts and the 
gathering of corresponding results continue, and will be reported in due course. The 
crude purities of selected products utilizing silica-supported alkylating reagents were also 

























































































1) R2–XH (1.0 equiv.) 
   Cs2CO3 (3.0 equiv.) 
   NaI (0.2 equiv.)
   DMF, 80 ºC, 12 h
(1.5 equiv.)
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Table 3.3.3: Crude Purity analysis by LC/HRMS.  
 
 In conclusion, grafting of Nb-tagged silica particles with functionalized Nb-
tagged heterocyclic phosphate monomers using ROM polymerization efficiently yields 
high-load, hybrid Si-immobilized oligomeric hetero-benzyl (Si-OHBPn) and triazolyl 
phosphates (Si-OHTPn).  The application of these ROMP-derived oligomeric heterocyclic 
phosphate reagents have been demonstrated for diversification of various N-, O- and S-
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Section: 4.1 Recyclable Magnetic Co/C Hybrid ROMP Benzenesulfonate Ester 
(Co/C-OBSE) and Benzenesulfonyl Chloride (Co/C-OBSC) Nanoparticles as Facile 
Methylating/Alkylating Reagent: Development and Applications. 
 
4.1.1 Introduction 
Growing material consumption has resulted in an increasing need for the 
development of sustainable technologies in the production of chemical entities. Recovery 
and recycling of expensive reagents in a more sustainable manner is an important area in 
minimizing environmental impact. The advances in the area of immobilized reagents and 
ring-opening metathesis polymerization (ROMP) for immobilization for a variety of 
soluble, silica and magnetic reagents/scavengers and catalyst were summarized in 
Chapter 1. In Chapter 2 and Chapter 3 we report the development and utilization of 
soluble and silica supported alkylating reagent respectively. In Chapter 4 (Section 4.1) we 
describe the synthesis and utilization of Co/C ROMP-derived oligomeric benzene 
sulfonate ester and benzene sulfonyl chloride (Co/C-OBSCn) as efficient 
methylating/alkylating reagents for various carboxylic acids. 
 Among many grafted-hybrid materials, magnetic-immobilized nanoparticle (NPs) 
reagents and catalysts have emerged recently as a powerful approach combining the high-
load nature of grafted-polymers with the adventitious isolation and recyclability.1 The 
synthesis of hybrid materials, which combine the properties of Co/C magnetic 
nanoparticles with a high-load functionalized material, are well suited to address the 
limitations of traditional immobilized reagents (e.g functionalized silicas and polystyrene 
resins). In this regard,2 recent developments in our laboratories in collaboration with 
Oliver Reiser (University of Regensburg), Robert Grass (TurboBead), and Materia, Inc. 
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(Pasadena, CA) have demonstrated advancements in grafting high load ROMP-derived 
oligomeric reagents and scavengers onto SiO23 and magnetic Co/C surfaces4 for 
application in facilitated synthesis and sequestration protocols. 
Previous efforts in the Hanson group have demonstrated a sequestration protocol 
as a variant of the Mitsunobu reaction5 utilizing Nb-tagged reagents in conjunction with 
Nb-tagged Silica and Co/C NPs to sequester all by-products in the reaction (Figure 
4.1.1).4c Several variants of the Mitsunobu reaction have been developed for facile 
purification of the desired product from unwanted by-products, which include tagged, 
immobilized and water-soluble reagents.6 In this protocol, facile sequestration of the 
utilized and excess reagents was achieved by three methods such as: (i) free catalyst in 
solution, (ii) surface-initiated catalyst-armed silica,7 or (iii) surface-initiated catalyst-
armed carbon-coated (Co/C) magnetic nanoparticles (Nps).8 In, 2013, using the same 
protocol, Hanson and coworkers reported an intramolecular Mitsunobu cyclization4d for 
the synthesis of various benzofused thiadiazepine-dioxides analogs (Figure 4.1.1). 
 
Figure 4.1.1 Norbornenyl-tagged Reagents Nb-TPP and Nb-DEAD and Co/C Np’s for 
MoM Mitsunobu Reactions. 
   
 In continuation to our recent interest for the development of Co/C based ROMP 
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for conducting methylation/alkylation reactions. Common methylating reagents, such as 
dimethyl sulfate, methyl iodide and diazomethane are extensively used in organic and 
medicinal chemistry, but have undesirable physical characteristics that pose safety issues 
when used for routine synthesis, such as toxicity, carcinogenicity and their explosive 
nature.9 Alternative, safe, bench stable, polymer-supported and recyclable methylating or 
alkylating reagents represent a better platform with enhanced safety/toxicity profiles for 
routine synthetic transformations.10 In this section of Chapter 4, we demonstrate the 
synthesis of magnetic Co/C ROMP-derived oligomeric benzenesulfonate ester (Co/C-
OBSEn) and the in situ use of benzenesulfonyl chloride (Co/C-OBSCn)/ROH as efficient 
methylating/alkylating reagents for various carboxylic acids in purification free protocols. 
 
4.1.2 Result and Discussion 
 Starting with the previously reported soluble ROMP-derived oligomeric sulfonyl 
chloride OSC reagent11 sulfonate ester12 and benzenesulfonyl chloride OBSC,13 efforts 
were directed towards the development of the first example of high load magnetic Co/C 
ROMP-derived oligomeric benzenesulfonate ester (Co/C-OBSEn), and benzenesulfonyl 
chloride (Co/C-OBSCn)/ROH (in situ) as efficient methylating/alkylating reagents for 
various carboxylic acids. The alkylated ester reaction products were obtained by simple 
decantation/filtration, evaporation procedure, which makes this method suitable for 
automated parallel synthesis. For this purpose, we first synthesized the soluble OBSEn 
using our previously reported procedure,13 (Scheme 4.1.1), where commercially available 
sodium 4-styrenesulfonate 4.1.1 is treated with thionyl chloride to form sulfonyl chloride. 
ROM polymerization of monomer 4.1.2 is achieved with use of the Grubbs-II catalyst 
 125 
(G-II) and further grinding of resulting oligomeric sulfonyl chloride in wet MeOH 
afforded the desired oligomeric sulfonate ester OBSE 4.1.3. The desired methylations of 
carboxylic acids were achieved in greater than 90% yield, when oligomeric 
benzenesulfonate ester is treated with carboxylic acid in the presence of potassium 
carbonate. However the isolation and regeneration of the spent polymeric reagent is 
generally tedious after filtration with SPE cellite or silica. 
Scheme 4.1.1. Synthesis of Soluble Oligomeric Benzenesulfonate Ester (OBSE) 
 
 To synthesize the magnetic version of oligomeric benzenesulfonate ester Co/C-
OBSE, we first generated the Nb-tagged magnetic linker (Co/C-Nb) 4.1.6, which has 
been found to be a suitable precursor for the surface-initiated ROMP of various Nb-
tagged monomers.4 The synthesis of Co/C-Nb 4.1.6 is achieved by copper(I)-catalyzed 
alkyne/azide cyclo-addition reaction using commercially available Co/C-azide 4.1.4 and 
the propargylated bicycle[2.2.1]hept-5-en-2-ylmethanol 4.1.5, (Scheme 4.1.2). The 
reaction was performed under sonication/stirring for 48 hours then Nb-tagged Co/C Nps 
were recovered from the reaction mixture with the aid of a neodymium-based magnet. 
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Scheme 4.1.2. Synthesis of Nb-tagged Co/C Nanoparticles (Co/C-Nb). 
 
 In the next step, Nb-tagged benzenesulfonate ester monomer 4.1.7 is synthesized by 
grinding Nb-tagged sulfonyl chloride 4.1.2 in wet MeOH to afford the desired compound 
4.1.7 in excellent yield and high purity without column chromatography (Scheme 4.1.3). 
Scheme 4.1.3. Magnetic Co/C Hybrid ROMP Benzene Sulfonate Ester NPs (Co/C-OBSE) 
 
 Utilizing our previously reported protocol4 to generate an active ruthenium carbene 
species on the surface of Nb-tagged Co/C nanobeads,  Material 4.1.6 is sonicated with 
Grubbs-II catalyst (G-II, 1.0 equiv. with respect to the loading of Co/C-Nb 4.1.6) at 45 
ºC. Next, Nb-tagged sulfonate 4.1.7 (50 equiv.) monomer was added in solution and 
sonication was carried out further for 6-8 hours to afford the desired ROMPgel-grafted 
onto the surface of the Co/C nano-beads. After quenching with ethyl vinyl ether (EVE), 
the solvent was decanted, and the resulting magnetic solid gel was dried rigorously under 
vacuum, and next crushed for further use. Based on the gain in mass of magnetic polymer 
4.1.8, more than 95% of monomer 4.1.7 was incorporated into the hybrid material, 
resulting in magnetic NPs with a load of 2.1–2.2 mmol/g. For utilization, initial studies 
were focused on the methylation of simple carboxylic acid substrates. The reagent Co/C-

















































4.1.9a–4.1.9e (shown in Table 4.1.2), which afforded excellent yield (88-95%) and purity 
after celite SPE filtration. The spent Co/C-OBSE reagent was isolated with the help of a 
neodymium magnet. 
Table 4.1.2. Methylation of Various Carboxylic Acids Utilizing Magnetic Co/C-OBSE. 
 
 Efforts were next directed towards in situ generation from the magnetic 
benzenesulfonyl chloride, Co/C-OBSCn, which could subsequently be used for direct 
alkylations of carboxylic acid in the presence of alcohols.  As a result, we focused our 
attention towards the synthesis and utilization of magnetic sulfonyl chloride Co/C-
OBSCn. In this regard, grafting of Nb-tagged benzenesulfonyl chloride 4.1.2 was 
successfully achieved on gram scale by using a previously described ROMP protocol, 
which afforded hybrid ROMP-derived magnetic benzenesulfonyl chloride NPs Co/C-
















































Scheme 4.1.4. Synthesis of Magnetic Co/C Hybrid ROMP Benzene Sulfonyl Chloride 
NPs Co/C-OBSC 4.1.10. 
 
 The images were taken by transmission electron microscopy (TEM) to observe and 
evaluate the graphting of the corresponding Nb-tagged monomers onto the surface of the 
Co/C-particles nanoparticle. 
 I-----------100nm-------------I    I--------------20nm------------I  
 Figure 4.1.2 TEM Images of Co/C-OBSE 4.1.8 and Co/C-OBSC 4.1.10. 
 Direct methylations of carboxylic acids were successfully achieved by utilizing 
magnetic reagent Co/C-OBSCn 4.1.10 in the presence of a slight excess of MeOH (6–10 
equiv.). Various simple aromatic and aliphatic carboxylic acids were subjected to 
methylation 4.1.11a–4.1.11h, which afforded the majority of products in excellent yields 
(>90%) and purity (shown in Table 4.1.3). In addition, chemoselective methylation of a 


























Table 4.1.3. Methylation of Various Carboxylic Acids Utilizing Magnetic Co/C-OBSCn 
 
 In light of the wide applications of esterification reactions in pharmaceutical, 
agrochemicals, plastics, perfumes, and biodiesels,14 we next directed studies to further 
explore the scope of the magnetic Co/C-OBSC reagent for alkylation of carboxylic acids 
with various alcohols. In this regard, reaction of carboxylic acids with deuterated 
methanol was successfully achieved in excellent yield 90–95 % and purity (Table 4.1.4). 
Alkylation in the presence of different alcohols afforded the desired alkylated ester in  
72–82% yield. Moreover, the continued extensive alkylation studies with a variety of 

























































Table 4.1.4. Alkylation of Carboxylic Acids Utilizing Magnetic (Co/C-OBSCn). 
 
 Our next focus was to regenerate the corresponding byproduct magnetic sulfonic 
acid NP salts, Co/C-OBSA 4.1.13. To achieve this goal, the spent reagent was treated 
with SOCl2 in toluene in the presence of a catalytic amount of DMF, which successfully 
afforded magnetic sulfonyl chloride NPs, Co/C-OBSCn 4.1.10 (Scheme 4.1.5), without 
considerable loss of magnetic material. Multiple regenerations (up to ten times) were 
successfully achieved without any reduction in performance using the same protocol.   
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 This exciting result is currently being pursued in several related studies. In 
additional to successful regeneration, we further utilized the spent magnetic 
benzenesulfonic acid Co/C-OBAS for acid-catalyzed coupling of indole with methyl 
vinyl ketone, as well as for the alcoholysis of cyclic anhydride at room temperature 
(Scheme 4.1.6). The spent magnetic sulfonic acid was recovered by external magnet and 
the coupling products were achieved in 85–90 % yield. 
 
Scheme 4.1.6. Acid Catalyzed Reactions Using Co/C Benzenesulfonic acid NPs (Co/C-
OBSAn). 
 
 In conclusion, we have demonstrated the utilization of high load magnetic Co/C 
ROMP-derived oligomeric benzenesulfonate ester Co/C-OBSEn and benzenesulfonyl 
chloride Co/C-OBSCn as an efficient methylating/alkylating reagent for a variety of 
carboxylic acids. These alkylations were achieved by simple decantation and filtrations of 
alkylated products in purification free protocols. The spent byproduct magnetic 
benzenesulfonic acid Co/C-OBSAn has been successfully recycled and re-used multiple 
times without loss of activity. 
 
  




























Section: 4.2 Synthesis of High-load, Hybrid Co/C-Oligomeric Phosphonyl 




The development of purification free protocols based on ROMP strategies in 
combination with magnetic Co/C tagging have recently introduced several efficient 
magnetic reagents and catalyst in the area of facilitated synthesis.4 Despite advances in 
this area, high-load Co/C hybrid ROMP reagents are still desired for its applications as a 
green, recyclable ligands/catalysts, reagents and scavengers. In Chapter 4 (Section 4.2) 
we describe the synthesis and utilization of Co/C ROMP-derived oligomeric phosphonyl 
dichlorides Co/C-OPCn as an efficient magnetic scavenging agent for a variety of amines. 
In 2006, Hanson and coworkers generated a ROMP-derived oligomeric soluble 
phosphonyl dichloride OPCn as a scavenging agent for a variety of amines.15 The 
synthesis of Nb-tagged bicyclo[2.2.1]hept-5-en-2-ylphosphonic monomer (Nb-PC) 4.2.2 
was conveniently achieved via Diels–Alder reaction of cyclopentadiene and vinyl 
phosphonic dichloride 4.2.1 which was derived from vinyl phosphonic acid 4.2.1 
(Scheme 4.2.1). The soluble OPC reagent 4.2.3 was exploited in efficient room 
temperature scavenging of primary and secondary amines (present in excess) following a 




Scheme 4.2.1. Soluble High-load Oligomeric Phosphonyl Dichloride (OPC). 
 
The inherent chemistry of phosphonyl dichlorides allowed efficient and 
exhaustive scavenging for a variety of amines (present in excess) in the reaction mixture. 
In this regard, we aimed to prepare a magnetic version of oligomeric phosphonyl chloride 
OPCn as a scavenging agent for amines. It was envisioned that the magnetic version of 
this reagent could enable simple and rapid isolation through magnetic decantation. 
 
4.2.2 Results and Discussion 
The Co/C magnetic variant 4.2.4 was generated via ROM polymerization of (Nb-
PC) 4.2.2, with Nb-tagged Co/C nanobeads linker 4.2.6 using the same protocol as 
outlined in Section 4.2. Under optimized conditions, Co/C-OPCn 4.2.4 was produced on 
gram scale with a load value of 4.4 mmol/g. The Co/C-OPCn was developed as a 
magnetically recoverable scavenging agent with several attractive attributes, including: 
(i) exhaustive scavenging (ii) the facile and selective hydrolysis of phosphonamides and 
phosphonamidates, as well as (iii) potential regeneration.  It should be noted that the 
superiority of the hydrolysis of phosphonamides vs sulfonamides and amides, provides a 
potential application in the recovery of precious amine components used in combinatorial 


























Scheme 4.2.2. Synthesis of Magnetic Co/C Hybrid Oligomeric Phosphonyl Dichloride 
(Co/C-OPCn). 
 
The Co/C-OPCn 4.2.4 was produced on gram-scale (3 grams) and tested for 
efficient scavenging of various amines. In this regard, 0.6 equiv. of Co/C-OPCn was 
found to be sufficient to scavenge excess amines after their reaction with acid chlorides. 
The resulting amides were isolated in high yield and good purity (Scheme 4.2.3). 
Scheme 4.2.3. Utilization of Magnetic Co/C-OPCn for Amide Formations. 
 
 In the next step, various sulfonylation reactions were achieved with an array of 
amines used in excess. In all cases, the excess amines were easily scavenged by magnetic 
Co/C-OPC, and the desired products were isolated with high yield and purity (Scheme 
4.2.4). The magnetic Co/C-OPC was also tested for simple urea-forming reactions using 
an array of isocyanates in the presence of excess amine. It is noteworthy to mention that 
in the reaction with hydroxyl-amines, the magnetic Co/C-OPC displayed chemoselective 
scavenging, whereby it reacted with only the excess of starting amines at RT, leaving the 
carbinol-containing product in solution. The selective scavenging further highlights the 







































Then scav xs amine 


















Scheme 4.2.4 Utilization of Magnetic Co/C-OPCn for Scavenging Amines in 
Sulfonylations and Urea Formations. 
 
 In conclusion, we have demonstrated the synthesis and utilization of high load 
hybrid magnetic oligomeric phosphonyl dichloride Co/C-OPCn as an efficient 
chemoselective scavenger of amines (over alcohols) for use in a variety of coupling 
reactions. The magnetic Co/C-OPCn scavenger is efficiently utilized in amide formations, 
sulfonylations and urea formations with a variety of primary and secondary amines. 
These coupling reactions were achieved by simple decantation and filtrations of desired 
products in purification free protocols. The spent magnetic scavenger is easily isolated 









    Et3N, CH2Cl2
2) Co/C-OPC NPs 
(0.6 equiv.)






















































R = NO2 (95%) 4.2.11d
       Cl    (94%) 4.2.11e
1) 1.5 equiv. R1NH2 
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5.1 General Experimental Methods 
All air- and moisture-sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere. Stirring was achieved with oven-dried magnetic 
stir bars. CH2Cl2, THF, toluene, CH3CN, and Et2O were purified by passage through a 
Solv-Tek (www.solvtek.com) purification system employing activated Al2O2 
(Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518−1520). 
CHCl3 was passed through basic alumina and dried over molecular sieves. Et3N was 
purified by passage through basic alumina or distilled over CaH2 and stored over 
KOH. Flash column chromatography was performed with SiO2 from Mallinckrodt 
Chemicals (V120-25, Silica gel, 60 A, 40–63 μm). SPE purification was performed 
with SiO2 purchased from Sorbent Technology (30930M-25, Silica Gel 60A, 40-63 
µm) and 6 mL empty cartridges were purchased from Silicycle Inc. Thin layer 
chromatography was performed on silica gel 60F254 plates (EMD-5715-7, Merck. For 
Celite-SPE 6 mL empty cartridges were purchased from Silicycle Inc. 
(www.silicycle.com/). Crude mixture was also purified using a Biotage® Isolera 
automated flash column chromatography system. TLC spots were observed using 
KMnO4 stain. Deuterated solvents were purchased from Cambridge Isotope 
laboratories. 1H, 13C NMR spectra were recorded on a Bruker DRX-400 spectrometer 
operating at 400 MHz, 100 MHz respectively as well as a Bruker DRX-500 
spectrometer operating at 500 MHz, 125 MHz respectively. Gas chromatography 
(GC) was performed using an Agilent Technologies 6890N with data processing on a 
Dell desktop. GC/mass spectrometry was performed using a Quattro micro GC 
(Micromass UK Limited).  High-resolution mass spectrometry (HRMS) was recorded 
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on a LCT Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH). 
Silica and Magnetic nanoparticles were analyzed by transmission electron 
microscopy (CM30 ST-Philips, LaB6 cathode, operated at 300 kV point resolution ~ 4 
Å), scanning electron microscopy (Hitachi S-2700 equipped with a quartz PCI digital 
capture). FTIR spectroscopy on soluble compounds was performed using a Shimadzu 
FTIR-8400S instrument. Grubbs catalysts (G-I, G-II) were generously provided by 
Materia Inc.  Azide bearing magnetic nanoparticles was purchased from Turbo Beads 
ETH Zurich. Observed rotations at 589 nm, 20 ºC were measured using an 
AUTOPOL IV Model automatic polarimeter. All library syntheses were carried out in 
1-dram vials utilizing Anton Parr ® Synthon 3000 microwave platform with parallel 
evaporations performed using a GeneVac EZ-2 plus evaporator. Samples were diluted 
in DMSO and purified utilizing an elution of water (modified to pH 9.8 through 
addition of NH4OH) and CH3CN, with a gradient increasing to 20% in CH3CN over 4 
minutes at a flow rate of 20 mL/min.  The preparative gradient, triggering thresholds, 
and UV wavelength were selected based on the HPLC analysis of each crude sample.  
Analytical analysis of each sample after purification employed a Waters Acquity 
system with UV and mass detection (Waters LCT Premier).  The analytical method 
utilized a Waters Aquity BEH C18 column (2.1 x 50 mm, 1.7 um) eluting with a 
linear gradient of 5% water (modified to pH 9.8 through addition of NH4OH) to 100% 




5.2 Experimentals for Chapter 2.1 
“Click”-Capture, Ring-Opening Metathesis Polymerization (ROMP), Release: 
Facile Triazolation Utilizing ROMP-Derived Oligomeric Phosphates. 
Experimental Section and Characterization data        (SI-146–SI-173) 
1H, 13C, Spectra for all Relevant Compounds         (SI-174–SI-215) 
General procedure A for phosphorylation of propargyl alcohol with Nb-tagged 
phosphonyl chloride. 
 
 To a flame-dried 25 mL RB flask under argon atmosphere was added Nb-
tagged phosphoryl chloride 2.1.3 (1.55 g, 6.61 mmol) in CH2Cl2 (30 mL), followed by 
the addition of anhydrous Et3N (2.3 mL, 16.5 mmol) and anhydrous DMAP (45 mg, 
0.33 mmol) at 0 ºC.  To this mixture was added propargyl alcohol (0.63 mL, 10.6 
mmol), which was stirred for 5 hrs at rt (TLC analysis).  Upon completion, the 
reaction was concentrated in vacuo and purified by gradient flash chromatography 



















Utilizing general procedure A, 2.1.4 (1.36 g, 5.35 mmol, 80%) was isolated as a white 
solid. 
Mp = 101 ºC. 
FTIR (neat): 3290, 2968, 2123, 1288, 1068, 1029 cm-1; 
1H NMR (400 MHz, CDCl3): δ 6.23 (s, 2H), 4.74 (dd, J = 10.0, 2.5 Hz, 2H), 4.26-
4.18 (m, 4H), 2.55-2.49 (m, 3H), 2.10-2.07 (m, 2H), 1.39-1.28 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 137.5, 76.4, 69.7 (d, JCP = 8.0 Hz), 54.6 (d, JCP = 4.4 
Hz), 45.0, 43.8, 42.1; 
31P NMR (CDCl3, 162 MHz) δ 2.32, -3.84 (dr = 7.4:1); 








General procedure B for the [3+2] Huisgen “click” reaction for the generation of 
Monomers 2.1.5a–i. 
 
 To a stirring mixture of 2.1.4 (1 equiv.) and azide (2 equiv.) in CH2Cl2 was 
added CuSO4•5H2O (0.3 equiv) and Na•ascorbate (0.3 equiv) in tBuOH:H2O:CH2Cl2 
(2:2:1) (0.2 M).  The reaction mixture was stirred at rt for 14 hrs, after which the 
reaction mixture was quenched with water and extracted with CH2Cl2.  The combined 
organic layer was washed with brine, dried (Na2SO4), and concentrated in vacuo.  The 
crude mixture was purified by gradient flash chromatography (8:2 EtOAc:hexane to 

























Utilizing general procedure B, 2.1.5a (6.0 g, 14.38 mmol, 82%) was isolated as a 
white solid. 
Mp = 128 ºC 
FTIR (neat):  3137, 2925, 1612, 1514, 1463, 1286, 1251, 1178, 1033 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.65 (s, 1H), 7.27-7.25 (m, 2H), 6.92-6.90 (m, 2H), 
6.21 (t, J = 1.8 Hz, 2H), 5.48 (s, 2H), 5.19 (d, J = 9.9 Hz, 2H), 4.14-4.01 (m, 4H), 
3.82 (s, 3H), 2.51 (quin, J = 1.7 Hz, 2H), 2.11-2.05 (m, 2H), 1.39-1.29 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 160.1, 137.6, 137.4, 129.9, 126.4, 124.0, 114.6, 69.5 
(d, JCP = 7.9 Hz), 59.8 (d, JCP = 5.0 Hz), 55.4, 53. 9, 45.0, 43.7, 42.4; 
31P NMR (CDCl3, 162 MHz) δ ppm 2.03, -3.66 (dr = 6.3:1); 
















Utilizing general procedure B, 2.1.5b (2.07 g, 5.16 mmol, 88%) was isolated as a 
colorless thick liquid. 
FTIR (neat):  2925, 1455, 1284, 1120, 1064, 1033, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.65 (s, 1H), 7.18-7.15 (m, 4H), 6.19 (s, 2H), 5.48 (s, 
2H), 5.16 (d, J = 9.9 Hz, 2H), 4.05-3.98 (m, 4H), 2.48 (m, 2H), 2.34 (s, 3H), 2.08-
2.05 (m, 2H), 1.36-1.24 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 143.0, 139.0, 137.5, 131.4, 130.0, 128.4, 124.1, 69.5 
(d, JCP = 7.9 Hz),, 59.9 (d, JCP = 5.0 Hz), 54.3, 44.9, 43.7, 42.1, 21.3; 
31P NMR (CDCl3, 162 MHz) δ ppm 1.97, -3.67 (dr = 8.2:1); 














Utilizing general procedure B, 2.1.5c (1.7 g, 4.23 mmol, 77%) was isolated as a 
colorless thick liquid. 
FTIR (neat):  2960, 1456, 1284, 1120, 1064, 1033, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.57 (s, 1H), 7.30-7.15 (m, 4H), 6.20 (s, 2H), 5.53 (s, 
2H), 5.16 (d, J = 9.9 Hz, 2H), 4.07-3.99 (m, 4H), 2.28 (s, 3H), 2.27-2.23 (m, 2H), 
2.10-2.06 (m, 2H), 1.37-1.29 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 142.8, 137.3, 136.9, 132.2, 131.1, 129.5, 129.3, 
126.8, 123.8, 69.5 (d, JCP = 7.9 Hz), 59.7 (d, JCP = 5.1 Hz) 52.4, 44.8, 43.6, 42.0, 19.0; 
31P NMR (CDCl3, 162 MHz) δ ppm 2.00, -3.74 (dr = 8.2:1); 














Utilizing general procedure B, 2.1.5d (1.74 g, 4.13 mmol, 71%) was isolated as a 
white solid. 
Mp = 125 ºC 
FTIR (neat):  3251, 2932, 1453, 1254, 1117, 1036, 1018 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.72 (s, 1H), 7.36 (dt, J = 9.1, 2.5 Hz, 2H), 7.24 (dt, J 
= 9.1, 2.5 Hz, 2H), 6.21 (s, 2H), 5.50 (s, 2H), 5.22 (d, J = 9.9 Hz, 2H), 4.07-4.03 (m, 
4H), 2.52-2.51 (m, 2H), 2.12-2.10 (m, 2H), 1.39-1.32 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 143.3, 137.3, 135.0, 132.9, 129.5, 129.4, 124.1, 69.4 
(d, JCP = 7.9 Hz), 59.7 (d, JCP = 5.1 Hz), 53.6, 44.8, 43.6, 42.0; 
31P NMR (CDCl3, 162 MHz) δ ppm -3.66; 














Utilizing general procedure B, 2.1.5e (1.76 g, 4.34 mmol, 74%) was isolated as a 
white solid. 
Mp = 147 ºC 
FTIR (neat):  2966, 1556, 1451, 1384, 1251, 1164, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.71 (s, 1H), 7.31-7.28 (m, 2H), 7.10-7.06 (m, 2H), 
6.21 (s, 2H), 5.50 (s, 2H), 5.22 (d, J = 9.9 Hz, 2H), 4.11-4.04 (m, 4H), 2.52-2.51 (m, 
2H), 2.12-2.10 (m, 2H), 1.40-1.32 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 163.1 (d, 1JCF = 245 Hz), 161.9, 143.5, 137.3, 130.1 
(3JC–F = 8.4 Hz), 124.1, 116.2 (2JC–F = 21.7 Hz), 69.6 (d, JCP = 7.9 Hz), 59.8 (d, JCP = 
5.1 Hz), 53.8, 44.9, 43.7, 41.9; 
31P NMR (CDCl3, 162 MHz) δ ppm 2.14, -3.66 (dr = 10.3:1); 













methanobenzo[e][1,3,2]dioxaphosphepine 3-oxide (2.1.5f). 
 
Utilizing general procedure B, 2.1.5f (2.6 g, 5.71 mmol, 73%) was isolated as a white 
solid. 
Mp = 159 ºC 
FTIR (neat):  2967, 1456, 1367, 1284, 1120, 1064, 1033, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.79 (s, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.1 
Hz, 2H) 6.22 (m, 2H), 5.60 (s, 2H), 5.23 (d, J = 10.1 Hz, 2H), 4.10-4.03 (m, 4H), 
2.58-2.51 (m, 2H), 2.12-2.05 (m, 2H), 1.39-1.32 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 143.4, 138.3, 137.5, 137.3, 128.3, 126.2, 124.8, 
123.5, 69.5 (d, JCP = 7.9 Hz), 59.7 (d, JCP = 5.1 Hz), 53.6, 44.8, 43.6, 42.0; 
31P NMR (CDCl3, 162 MHz) δ ppm 2.20, -3.66 (dr = 8.8:1); 














Utilizing general procedure B, 2.1.5g (1.1 g, 2.79 mmol, 70%) was isolated as a white 
solid. 
Mp = 148 ºC 
FTIR (neat):  2962, 1552, 1456, 1286, 1140, 1063, 1056, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.71 (s, 1H), 6.21 (t, J = 1.8 Hz, 2H), 5.24 (d, J = 10.2 
Hz, 2H), 4.19 (d, J = 7.5 Hz, 2H), 4.11-4.07 (m, 4H), 2.53-2.51 (m, 2H), 2.12-2.09 
(m, 2H), 1.89-1.86 (m, 1H), 1.76-1.61 (m, 4H), 1.41-1.32 (m, 2H), 1.20-1.13 (m, 4H), 
1.04-0.96 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 142.4, 137.3, 124.5, 69.4 (d, JCP = 7.9 Hz), 59.8 (d, 
JCP = 5.1 Hz), 56.6, 44.8, 43.6, 42.0, 38.7, 30.5, 26.0, 25.5; 
31P NMR (CDCl3, 162 MHz) δ ppm 1.95, -3.60 (dr = 8.4:1); 














Utilizing general procedure B, 2.1.5h (1.31 g, 2.8 mmol, 89%) was isolated as a white 
solid. 
Mp = 172 ºC 
FTIR (neat):  2925, 1452, 1287, 1250, 1164, 1037, 1018 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.73 (s, 1H), 7.54-7.52 (m, 2H), 7.20-7.18 (m, 2H), 
6.21 (t, J = 1.8 Hz, 2H), 5.51 (s, 2H), 5.22 (d, J = 10.2 Hz, 2H), 4.10-4.03 (m, 4H), 
2.53 (t, J = 1.7 Hz, 2H), 2.13-2.10 (m, 2H), 1.40-1.35 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 143.3, 137.3, 133.4, 132.4, 129.7, 124.1, 123.1, 
69.4(d, JCP = 7.9 Hz), 59.7 (JCP = 5.0 Hz), 53.6, 44.8, 43.6, 41.9. 
31P NMR (CDCl3, 162 MHz) δ ppm -3.67; 














Utilizing general procedure B, 2.1.5i (1.24 g, 3.28 mmol, 56%) was isolated as an off-
white solid. 
Mp = 143 ºC. 
FTIR (neat): 3139, 2962, 1461, 1286, 1064, 1033, 1008 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.77 (s, 1H), 6.48 (d, J = 3.2 Hz, 1H), 6.40 (dd, J = 
3.2, 1.9 Hz, 2H), 6.21 (t, J = 1.8 Hz, 2H), 5.55 (s, 2H), 5.21 (d, J = 10.2 Hz, 2H), 
4.13-4.03 (m, 4H), 2.52 (t, J = 1.7 Hz, 2H), 2.14-2.10 (m, 2H), 1.39-1.32 (m, 2H); 
13C NMR (126 MHz, CDCl3): δ 147.1, 144.0, 143.2, 137.5, 124.1, 111.1, 110.7, 69.6 
(d, JCP = 7.9 Hz), 59.9 (JCP = 5.0 Hz),, 47.0, 45.0, 43.8, 42.2; 
31P NMR (CDCl3, 162 MHz) δ ppm 1.82, -3.7 (dr = 11.2); 











General procedure C for synthesis of OTP 2.1.6a–i via ROMP polymerization. 
 
To a flame-dried flask under argon atmosphere was added OTP monomer 
2.1.6a–i (1 equiv.), which was solvated in anhydrous Ar-degassed CH2Cl2 (0.1M).  
To this stirring solution was added metathesis cat-A [RuCl2(PCy3)2=CHPh] (5 mol 
%).  The reaction was stirred and heated at 45 ºC for 2−3 hours monitored by TLC 
(100 % EtOAc, product Rf = 0).  Upon completion, the reaction was cooled and crude 
reaction quenched with ethyl vinyl ether (0.1 equiv.) and stirred for an additional 30 
minutes.  After such time Na2CO3 (1 equiv.) was added followed by the drop-wise 
addition of tetrakis(hydroxymethyl) phosphonium chloride (THPC) (1 equiv., 80% in 
H2O).  The reaction was then refluxed until complete disappearance of the purple 
color was observed.  After which time the reaction was cooled to room temperature 
and washed with deionized water and sat. brine.  The organic layer was dried 
(MgSO4), filtered through a celite plug, and concentrated in vacuo until slight 
viscosity of the solution was observed.  The resulting viscous solution was 
precipitated drop-wise in anhydrous Et2O (1 L/ 5mmol) with stirring.  Stirring was 
continued for 10 minutes after which time the oligomer was filtered and dried in 
vacuo to yield the desired oligomeric triazole phosphate (OTP) 2.1.6a–i as a white 
powder in quantitative yield.  Subsequent solubility tests (Table 1) confirmed the 


















45 ºC 2 h
56–89%2.5 a–i
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Table 5.1:  Solubility of OTP20 2.1.6a–i  
solvent conditions results 
CH2Cl2 RT w/ stirring soluble 
CHCl3 RT w/ stirring soluble 
THF reflux w/ stirring insoluble 
DME reflux w/ stirring insoluble 
1,3 dioxane reflux w/ stirring insoluble 
DMF RT w/ stirring soluble 
Toluene reflux w/ stirring insoluble 
CH3CN reflux w/ stirring insoluble 
 
General procedure D for the triazolation of nucleophilic species with OTP20 
2.1.6a–i. 
 
 To a 1-dram vial w/ teflon cap was added OTP20 2.1.6a–i (1.5 equiv.) 
followed by addition of NaI (0.2 equiv), Cs2CO3 (3 equiv), and dry DMF (0.2M).  
The mixture was stirred rapidly until the oligomer dissolved (< 30 s) after which the 
corresponding nucleophile (1 equiv) was added.  The reaction was heated to 90 ºC for 
2−14 hrs dependent on the nucleophile, after which time, DMF was removed in 
R2-XH
Cs2CO3, NaI






















vacuo.  The crude mixture was diluted in EtOAc, filtered through a SiO2 SPE, rinsed 




Utilizing general procedure D, 2.1.7a (56 mg, 0.151 mmol, 98%) was isolated as a 
white solid, Mp = 73 ºC. FTIR (neat):  2935, 2358, 1612, 1585, 1483, 1286 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.54 (s, 1H), 7.35 (d, J = 2.5 Hz, 2H), 7.25-7.22 (m, 
2H), 7.16 (dd, J = 8.8, 2.5 Hz, 1H), 7.04 (m, 1H), 6.90 (m, 1H) 5.46 (s, 2H), 5.23 (s, 
2H), 3.81 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 160.0, 152.6, 143.7, 130.0, 129.7, 
127.7, 126.4, 126.3, 123.9, 122.7, 115.2, 114.5, 63.5, 55.4, 53.9; HRMS calculated 
for C17H15Cl2N3O2Na (M+Na)+ 386.0439; found 386.0449 (TOF MS ES+). 
4-((4-fluorophenoxy)methyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazole 2.1.7b. 
 
Utilizing general procedure D, 2.1.7b (46 mg, 0.147 mmol, 92%) was isolated as a 
white solid. Mp = 70 ºC. FTIR (neat): 3001, 2935, 1612, 1504, 1249, 1205, 1031 cm-
1; 
1H NMR (400 MHz, CDCl3): δ 7.50 (s, 1H), 7.35-7.18 (m, 2H), 7.00-6.95 (m, 2H), 
6.93-6.90 (m, 4H), 5.48 (s, 2H), 5.14 (s, 2H), 3.83 (s, 3H); 13C NMR (126 MHz, 













115.9 (q, J = 8.0 Hz), 114.5, 62.7, 55.4, 53.8; HRMS calculated for C17H17FN3O2 




Utilizing general procedure D, 2.1.7c (50 mg, 0.142 mmol, 90%) was isolated as a 
white solid Mp = 88 ºC. FTIR (neat): 2960, 2358, 1610, 1511, 1463, 1250, 1184, 
1031 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.51 (s, 1H), 7.34-7.30 (m, 2H), 7.27-7.24 (m, 2H), 
6.94-6.90 (m, 4H), 5.47 (s, 2H), 5.17 (s, 2H), 3.83 (s, 3H), 1.31 (s, 9H); 13C NMR 
(126 MHz, CDCl3): δ 159.9, 156.0, 144.8, 143.9, 129.7, 126.5, 126.3, 122.3, 114.5, 
114.2, 62.2, 55.4, 53.8, 34.1, 31.5; HRMS calculated for C21H25N3NaO2 (M+Na)+ 
374.1844; found 374.1839 (TOF MS ES+). 
1-(4-Methoxybenzyl)-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (2.1.7d). 
 
Utilizing general procedure D, 2.1.7d (30 mg, 0.105 mmol, 70%) was isolated as a 
off-white solid, Mp = 94 ºC. FTIR (neat): 3053, 2935, 2835, 1612, 1579, 1514, 1461, 
1392, 1267, 1249, 1095 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.23 (d, J = 8.3 Hz, 
1H), 7.81 (d, J = 7.6, 1H), 7.58 (s, 1H), 7.53-7.44 (m, 3H), 7.38 (t, J = 8.0 Hz, 1H), 










(s, 3H); 13C NMR (126 MHz, CDCl3): δ 160.0, 153.9, 144.7, 134.5, 129.7, 127.5, 
126.5, 126.4, 125.8, 125.6, 125.2, 122.3, 122.0, 120.8, 114.5, 105.4, 62.5, 55.4, 53.8; 




Utilizing general procedure D, 2.1.7e (33 mg, 0.095 mmol, 60%) was isolated as an 
off-white solid, Mp = 108 ºC. FTIR (neat):  3109, 2916, 2837, 2358, 2341, 1612, 
1515, 1251, 1178, 1027 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.21-7.19 (m, 2H), 
7.16-7.08 (m, 5H), 6.90-6.87 (m, 2H), 5.39 (s, 2H), 4.14 (s, 2H), 3.82 (s, 3H), 2.45 (s, 
3H); 
13C NMR (126 MHz, CDCl3): δ 159.9, 145.1, 137.4, 131.4, 131.1, 129.5, 126.9, 
126.6, 121.8, 114.4, 55.4, 53.7, 29.6, 15.8; HRMS calculated for C18H20N3O2S2 
(M+H)+ 358.1048 found 358.1059 (TOF MS ES+). 
4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)morpholine (2.1.7f). 
 
Utilizing general procedure D, 2.1.7f (35 mg, 0.121 mmol, 72%) was isolated as a 
brown solid, Mp = 95 ºC, FTIR (neat): 2927, 2852, 1612, 1514, 1454, 1249, 1178, 
1114, 1003 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.35 (s, 1H), 7.22-7.20 (m, 2H), 












2.47 (t, J = 4.5 Hz, 4H); 13C NMR (126 MHz, CDCl3): δ 159.9, 144.1, 129.7, 126.6, 
124.4, 114.5, 66.7, 55.4, 53.7, 53.6, 53.3; HRMS calculated for C15H20N4O2Na 
(M+Na)+ 311.1484 found 311.1490 (TOF MS ES+). 
4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)thiomorpholine (2.1.7g). 
 
Utilizing general procedure D, 2.1.7g (54 mg, 0.177 mmol, 75%) was isolated as a 
thick liquid. FTIR (neat):  2916, 2837, 2358, 1515, 1431, 1251, 1178, 1027 cm-1;  
1H NMR (400 MHz, CDCl3): δ 7.34 (s, 1H), 7.25-7.23 (m, 2H), 6.92-6.90 (m 2H), 
5.45 (s, 2H), 3.82 (s, 3H), 3.66 (s, 2H), 2.79-2.74 (m, 4H), 2.70-2.65 (m, 4H); 13C 
NMR (126 MHz, CDCl3): δ 159.9, 144.5, 129.7, 126.6, 122.2, 114.5, 55.6, 54.6, 54.2, 
53.7, 27.8; 




Utilizing general procedure D, 2.1.7h (85 mg, 0.234 mmol, 95%) was isolated as a 
off-white solid, Mp = 137 ºC. FTIR (neat): 3132, 2939, 2833, 1600, 1514, 1454, 
1326, 1301, 1251, 1178, 1143 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.40 (s, 1H), 












3H), 3.71 (s, 2H), 3.19 (t, J = 5.0 Hz, 4H), 2.66 (t, J = 5.0 Hz, 4H); 13C NMR (126 
MHz, CDCl3): δ 159.8, 151.2, 144.5, 129.7, 129.0, 126.5, 122.3, 119.7, 116.0, 114.4, 
55.3, 53.6, 53.3, 52.9, 48.9; HRMS calculated for C21H26N5O (M+H)+ 364.2137; 
found 364.2134 (TOF MS ES+). 
1-((1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)indoline (2.1.7i) 
 
Utilizing general procedure D, 2.1.7i (71 mg, 0.221 mmol, 88%) was isolated as a 
thick brown liquid. 
FTIR (neat): 2952, 2931, 2835, 1608, 1514, 1487, 1460, 1249, 1178 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.33 (s, 1H), 7.22-7.19 (m, 2H), 7.09-7.04 (m, 2H), 
6.90-6.88 (m, 2H), 6.68 (t, J = 7.6 Hz, 1H), 6.53 (d, J = 7.8 Hz, 1H), 5.43 (s, 2H), 
4.39 (s, 2H), 3.81 (s, 3H), 3.36 (t, J = 8.3, 2H), 2.94 (t, J = 8.3, 2H); 13C NMR (126 
MHz, CDCl3): δ 159.8, 151.6, 145.1, 130.2, 129.5, 127.2, 126.6, 124.5, 121.6, 118.1, 
114.4, 107.4, 55.3, 53.6, 53.4, 44.8, 28.5; 











Utilizing general procedure D, 2.1.7j (53 mg, 0.143 mmol, 62%) was isolated as a 
thick brown liquid. FTIR (neat): 2966, 2931, 2835, 1612, 1573, 1514, 1461, 1249, 
1178, 1045 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.32-8.31 (m, 1H), 7.83-7.81 (m, 
1H), 7.54 (d, J = 8.2 Hz 1H), 7.49-7.45 (m, 2H), 7.31 (t, J = 7.6 Hz, 1H), 7.06-7.00 
(m, 3H), 6.94 (s, 1H), 6.84-6.81 (m, 2H), 5.33 (s, 2H), 4.46 (s, 2H), 3.81 (s, 3H), 3.19 
(q, J = 7.1 Hz, 2H), 1.09 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 159.7, 
146.8, 145.7, 134.8, 130.5, 129.2, 128.2, 126.9, 125.8, 125.4, 125.4, 123.8, 123.7, 
122.0, 118.4, 114.3, 55.3, 53.5, 49.2, 47.8, 12.2; HRMS calculated for C23H25N4O 
(M+H)+ 373.2028; found 373.2032 (TOF MS ES+). 
1-(4-Methylbenzyl)-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (2.1.8b). 
 
Utilizing general procedure D, 2.1.8b (54 mg, 0.157 mmol, 90%) was isolated as an 
off-white solid, Mp = 85 ºC. FTIR (neat):  3053, 2923, 2358, 1595, 1579, 1508, 1461, 
1392, 1267, 1238, 1095 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.3 Hz, 
1H), 7.80 (d, J = 7.7 Hz, 1H), 7.58 (s, 1H), 7.51-7.42 (m, 3H), 7.38 (t, J = 7.9 Hz, 










13C NMR (126 MHz, CDCl3): δ 153.7, 144.7, 138.8, 134.5, 131.5, 129.8, 128.2, 
127.5, 126.5, 125.8, 125.6, 125.3, 122.5, 122.0, 120.8, 105.4, 62.5, 54.1, 21.2; 
HRMS calculated for C21H20N3O (M+H)+ 330.1606; found 330.1605 (TOF MS ES+). 
1-(2-Methylbenzyl)-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole(2.1.8c). 
 
Utilizing general procedure D, 2.1.8c (22 mg, 0.095 mmol, 55%) was isolated as a 
brown solid, Mp = 64 ºC. FTIR (neat):  3053, 2925, 2355, 1577, 1509, 1460, 1392, 
1267, 1238, 1095, 1047 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 8.3 Hz, 
1H), 7.80 (d, J = 7.7 Hz, 1H), 7.50-7.43 (m, 4H), 7.37 (t, J = 7.8 Hz, 1H), 7.34-7.29 
(m, 1H), 7.25-7.21 (m, 2H), 7.18-7.15 (m, 1H), 6.96 (d, J = 7.4 Hz, 1H), 5.57 (s, 2H), 
5.39 (s, 2H), 2.94 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 153.9, 144.6, 136.9, 134.5, 
132.4, 131.1, 129.4, 129.2, 127.5, 126.7, 126.4, 125.8, 125.6, 125.3, 122.5, 121.9, 
120.9, 105.5, 62.5, 52.5, 19.0; HRMS calculated for C21H20N3O (M+H)+ 330.1606; 
found 330.1597 (TOF MS ES+). 
1-(4-Chlorobenzyl)-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (2.1.8d). 
 
Utilizing general procedure D, 2.1.8d (41 mg, 0.117 mmol, 68%) was isolated as an 
off-white solid. Mp = 116 ºC. FTIR (neat): 3053, 2925, 1579, 1492, 1461, 1392, 










Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.60 (s, 1H), 7.51-7.43 (m, 3H), 7.39-7.35 (m, 3H), 
7.22 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 5.52 (s, 2H), 5.40 (s, 2H); 
13C NMR (126 MHz, CDCl3): δ 153.9, 145.0, 134.9, 134.5, 133.0, 129.4 (3C), 127.5, 
126.5, 125.8, 125.6, 125.3, 122.5, 121.9, 120.9, 105.5, 62.5, 53.5; 




Utilizing general procedure D, 2.1.8e ( 40 mg, 0.121 mmol, 70%) was isolated as an 
off-white solid, Mp = 97 ºC. FTIR (neat): 2925, 1579, 1510, 1461, 1392, 1267, 1226, 
1159, 1095, 1049 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.2 Hz, 1H), 7.81 
(d, J = 8.2 Hz, 1H), 7.60 (s, 1H), 7.51-7.43 (m, 3H), 7.38 (dd, J = 8.1, 7.7 Hz, 1H), 
7.29-7.26 (m, 2H), 7.09-7.05 (m, 2H), 6.96 (d, J = 7.5 Hz, 1H), 5.52 (s, 2H), 5.40 (s, 
2H); 13C NMR (126 MHz, CDCl3): δ 162.9 (1JC–F = 248.2 Hz), 153.9, 145.0, 134.5, 
130.3 (4JC–F = 3.3 Hz), 129.9 (3JC–F = 8.4 Hz), 127.5, 126.5, 125.8, 125.6, 125.3, 
122.5, 121.9, 120.9, 116.2, (2JC–F = 21.9 Hz), 105.4, 62.5, 53.5; HRMS calculated for 










Utilizing general procedure D, 2.1.8f (30 mg, 0.113 mmol, 65%) was isolated as an 
off-white solid, Mp = 144 ºC. FTIR (neat):  2924, 1595, 1579, 1508, 1461, 1392, 
1325, 1267, 1164, 1124, 1066 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.2 
Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.65-7.63 (m, 3H), 7.51-7.42 (m, 3H), 7.39-7.35 
(m, 3H), 6.96 (d, J = 7.4 Hz, 1H), 5.62 (s, 2H), 5.42 (s, 2H); 13C NMR (126 MHz, 
CDCl3): δ 153.8, 145.2, 138.5, 134.5, 130.9, 128.2, 127.5, 126.5, 126.2, 126.1, 125.8, 
125.6, 125.3, 122.7, 121.9, 121.0, 105.5, 62.5, 53.6; HRMS calculated for 
C21H17F3N3O (M+H)+ 384.1324; found 384.1322 (TOF MS ES+). 
1-(cyclohexylmethyl)-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (2.1.8g). 
 
Utilizing general procedure D, 2.1.8g (28mg, 0.084 mmol, 48%) was isolated as a 
brown solid, Mp = 67 ºC. FTIR (neat): 3053, 2923, 2850, 2358, 1579, 1508, 1461, 
1392, 1267, 1238, 1095 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.28-8.25 (m, 1H), 
7.83-7.80 (m, 1H), 7.62 (s, 1H), 7.52-7.45 (m, 3H), 7.39 (t, J = 7.7 Hz, 1H), 6.98 (d, J 
= 7.3 Hz, 1H), 5.43 (s, 2H), 4.21 (d, J = 7.2 Hz, 2H), 1.92-1.84 (m, 1H), 1.77-1.73 










13C NMR (126 MHz, CDCl3): δ 154.0, 144.2, 134.5, 127.5, 126.5, 125.8, 125.7, 
125.3, 122.9, 122.0, 120.8, 105.5, 62.6, 56.6, 38.8, 30.5, 26.1, 25.5; 




Utilizing general procedure D, 2.1.8i (35 mg, 0.095 mmol, 55%) was isolated as a 
thick brown liquid. FTIR (neat):  2968, 2925, 2852, 1573, 1515, 1458, 1398, 1382, 
1224, 1120, 1045 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.31-8.29 (m, 1H), 7.83-7.81 
(m, 1H), 7.53 (dd, J = 8.6, 3.6 Hz, 1H), 7.48-7.44 (m, 2H), 7.32-7.24 (m, 1H), 7.15-
7.10 (m, 2H), 7.01-6.98 (m, 3H), 6.95 (s, 1H), 5.36 (d, J = 3.1 Hz, 2H), 4.46 (d, J = 
2.9 Hz, 2H), 3.19 (q, J = 7.1 Hz, 2H), 2.34 (d, J = 3.4 Hz, 3H).1.15 (m, 3H). 13C 
NMR (126 MHz, CDCl3): δ 146.8, 145.7, 138.4, 134.8, 131.8, 130.4, 129.6, 128.2, 
127.7, 125.8, 125.4, 125.3, 123.8, 123.7, 122.1, 118.4, 53.7, 49.2, 47.8, 21.2, 12.2; 










Utilizing general procedure D, 2.1.8j (31 mg, 0.109 mmol, 63%) was isolated as a 
thick brown liquid. FTIR (neat): 3047, 2968, 2927, 1573, 1460, 1398, 1224, 1122, 
1045 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.31-8.29 (m, 1H), 7.83-7.80 (m, 1H), 7.52 
(d, J = 8.2 Hz, 1H), 7.48-7.43 (m, 2H), 7.31-7.22 (m, 2H), 7.15-7.11 (m, 2H), 7.00 (d, 
J = 7.3 Hz, 1H), 6.90 (d, J = 7.4 Hz, 1H), 6.82 (s, 1H), 5.40 (s, 2H), 4.47 (s, 2H), 3.19 
(q, J = 7.1 Hz, 2H), 2.10 (s, 3H), 1.10 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, 
CDCl3): δ 146.7, 145.7, 136.6, 134.8, 132.6, 130.8, 130.5, 128.8 (2C), 128.2, 126.5, 
125.8, 125.4, 125.3, 123.8, 123.7, 122.2, 118.5, 52.2, 49.2, 47.9, 18.8, 12.2; HRMS 




Utilizing general procedure D, 2.1.8k (22 mg, 0.115 mmol, 50%) was isolated as a 
thick brown liquid. FTIR (neat):  2968, 2925, 2358, 1573, 1492, 1400, 1224, 1089, 
1045, 1016 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.31 (m, 1H), 7.82 (m, 1H), 7.55 (d, 
J = 8.2 Hz, 1H), 7.48-7.45 (m, 2H), 7.31 (dd, J = 8.0, 7.6 Hz, 1H), 7.28-7.25 (m, 2H), 











2H), 3.20 (q, J = 7.1 Hz, 2H), 1.11 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): 
δ 146.7, 146.1, 134.8, 134.5, 133.3, 130.5, 129.2, 128.9, 128.3, 125.8, 125.5, 125.4, 
123.9, 123.7, 122.2, 118.4, 53.1, 49.1, 48.2, 12.2; HRMS calculated for C22H22ClN4 




Utilizing general procedure D, 2.1.8l (40 mg, 0.115 mmol, 50%) was isolated as a 
thick brown liquid. FTIR (neat):  3047, 2970, 2929, 1573, 1510, 1400, 1224, 1159, 
1047 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.33-8.30 (m, 1H), 7.83-7.81 (m, 1H), 7.54 
(d, J = 8.2 Hz, 1H), 7.48-7.46 (m, 2H), 7.31 (dd, J = 8.0, 7.6 Hz, 1H), 7.06-6.96 (m, 
5H), 6.93 (s, 1H), 5.36 (s, 2H), 4.49 (s, 2H), 3.20 (q, J = 7.1 Hz, 2H), 1.11 (t, J = 7.1 
Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 162.6 (1JC–F = 248.2 Hz), 146.7, 146.1, 
134.8, 130.7, 130.5, 129.5 (3JC–F = 8.4 Hz), 128.3, 125.8, 125.5, 125.4, 123.8, 123.7, 
122.1, 118.4, 116.0, (2JC–F = 21.9 Hz), 53.1, 49.1, 48.1, 12.2; HRMS calculated for 










Utilizing general procedure D, 2.1.8m (22 mg, 0.106 mmol, 60%) was isolated as a 
thick brown liquid. FTIR (neat): 2927, 1573, 1458, 1421, 1400, 1325, 1164, 1124, 
1066, 1018 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.32-8.30 (m, 1H), 7.83-7.80 (m, 
1H), 7.55-7.52 (m, 3H), 7.49-7.44 (m, 2H), 7.30 (t, J = 7.8 Hz, 1H), 7.10 (d, J = 8.1 
Hz, 2H), 7.03 (d, J = 7.4 Hz, 1H), 6.95 (s, 1H), 5.44 (s, 2H), 4.51 (s, 2H), 3.22 (q, J = 
7.1 Hz, 2H), 1.12 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 146.6, 146.3, 
138.8, 134.8, 130.6, 128.3, 128.2, 127.7, 126.2, 125.9, 125.8, 125.5, 123.9, 123.7, 
122.4, 118.5, 116.6, 53.2, 48.9, 48.4, 12.2; HRMS calculated for C23H22F3N3 (M+H)+ 




Utilizing general procedure D, 2.1.8n (40 mg, 0.116 mmol, 66%) was isolated as a 
thick brown liquid. FTIR (neat):  2925, 2850, 1573, 1448, 1398, 1382, 1220, 1045 
cm-1; 
1H NMR (400 MHz, CDCl3): δ 8.37 (dd, J = 8.1, 1.0 Hz, 1H), 7.83 (dd, J = 7.6, 1.5 











7.03 (d, J = 7.4 Hz, 1H), 6.92 (s, 1H), 4.50 (s, 2H), 4.02 (d, J = 7.3 Hz, 2H), 3.23 (q, J 
= 7.1 Hz, 2H), 1.73-1.65 (m, 5H), 1.44-1.40 (m, 2H), 1.16-1.11 (m, 2H), 1.14 (t, J = 
7.1 Hz, 3H), 0.87-0.80 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 146.8, 145.0, 134.8, 
130.6, 128.3, 125.8, 125.5, 125.4, 123.9, 123.8, 122.6, 118.5, 56.2, 49.2, 48.0, 38.7, 
30.3, 26.1, 25.5, 12.2; HRMS calculated for C22H29N4 (M+H)+ 349.2392; found 
349.2386 (TOF MS ES+). 
  
 174 
5.3 Spectra for Chapter 2.1  
(5aR,6R,9S,9aS)-3-(prop-2-yn-1-yloxy)-1,5,5a,6,9,9a-hexahydro-






































































































































































































































































































































































































































































































































































































5.4 Experimental for Chapter 2.2 
Facile (Triazolyl)methylation of MACOS-derived Benzofused Sultams 
Utilizing ROMP-derived OTP Reagents. 
Experimental Section and Characterization data        (SI-216–SI-233) 
1H, 13C, Spectra for all Relevant Compounds         (SI-234–SI-249) 
 
General procedure A: Triazolation of nucleophilic species (2.2.1–2.2.10) with 
OTP20 {2.2.1–2.2.14}. 
 
 To a 1-dram vial w/ teflon cap was added OTP20 {2.2.1–2.2.14} (1.5 equiv) 
followed by addition of sodium iodide (0.2 equiv), Cs2CO3 (3 equiv), and dry DMF 
(0.2M).  The mixture was stirred rapidly until the oligomer dissolved (< 30 s) after 
which the corresponding nucleophile (2.2.1–2.2.10) (1 equiv.) was added.  The 
reaction was heated to 90 ºC for 2−14 h dependent on the nucleophile, after which 
time, DMF was removed in vacuo.  The crude mixture was diluted in EtOAC, filtered 
via SiO2 SPE and rinsed several times with a mixture of EtOAc and concentrated in 






































dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.1{2.2.21}. 
 
Utilizing general procedure A, 2.2.1{2.2.21} (62 mg, 0.108 mmol, 85%) was isolated 
as an off white solid. [α]D20 = –69.8 º (c = 1.0, CH2Cl2);  
MP = 180 ºC;  
FTIR (neat): 3143, 2385, 2084, 1633, 1579, 1454, 1402, 1332, 1213, 1159, 1018 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J = 8.5 Hz, 1H), 7.35–7.30 (m, 2H), 7.30–
7.22 (m, 4H), 7.22–7.17 (m, 2H), 7.16 (s, 1H), 7.10 (d, J = 1.7 Hz, 1H), 7.03 (d, J = 
7.3 Hz, 1H), 6.81 (s, 1H), 5.30 (d, J = 15.0 Hz, 1H), 5.25 (d, J = 15.0 Hz, 1H), 4.75 (t, 
J = 11.8 Hz, 1H), 4.39–4.23 (m, 3H), 4.19 (d, J = 15.6 Hz, 1H), 3.06 (dd, J = 13.7, 
9.0 Hz, 1H), 2.81 (dd, J = 13.7, 6.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 156.0, 143.1, 137.1, 136.1, 135.0, 130.9, 130.4, 129.5 
(2C), 129.0 (2C), 128.1, 127.3, 126.5, 126.3, 126.0, 124.6, 123.0, 73.0, 62.9, 53.3, 
46.0, 36.6. 











dihydro-2H-benzo[b] [1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.2{2.2.22}. 
 
Utilizing general procedure A, 2.2.2{2.2.22}  (45 mg, 0.076 mmol, 62%) was isolated 
as a yellow solid. [α]D20 = +55.0 º (c = 0.8, CH2Cl2); 
MP = 116 ºC; 
FTIR (neat): 3421, 2923, 2082, 1629, 1579, 1332, 1159, 1016 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.65 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 7.1 Hz, 1H), 
7.37–7.17 (m, 8H), 7.10 (dd, J = 14.5, 4.5 Hz, 2H), 6.93 (s, 1H), 5.57–5.34 (m, 2H), 
4.77 (t, J = 11.5 Hz, 1H), 4.41–4.24 (m, 3H), 4.20 (d, J = 15.5 Hz, 1H), 3.07 (dd, J = 
13.4, 8.7 Hz, 1H), 2.83 (dd, J = 13.7, 6.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 156.0, 142.7, 137.0, 133.5, 132.1 130.9, 130.3, 130.2, 
129.9, 129.6, 129.5 (2C), 128.5 (2C), 127.7, 126. 6, 126.3, 124.6, 123.2, 73.9, 62.8, 
51.3, 45.9, 36.7, 29.7. 












dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.3{2.2.21}. 
 
Utilizing general procedure A, 2.2.3{2.2.21} (74 mg, 0.137 mmol, 97%) was isolated 
as a white solid. 
[α]D20 = –84.7 º (c = 0.9, CH2Cl2); 
MP = 169 ºC; 
FTIR (neat): 2958, 2867, 2358, 2088, 1635, 1581, 1552, 1328, 1213, 1153 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J = 8.4 Hz, 1H), 7.37–7.26 (m, 4H), 7.22 (s, 
1H), 7.16 (s, 1H), 7.10 (d, J = 7.1 Hz, 1H), 5.46 (d, J = 15.0 Hz, 1H), 5.37 (d, J = 
15.0 Hz, 1H), 4.43–4.29 (m, 3H), 4.28–4.15 (m, 2H), 1.69 (ddd, J = 13.9, 8.8, 5.4 Hz, 
1H), 1.44 (dt, J = 20.2, 6.6 Hz, 1H), 1.28–1.16 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H), 0.79 
(d, J = 6.6 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ 156.1, 144.2, 136.3, 135.1, 130.45, 130.4, 130, 
129.1, 128.1, 127.5, 126.6, 126, 125.5, 123.4, 73.8, 59.8, 53.5, 44.1, 38.7, 24.6, 22.8, 
21.9. 












dihydro-2H-benzo[b] [1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.3{2.2.22}. 
 
Utilizing general procedure A, 2.2.3{2.2.21} (70 mg, 0.129 mmol, 92%) was isolated 
as a white solid. 
[α]D20 = –73.9 º (c = 0.9, CH2Cl2); 
MP = 155 ºC; 
FTIR (neat): 3126, 2956, 2867, 2358, 2331, 1579, 1550, 1473, 1402, 1365, 1328, 
1153, 1041 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J = 8.4 Hz, 1H), 7.45 (dd, J = 7.9, 1.3 Hz, 
1H), 7.39 (s, 1H), 7.34 (td, J = 7.7, 1.8 Hz, 1H), 7.31–7.25 (m, 2H), 7.17 (dt, J = 4.1, 
1.9 Hz, 2H), 5.57 (q, J = 15.0 Hz, 2H), 4.48–4.34 (m, 3H), 4.27–4.19 (m, 2H), 1.71 
(ddd, J = 14.1, 8.9, 5.6 Hz, 1H), 1.48–1.42 (m, 1H), 1.24 (ddd, J = 13.9, 6.9, 4.1 Hz, 
1H), 0.81 (d, J = 6.6 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ 156.1, 143.0, 133.6, 132.1, 131.6, 130.4 130.3, 130.1, 
129.9, 127.6, 127.5, 126.6, 125.3, 123.6, 73.9, 59.7, 51.5, 44.4, 38.8, 24.6, 22.8, 22.0. 












dihydro-2H-benzo[b] [1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.5{2.2.22}. 
 
Utilizing general procedure A, 2.2.5{2.2.22}  (50 mg, 0.1004 mmol, 70%) was 
isolated as an off white solid. 
[α]D20 = –64.8 º (c = 0.8, CH2Cl2); 
MP = 126 ºC; 
FTIR (neat):  3139, 2977, 2931, 1579, 1554, 1460, 1340, 1213, 1157, 1135, 1060, 
1022 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.62 (d, J = 8.4 Hz, 1H), 7.44 (dd, J = 7.9, 1.3 Hz, 
1H), 7.37–7.35 (m, 1H), 7.34–7.29 (m, 1H), 7.28–7.23 (m, 2H), 7.16–7.13 (m, 2H), 
5.56 (q, J = 15.0 Hz, 2H), 4.52–4.37 (m, 3H), 4.34–4.18 (m, 2H), 1.25 (d, J = 6.8 Hz, 
3H). 
13C NMR (126 MHz, CDCl3): δ 155.9, 143.9, 133.6, 132.0, 131.6 130.5, 130.4, 130.0, 
129.6, 127.6, 127.3, 126.4, 125.1, 123.3, 74.4, 56.9, 51.3, 30.9, 15.7. 












dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.6{2.2.21}. 
 
Utilizing general procedure A, 2.2.6{2.2.21} (78 mg, 0.157 mmol, 98%) was isolated 
as a white solid. 
[α]D20 = +71.7 º (c = 1.0, CH2Cl2); 
MP = 137 ºC; 
FTIR (neat): 3149, 3087, 2933, 1579, 1460, 1338, 1213, 1157, 1022 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.63 (d, J = 8.4 Hz, 1H), 7.36–7.31 (m, 3H), 7.29–
7.25 (m, 1H), 7.20 (s, 1H), 7.15 (d, J = 1.8 Hz, 1H), 7.09 (d, J = 7.0 Hz, 1H), 5.45 (d, 
J = 15.0 Hz, 1H), 5.38 (d, J = 15.0 Hz, 1H), 4.51–4.36 (m, 3H), 4.31–4.21 (m, 2H), 
1.25 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 156.0, 144.4, 136.2, 135.0, 131.6, 130.4, 129.7, 
129.1, 128.0, 127.4, 126.5, 126.0, 125.2, 123.1, 74.3, 57.1, 53.5, 43.7, 15.7. 












dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.8{2.2.21} 
 
Utilizing general procedure A, 2.2.8{2.2.21} (63 mg, 0.131 mmol, 98%) was isolated 
as off white solid. 
[α]D20 = –78.0 º (c = 0.7, CH2Cl2);  
MP = 153 ºC; 
FTIR (neat): 3134, 3082, 2956, 2867, 1604, 1579, 1477, 1421, 1367, 1326, 1155, 
1074 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.77 (dd, J = 8.8, 6.3 Hz, 1H), 7.39 (s, 1H), 7.37–7.26 
(m, 2H), 7.22 (s, 1H), 7.11 (d, J = 7.2 Hz, 1H), 6.84 (ddd, J = 8.8, 7.6, 2.5 Hz, 1H), 
6.66 (dd, J = 9.5, 2.4 Hz, 1H), 5.44–5.39 (m, 2H), 4.43–4.31 (m, 3H), 4.28–4.15 (m, 
2H), 1.75–1.64 (m, 1H), 1.48–1.35 (m, 1H), 1.25–1.18 (m, 1H), 0.81 (d, J = 3.6 Hz, 
3H), 0.79 (d, J = 3.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 165.3 (d, J = 255.2 Hz), 157.5 (d, J = 12.6 Hz), 
144.3, 136.3, 135.0, 130.9 (d, J = 10.5 Hz), 130.4, 129.1, 128.8, 128.1 126.1, 123.4, 










HRMS calculated for C22H24ClFN4O3SNa (M+Na)+ 501.1139 found 501.1126 (TOF 
MS ES+). 
(S)-2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-9-fluoro-3-isobutyl-3,4-
dihydro-2H-benzo[b] [1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.8{2.2.22} 
 
Utilizing general procedure A, 2.2.8{2.2.22} (60 mg, 0.125 mmol, 94%) was isolated 
as a white solid. 
[α]D20 = –61.8 º (c = 1.0, CH2Cl2);  
MP = 85 ºC; 
FTIR (neat): 2958, 2358, 1602, 1583, 1473, 1421, 1334, 1265, 1157, 1116, 1074, 
1041 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.76 (dd, J = 8.8, 6.3 Hz, 1H), 7.44 (dd, J = 7.9, 1.3 
Hz, 1H), 7.41 (s, 1H), 7.34 (td, J = 7.7, 1.8 Hz, 1H), 7.29 (td, J = 7.2, 1.4 Hz, 1H), 
7.18 (dd, J = 7.6, 1.7 Hz, 1H), 6.82 (ddd, J = 8.8, 7.6, 2.5 Hz, 1H), 6.64 (dd, J = 9.5, 
2.4 Hz, 1H), 5.63–5.52 (m, 2H), 4.48–4.34 (m, 3H), 4.28–4.14 (m, 2H), 1.70 (ddd, J 
= 14.1, 8.9, 5.6 Hz, 1H), 1.46 (tt, J = 13.1, 6.5 Hz, 1H), 1.23 (ddd, J = 13.9, 8.3, 5.4 
Hz, 1H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3): δ 166.3 (d, J = 254.3 








130.0, 128.8, 127.7, 123.6, 110.9 (d, J = 22.3 Hz), 109.4 (d, J = 23.7 Hz), 73.8, 59.6, 
51.5, 44.3, 38.8, 24.7, 22.7, 22.0; 
HRMS calculated for C22H24ClFN4O3SNa (M+Na)+ 501.1139; found 501.1156 (TOF 
MS ES+). 
(S)-3-Benzyl-7-fluoro-2-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.9{2.2.11}. 
 
Utilizing general procedure A, 2.2.9{2.2.11} (52 mg, 0.102 mmol, 63%) was isolated 
as an off white solid. 
[α]D20 = –67.4 º (c = 1.0, CH2Cl2);  
MP = 176 ºC; 
FTIR (neat): 2956, 2933, 2358, 1602, 1583, 1514, 1477, 1330, 1249, 1161, 1074, 
1031 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.76 (dd, J = 8.9, 6.3 Hz, 1H), 7.30–7.23 (m, 3H), 
7.21–7.16 (m, 2H), 7.11 (d, J = 8.6 Hz, 2H), 6.90–6.84 (m, 2H), 6.84–6.78 (m, 2H), 
6.57 (dd, J = 9.6, 2.3 Hz, 1H), 5.34–5.16 (m, 2H), 4.76 (t, J = 11.6 Hz, 1H), 4.38–
4.22 (m, 3H), 4.17 (d, J = 15.5 Hz, 1H), 3.81 (s, 3H), 3.04 (dd, J = 13.6, 8.6 Hz, 1H), 









13C NMR (126 MHz, CDCl3): δ 165.1, (d, J = 254.4 Hz), 159.9, 157.3 (d, J = 12.7 
Hz),  142.7, 137.1, 130.4 (d, J = 10.6 Hz), 129.6 (2C), 129.5 (2C) , 128.5 (2C), 128.2, 
126.5, 126.1, 122.6, 114.5 (2C), 110.6 (d, J = 22.4 Hz), 108.6 (d, J = 23.8 Hz), 73.8, 
62.6, 55.3, 53.6, 45.9, 36.7; 




dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.9{2.2.12}. 
 
Utilizing general procedure A, 2.2.9{2.2.12} (67 mg, 0.136 mmol, 89%) was isolated 
as a white solid. 
[α]D20 = –100.1 º (c = 0.9, CH2Cl2);  
MP = 164 ºC; 
FTIR (neat): 3028, 2923, 2358, 1602, 1581, 1477, 1419, 1330, 1161, 1074 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.76 (dd, J = 8.8, 6.3 Hz, 1H), 7.31–7.23 (m, 3H), 
7.21–7.13 (m, 4H), 7.06 (d, J = 8.0 Hz, 2H), 6.84–6.78 (m, 2H), 6.57 (dd, J = 9.6, 2.2 
Hz, 1H), 5.32 (d, J = 14.6 Hz, 1H), 5.22 (d, J = 14.6 Hz, 1H), 4.76 (t, J = 11.5 Hz, 
1H), 4.39–4.23 (m, 3H), 4.18 (d, J = 15.5 Hz, 1H), 3.05 (dd, J = 13.5, 8.5 Hz, 1H), 
2.82 (dd, J = 13.6, 6.5 Hz, 1H), 2.35 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.1 (d, J = 254.4 Hz), 157.4 (d, J = 12.7 Hz), 
142.7, 138.8, 137.1, 131.1, 130.5 (d, J = 10.6 Hz), 129.7 (2C), 129.5 (2C), 128.5 
(2C), 128.1 (2C), 126.5, 122.7, 110.7, 110.6 (d, J = 22.4 Hz), 108.6 (d, J = 24.3 Hz), 
73.8, 62.6, 53.4, 45.9, 36.7, 21.1. 











dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.9{2.2.14}. 
 
Utilizing general procedure A, 2.2.9{2.2.14} (62 mg, 0.124 mmol, 82%) was isolated 
as a white solid. 
[α]D20 = –75.8 º (c = 0.8, CH2Cl2);  
MP = 182 ºC; FTIR (neat): 3136, 2952, 2339, 1602, 1512, 1419, 1328, 1265, 1224, 
1161, 1074 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.78 (dd, J = 8.9, 6.2 Hz, 1H), 7.32–7.24 (m, 3H), 
7.23–7.15 (m, 4H), 7.08–7.02 (m, 2H), 6.86–6.80 (m, 2H), 6.59 (dd, J = 9.6, 2.3 Hz, 
1H), 5.37–5.21 (m, 2H), 4.77 (t, J = 11.8 Hz, 1H), 4.40–4.24 (m, 3H), 4.23–4.16 (m, 
1H), 3.07 (dd, J = 13.7, 8.8 Hz, 1H), 2.82 (dd, J = 13.7, 6.5 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 164.1 (d, J = 254.5 Hz), 161.1 (d, J = 248.5 Hz), 
156.4 (d, J = 12.6 Hz), 142.0, 136.1, 129.5 (d, J = 10.6 Hz), 129.1 (d, J = 3.3. Hz) 
128.9 (d, J = 8.4 Hz, 2C), 128.5 (2C), 127.5 (2C), 127.2, 125.5 (2C), 121.7, 115.1 (d, 
J = 21.7 Hz), 109.6 (d, J = 22.3 Hz), 107.5 (d, J = 24.1 Hz), 72.8, 61.7, 52.3, 44.8, 
35.6. 












dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library Member 
2.2.9{2.2.19}. 
 
Utilizing general procedure A, 2.2.9{2.2.19} (57 mg, 0.121 mmol, 79%) was isolated 
as a white solid. 
[α]D20 = –71.7 º (c = 1.0, CH2Cl2); MP = 145 ºC; 
FTIR (neat): 2925, 2854, 2349, 1604, 1583, 1477, 1419, 1330, 1161, 1074 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.78 (dd, J = 8.9, 6.2 Hz, 1H), 7.39 (t, J = 1.3 Hz, 
1H), 7.30–7.22 (m, 3H), 7.23–7.18 (m, 2H), 6.93 (s, 1H), 6.82 (ddd, J = 8.9, 7.6, 2.5 
Hz, 1H), 6.61 (dd, J = 9.6, 2.4 Hz, 1H), 6.37 (d, J = 1.4 Hz, 2H), 5.36 (d, J = 15.4 Hz, 
1H), 5.27 (d, J = 15.4 Hz, 1H), 4.77 (t, J = 11.8 Hz, 1H), 4.38–4.23 (m, 3H), 4.19 (d, 
J = 15.5 Hz, 1H), 3.06 (dd, J = 13.6, 8.7 Hz, 1H), 2.81 (dd, J = 13.7, 6.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 165.1(d, J = 254.4 Hz), 157.4 (d, J = 12.7 Hz), 146.8, 
143.7, 142.7, 137.1, 130.5 (d, J = 10.6.4 Hz), 129.5 (2C), 128.5 (2C), 128.1, 126.5, 
122.8, 110.8, 110.6 (d, J = 22.4 Hz), 110.4, 108.6 (d, J = 24.1 Hz), 73.8, 62.7, 46.5, 
45.9, 36.7; 












Library Member 2.2.10{2.2.11}. 
 
Utilizing general procedure A, 2.2.10{2.2.11} (58 mg, 0.114 mmol, 68%) was 
isolated as a thick liquid. 
[α]D20 = +218.1 º (c = 1.0, CH2Cl2); 
FTIR (neat): 3137, 2941, 1589, 1514, 1471, 1340, 1240, 1249, 1164, 1153, 1120, 
1072, 1000 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.81 (dd, J = 8.7, 6.2 Hz, 1H), 7.46–7.36 (m, 5H), 
7.35–7.29 (m, 1H), 7.18–7.12 (m, 2H), 6.90–6.80 (m, 4H), 5.45 (d, J = 14.6 Hz, 1H), 
5.33 (d, J = 14.6 Hz, 1H), 4.96 (s, 1H), 4.67 (d, J = 15.5 Hz, 1H), 4.53 (d, J = 15.5 
Hz, 1H), 3.95–3.85 (m, 1H), 3.81 (s, 3H), 1.30 (d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 165.4 (d, J = 255.9 Hz), 160.0, 157.8 (d, J = 12.2 
Hz), 143.6, 137.8, 131.9, 129.8 (d, J = 254.4 Hz), 129.6 (2C) 128.5 (2C), 127.8, 
126.1, 125.4 (2C), 122.8, 114.5 111.7 (d, J = 22.2 Hz), 111.4 (d, J = 23.3 Hz, 2C), 
83.3, 61.9, 53.8, 53.6, 46.1, 14.2; 











4-phenyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library 
Member 2.2.10{2.2.12}. 
 
Utilizing general procedure A, 2.2.10{2.2.12} (56 mg, 0.113 mmol, 75%) was 
isolated as a thick liquid. 
[α]D20 = –79.3 º (c = 1.0, CH2Cl2); FTIR (neat): 3173, 2943, 2389, 2333, 1589, 1471, 
1421, 1340, 1164, 1072, 1000 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.84–7.78 (m, 1H), 7.47–7.38 (m, 5H), 7.33 (ddd, J = 
7.0, 3.8, 1.4 Hz, 1H), 7.16 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 6.89–6.81 (m, 
2H), 5.47 (d, J = 14.7 Hz, 1H), 5.36 (d, J = 14.6 Hz, 1H), 4.98 (d, J = 1.5 Hz, 1H), 
4.68 (d, J = 15.5 Hz, 1H), 4.54 (d, J = 15.5 Hz, 1H), 3.93–3.90 (m, 1H), 2.37 (s, 3H), 
1.30 (d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 165.4 (d, J = 256.0 Hz),157.8 (d, J = 12.2 Hz), 143.7, 
138.9, 137.8, 131.9, 131.1, 130.0 (2C), 129.8 (d, J = 10.6 Hz), 128.5 (2C), 128.1 
(2C), 127.8, 125.4 (2C), 122.9, 111.7 (d, J = 22.2 Hz), 111.32 (d, J = 23.4 Hz), 83.3, 
61.9, 54.2, 46.0, 21.2, 14.2. 













phenyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide, Library 
Member 2.2.10{2.2.14}. 
` 
Utilizing general procedure A, 2.2.10{2.2.14} (55 mg, 0.110 mmol, 72%) was 
isolated as a thick liquid. [α]D20 = +80.0 º (c = 0.9, CH2Cl2); 
FTIR (neat): 3070, 2943, 2358, 2341, 1589, 1512, 1473, 1421, 1224, 1164, 1072, 
1000 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.83 (dd, J = 8.7, 6.2 Hz, 1H), 7.48 (s, 1H), 7.46–7.37 
(m, 4H), 7.35–7.30 (m, 1H), 7.24–7.17 (m, 2H), 7.07–6.98 (m, 2H), 6.88 (ddd, J = 
11.5, 8.5, 2.4 Hz, 2H), 5.49 (d, J = 14.8 Hz, 1H), 5.39 (d, J = 14.8 Hz, 1H), 5.01 (d, J 
= 1.2 Hz, 1H), 4.69 (d, J = 15.6 Hz, 1H), 4.51 (d, J = 15.5 Hz, 1H), 3.90 (qd, J = 7.2, 
2.2 Hz, 1H), 1.30 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 166.5 (d, J = 
256.1 Hz), 162.9 (d, J = 248.7 Hz), 157.9 (d, J = 12.2 Hz), 157.8, 144.1, 137.7, 131.7, 
130.1 (d, J = 3.4 Hz), 130.0, 129.9, 129.8, 128.5 (2C), 127.9, 125.9 (2C), 123.0, 
116.2 (d, J = 21.8 Hz), 111.8 (d, J = 22.2 Hz), 111.3 (d, J = 23.3 Hz), 83.3, 62.0, 
53.5, 45.9 14.3; 












Library Member 2.2.10{2.2.19}. 
 
Utilizing general procedure A, 2.2.10{2.2.19} (53 mg, 0.113 mmol, 75%) was 
isolated as a thick liquid. 
[α]D20 = +96.8 º (c = 0.8, CH2Cl2); 
FTIR (neat):  2943, 2358, 1589, 1473, 1340, 1164, 1153, 1118, 1164, 1153, 1074, 
1010 cm-1 
1H NMR (400 MHz, CDCl3): δ 7.84 (dd, J = 8.7, 6.2 Hz, 1H), 7.56 (s, 1H), 7.46–7.37 
(m, 5H), 7.35–7.29 (m, 1H), 6.95–6.85 (m, 2H), 6.44–6.37 (m, 2H), 5.51 (d, J = 15.5 
Hz, 1H), 5.44 (d, J = 15.5 Hz, 1H) 5.03 (s, 1H), 4.70 (d, J = 15.5 Hz, 1H), 4.52 (d, J = 
15.5 Hz, 1H), 3.90 (qd, J = 7.2, 2.3 Hz, 1H), 1.31 (d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 166.5 (d, J = 256.4 Hz), 157.8 (d, J = 12.1 Hz), 
146.7, 143.8, 143.7, 137.8, 131.8, 131.7, 129.8 (d, J = 10.5 Hz), 128.5 (2C), 127.8, 
125.4 (2C), 123.0, 111.8, (d, J = 22.2 Hz), 111.4 (d, J = 23.4 Hz), 110.7 (d, J = 42.7 
Hz), 83.2, 61.9, 46.8, 46.0, 14.3; 










5.5 Spectra for Chapter 2.2  
(S)-3-Benzyl-7-bromo-2-((1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydro-





















































































































































































































































































































5.5.1 Table 5.2 Library Data Set –Thiadiazepin-1,1-dioxide 4-ones 
Comp. HRMS Expected  M/z (M)+ 








2.2.1{2.2.11} 568.0779 569.0867 24.0mg 32 99.1% 
2.2.2{2.2.11} 568.0779 569.0857 44.7mg 60 98.9% 
2.2.3{2.2.11} 534.0936 535.1046 21.3mg 30 100.0% 
2.2.4{2.2.11} 534.0936 535.1015 20.0mg 28 100.0% 
2.2.5{2.2.11} 492.0466 493.0539 53.1mg 70 100.0% 
2.2.6{2.2.11} 492.0466 493.0520 54.1mg 72 100.0% 
2.2.8{2.2.11} 490.1441 491.1516 9.0mg 11 100.0% 
2.2.1{2.2.12} 552.0830 553.0902 14.1mg 19 100.0% 
2.2.2{2.2.12} 552.0830 553.0913 56.9mg 76 97.6% 
2.2.3{2.2.12} 518.0987 519.1038 37.1mg 48 100.0% 
2.2.4{2.2.12} 518.0987 519.1068 39.9mg 52 97.9% 
2.2.5{2.2.12} 476.0517 477.0577 50.9mg 63 100.0% 
2.2.6{2.2.12} 476.0517 477.0612 55.0mg 68 99.2% 
2.2.7{2.2.12} 538.0674 539.0788 11.0mg 15 92.4% 
2.2.8{2.2.12} 458.1787 459.1893 21.1mg 29 97.3% 
2.2.1{2.2.13} 552.0830 553.0891 54.9mg 74 100.0% 
2.2.2{2.2.13} 552.0830 553.0861 60.0mg 80 97.9% 
2.2.3{2.2.13} 518.0987 519.1070 32.2mg 42 100.0% 
2.2.4{2.2.13} 518.0987 519.1078 35.4mg 46 98.6% 
2.2.5{2.2.13} 476.0517 477.0608 56.4mg 70 99.6% 
2.2.6{2.2.13} 476.0517 477.0594 63.0mg 77 100.0% 
2.2.7{2.2.13} 538.0674 539.0767 40.2mg 55 71.2% 
2.2.8{2.2.13} 458.1787 459.1848 46.6mg 62 98.5% 
2.2.1{2.2.14} 556.0580 557.0670 48.1mg 64 98.3% 
2.2.2{2.2.14} 556.0580 557.0622 56.9mg 76 98.4% 
2.2.3{2.2.14} 522.0736 523.0776 34.6mg 44 98.7% 
 251 
2.2.4{2.2.14} 522.0736 523.0817 37.4mg 48 100.0% 
2.2.5{2.2.14} 480.0267 481.0358 58.6mg 79 99.5% 
2.2.6{2.2.14} 480.0267 481.0338 59.0mg 80 98.7% 
2.2.7{2.2.14} 542.0423 543.0486 36.5 49 65% 
2.2.8{2.2.14} 462.1537 463.1593 43.2mg 57 100.0% 
2.2.1{2.2.15} 544.1143 545.1255 55.2mg 75 100.0% 
2.2.2{2.2.15} 544.1143 545.1237 43.2mg 60 97.5% 
2.2.3{2.2.15} 510.1300 511.1394 30.1mg 40 98.0% 
2.2.4{2.2.15} 510.1300 511.1376 19.3mg 26 97.9% 
2.2.5{2.2.15} 468.083 469.0902 58.7mg 82 98.0% 
2.2.6{2.2.15} 468.083 469.0927 56.2mg 78 99.2% 
2.2.7{2.2.15} 530.098 531.1015 4.6mg 10 100.0% 
2.2.8{2.2.15} 450.2100 451.2160 45.3mg 62 100.0% 
2.2.1{2.2.16} 615.9779 616.9811 39.6mg 48 98.9% 
2.2.3{2.2.16} 581.9935 583.0014 33.4mg 40 99.2% 
2.2.4{2.2.16} 581.9935 583.0010 32.4mg 38 98.5% 
2.2.5{2.2.16} 539.9466 540.9524 45.4mg 50 99.6% 
2.2.6{2.2.16} 539.9466 540.9562 36.4mg 41 100.0% 
2.2.7{2.2.16} 601.9622 602.9688 17.3mg 20 86.5% 
2.2.1{2.2.17} 548.0729 549.0802 57.3mg 77 100.0% 
2.2.2{2.2.17} 548.0729 549.0822 59.0mg 79 98.5% 
2.2.3{2.2.17} 514.0885 515.0986 40.9mg 59 98.7% 
2.2.4{2.2.17} 514.0885 515.0984 39.6mg 57 98.6% 
2.2.5{2.2.17} 472.0416 473.0495 38.3mg 59 100.0% 
2.2.6{2.2.17} 472.0416 473.0522 48.0mg 74 100.0% 
2.2.7{2.2.17} 534.0572 535.0626 43.8mg 63 100.0% 
2.2.8{2.2.17} 454.1686 455.1773 47.4mg 64 96.7% 
2.2.1{2.2.18} 562.0885 563.0957 33.0mg 44 99.7% 
2.2.2{2.2.18} 562.0885 563.0939 64.6mg 85 99.3% 
2.2.3{2.2.18} 528.1042 529.1111 43.9mg 62 100.0% 
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2.2.4{2.2.18} 528.1042 529.1146 35.3mg 50 100.0% 
2.2.5{2.2.18} 486.0572 487.0650 52.4mg 79 99.7% 
2.2.6{2.2.18} 486.0572 487.0651 57.0mg 86 100.0% 
2.2.7{2.2.18} 548.0729 549.0795 18.6mg 25 100.0% 
2.2.8{2.2.18} 468.1842 469.1915 52.9mg 70 98.0% 
2.2.2{2.2.19} 528.0466 529.0527 50.4mg 70 98.5% 
2.2.3{2.2.19} 494.0623 495.0708 35.4mg 53 99.3% 
2.2.4{2.2.19} 494.0623 495.0722 36.3mg 55 100.0% 
2.2.5{2.2.19} 452.0153 453.0256 41.5mg 67 99.6% 
2.2.7{2.2.19} 514.0310 515.0389 5.1mg 8 86.2% 
2.2.8{2.2.19} 434.1424 435.1528 46.5mg 65 98.1% 
2.2.1{2.2.20} 572.0284 573.0357 56.6mg 73 100.0% 
2.2.2{2.2.20} 572.0284 573.0383 60.5mg 78 95.8% 
2.2.3{2.2.20} 538.0441 539.0563 38.6mg 48 100.0% 
2.2.4{2.2.20} 538.0441 539.0521 40.5mg 51 100.0% 
2.2.5{2.2.20} 495.9971 497.0025 53.2mg 70 99.0% 
2.2.6{2.2.20} 495.9971 497.0061 59.5mg 78 100.0% 
2.2.7{2.2.20} 558.0128 559.023 3.9mg 5.1 66% 
2.2.8{2.2.20} 478.1241 479.1340 46.8mg 60 96.4% 
2.2.1{2.2.23} 538.0674 539.0740 57.9mg 79 97.7% 
2.2.2{2.2.23} 538.0674 539.0745 59.1mg 81 95.6% 
2.2.3{2.2.23} 504.08307 505.0896 16.6mg 22 99.5% 
2.2.4{2.2.23} 504.08307 505.0960 44.4mg 65 99.3% 
2.2.5{2.2.23} 462.03612 463.0403 49.4mg 63 99.4% 
2.2.6{2.2.23} 462.03612 463.0405 64.0mg 81 99.2% 
2.2.7{2.2.23} 524.0517 525.0556 52.5mg 70 99.3% 
2.2.1{2.2.24} 606.0548 607.0640 30.0mg 37 97.9% 
2.2.2{2.2.24} 606.0548 607.0630 53.8mg 66 97.8% 
2.2.3{2.2.24} 572.0704 573.0773 31.0mg 39 100.0% 
2.2.4{2.2.24} 572.0704 573.0762 35.7mg 44 100.0% 
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2.2.5{2.2.24} 530.0235 531.0271 56.5mg 69 97.2% 
2.2.6{2.2.24} 530.0235 531.0343 40.5mg 50 97.5% 
2.2.7{2.2.24} 592.0339 593.0422 2.1mg 3 67% 
2.2.8{2.2.24} 512.1505 513.1599 31.2mg 37 99.1% 
 
5.6 Experimental for Chapter 3.1 
Silica-Supported Oligomeric Benzyl Phosphate (Si-OBP) and Triazole 
Phosphate (Si-OTP) Alkylating Reagents. 
Experimental Section and Characterization data        (SI-253–SI-269) 
1H, 13C, Spectra for all Relevant Compounds         (SI-270–SI-294) 
 
General Procedure for Synthesis of Silica Oligomeric Benzyl Phosphate (Si-
OBPn) and Triazole Phosphate (Si-OTPn).  
Si-Nb (load ~0.4 mmol/g, 1 equiv.) was heated with C848 (G-II, 0.2 equiv.) at 
45 ºC in dichloromethane for 2 hrs under argon.  The OBP or OTP monomer was 
added (50 equiv. w/r to cat. G-II) in CH2Cl2 and toluene to the reaction mixture and 
heated at 45 ºC for overnight. The reaction mixture was cooled to room temperature 
and EVE was added, with stirring for an additional 1 hour at room temperature.  The 
reaction mixture was filtered and washed with mixture of toluene:CH2Cl2 (1:1), and 




Procedure A: General procedure for different nucleophilic substitution with  
Si-OBPn.  
In a sealed pressure tube was added Si-OBPn (1.5 equiv.), followed by 
addition of sodium iodide (0.2 equiv.), Cs2CO3 (3.0 equiv.), and solvent THF (0.2M).  
The mixture was stirred rapidly and then nucleophiles were added.  The reaction was 
sealed under argon and heated to 80 ºC with stirring for 12 h.  After such time, the 
reaction was cooled to rt and the crude mixture was filtered via a Celite®-packed SPE 
and rinsed several times with a mixture of hexanes:EtOAc (1:2).  The resulting eluent 
was concentrated in vacuo to yield the benzylated products in good to excellent yields 
and purities. 
Procedure B: General procedure for different nucleophilic substitution with  
Si-OTPn.  
In a pressure tube was added Si-OTPn (1.5 equiv.), followed by addition of 
NaI (0.2 equiv.), Cs2CO3 (3.0 equiv.), and solvent DMF (0.2M).  The nucleophile was 
added and the resulting mixture was stirred rapidly.  The reaction was sealed under 
argon and heated to 90 ºC w/ stirring for (12−14 h) after which time, DMF was 
removed in vacuo.  The crude mixture was filtered via celite®-SPE and rinsed with 
EtOAc.  The resulting eluent was then concentrated in vacuo to yield the products in 
good to excellent yields and purities. 
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1-(benzyloxy)-4-(tert-butyl)benzene (3.1.8c).  
 
Utilizing general procedure A, 3.1.8c (18.5 mg, 0.077 mmol, 97%) was isolated as a 
white solid.  MP: 65 ºC; FTIR (neat): 3056, 3024, 2960, 2866, 1610, 1512, 1456, 
1242, 1182, 1024 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.46–7.43 (m, 2H), 7.42–7.38 
(m, 2H), 7.36–7.30 (m, 3H), 6.92–6.96 (m, 2H), 5.06 (s, 2H), 1.33 (s, 9H); 13C NMR 
(126 MHz, CDCl3): δ 156.6, 143.7, 137.3, 128.5 (2C), 127.9, 127.5 (2C), 126.2 (2C), 
114.2 (2C), 70.0, 34.1, 31.4 (3C);  GC-MS (EI+) calculated for C17H20O 240.15; found 
240.1 (M+ 7), 91.0 (100). 
1-(benzyloxy)-2,4-dichlorobenzene (3.1.8d).  
 
Utilizing general procedure A, 3.1.8d (30 mg, 0.119 mmol, 98%) was isolated as a 
thick liquid.  
FTIR (neat): 3031, 2931, 2835, 1597, 1481, 1452, 1382, 1290, 1249, 1060 cm-1;  
1H NMR (400 MHz, CDCl3): δ 7.47–7.44 (m, 2H), 7.43–7.38 (m, 3H), 7.37–7.33 (m, 
1H), 7.18 (dd, J = 2.6, 8.7 Hz, 1H), 6.90 (d, J = 8.9 Hz, 1H), 5.16 (s, 2H);  
13C NMR (126 MHz, CDCl3): δ 153.0, 136.1, 130.1, 128.7 (2C), 128.1, 127.5, 127.1 
(2C), 126.0, 124.1, 114.8, 71.2; GC-MS (EI+) C13H10Cl2O calculated 252.01; found 






Benzyl(2,4,6-trichlorophenyl)sulfane (3.1.8e).  
 
Utilizing general procedure A, 3.1.8e (21 mg, 0.07 mmol, 98%) was isolated as a 
yellow solid. MP: 112 ºC;  
FTIR (neat): 3087, 2935, 2850, 1583, 1454, 1321, 1116, 1054 cm-1.  
1H NMR (400 MHz, CDCl3): δ 7.47 (s, 1 H), 7.37–7.33 (m, 4H), 7.32–7.39 (m, 2H), 
4.15 (s, 2H);  
13C NMR (126 MHz, CDCl3): δ 136.3, 135.3, 132.0, 131.3, 130.6, 130.0, 129.5, 128.9 
(2C), 128.8 (2C), 127.8, 37.6; GC-MS (EI+) C13H9Cl3S calculated 301.95; found 
301.9 (32), 169 (7), 91.0 (100). 
Benzyl(3,4-dimethoxyphenyl)sulfane (3.1.8f).  
 
Utilizing general procedure A, 3.1.8f (22 mg, 0.085 mmol, 98%) was isolated as a 
thick liquid.  
FTIR (neat): 2933, 2833, 1595, 1504, 1251, 1228, 1135, 1026 cm-1. 1H NMR (400 
MHz, CDCl3): δ 7.31 –7.19(m, 5 H), 6.95 (dd J = 8.3, 2.2 Hz, 1H), 6.0–6.74 (m, 2H), 
4.02 (s, 2H), 3.88 (s, 3H), 3.75 (s, 3H);  
13C NMR (126 MHz, CDCl3): δ 148.7 (2C), 138.2, 129.0 (2C), 128.4 (2C), 127.0, 
126.2, 125.3, 115.9, 111.3, 55.9, 55.8, 41.2; GC-MS (EI+) C15H16O2S calculated 







N-benzyl-4-bromo-N-butyl-2-fluorobenzenesulfonamide (3.1.8g).  
 
Utilizing general procedure A, 3.1.8g (24 mg, 0.060 mmol, 99%) was isolated as a 
thick liquid. FTIR (neat): 3089, 3025, 2958, 2931, 1589, 1472, 1456, 1396, 1344, 
1161, 1135 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.79 (t, J = 7.70 Hz, 1H), 7.43–7.38 (m, 2H), 7.34–
7.28 (m, 5H), 4.47 (s, 2H), 3.19 (t, J = 7.60 Hz, 2H), 1.35–1.29 (m, 2H), 1.16–1.11 
(m, 2H), 0.76 (t, J = 7.45 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ 158.44 (1JC–F = 259 Hz), 136.1, 131.8, 128.6 (2C), 
128.2 (2C), 128.0, 127.8 (3C), 120.7 (2J = 25.0 Hz), 51.4, 47.3, 29.7, 19.7, 13.5. GC-
MS (EI+) C17H19BrFNO2S calculated 399.3; found 399.0 (M+ 3), 401.2 (M+2 2), 355.8 
(60), 357.8 (60), 91 (100). 
(S)-2,3-dibenzyl-7-bromo-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine1,1-
dioxide (3.1.8h).  
 
Utilizing general procedure A, 3.1.8h (30 mg, 0.066 mmol, 97%) was isolated as a 
white solid. MP: 170 ºC.  
FTIR (neat): 3026, 2921, 2852, 1595, 1552, 1325, 1153, 700 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.74 (d, J = 8.5 Hz, 1H), 7.33–7.28 (m, 4H), 7.25–











1H), 4.40 (d, J = 14.3 Hz, 1H), 4.26 (dd, J = 4.5, 13.42 Hz, 1H), 4.09 (d, J = 14.6 Hz, 
1H), 3.85 (m, 1H), 2.93 (m, 2H).  
13C NMR (126 MHz, CDCl3): δ 156.1, 137.4, 135.2, 129.8, 130.8, 129.0 (2), 128.7 
(2), 128.6 (2), 128.1 (2), 127.1 (2), 126.7, 126.4, 124.4, 73.7, 62.4, 55.2, 37.9. HRMS 
calculated for C22H20BrNO3SNa (M+Na)+ 480.0245; found 480.0258 (TOF MS). 
1-((4-bromobenzyl)oxy)-2,4-dichlorobenzene (3.1.8i).  
 
Utilizing general procedure A, 3.1.8i (29 mg, 0.088 mmol, 98%) was isolated as a 
yellow solid. MP: 87 ºC.  
FTIR (neat) 3070, 2923, 2866, 1585, 1571, 1480, 1456, 1290, 1262, 1103 cm-1. 1H 
NMR (500 MHz, CDCl3): δ 7.52–7.54 (m, J = 8.4 Hz, 2H), 7.40 (d, J = 2.7 Hz, 1H), 
7.32–7.34 (m, 2H), 7.15–7.18 (dd, J = 8.6, 2.4 Hz, 1H), 6.85 (d, J = 8.8, 1H), 5.10 (s, 
2H).  
13C NMR (126 MHz, CDCl3): δ 152.7, 135.0, 131.8 (2C), 130.1, 128.7 (2C), 127.5, 
126.3, 124.1, 122.1, 114.7, 70.3. GC-MS (EI+) C13H9BrCl2O calculated 329.92; found 






(4-bromobenzyl)(2,4,6-trichlorophenyl)sulfane (3.1.8j).  
 
Utilizing general procedure A, 3.1.8j (25 mg, 0.066 mmol, 94%) was isolated as a 
white solid. MP: 54 ºC. FTIR (neat) 2923, 1590, 1487, 1452, 1433, 1323, 1116, 1058, 
1012 cm-1.  
1H NMR (500 MHz, CDCl3): δ 7.44–7.47 (m, 3H), 7.27 (s, 1H), 7.20–7.22 (m, 2H), 
4.08 (s, 2H).  
13C NMR (126 MHz, CDCl3): δ 135.6, 134.5, 132.4, 131.9 (2C), 131.4, 130.7, 130.5 
(2C), 130.4, 129.9, 121.7, 37.1. GC-MS (EI+) C13H8Cl3BrS calculated 379.86; found 
379.8 (M+ 5), 381.8 (M+2, 7), 169 (100), 90 (25). 
2,4-dichloro-1-((4-fluorobenzyl)oxy)benzene (3.1.8k).  
 
Utilizing general procedure A, 3.1.8k (24 mg, 0.088 mmol, 96%) is isolated as a thick 
liquid.  
FTIR (neat) 2931, 1604, 1510, 1483, 1379, 1226, 1060, 823, 730 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.41–7.45 (m, 2H), 7.40 (d, J = 2.5 Hz, 1H), 7.15–
7.18 (dd, J = 8.6, 2.5 Hz, 1H), 7.07–7.11 (m, 2H), 6.88 (d, J = 7.5, 1H), 5.10 (s, 2H). 
13C NMR (126 MHz, CDCl3): δ 162.5 (1JC–F = 246.5 Hz) 152.8, 131.8, 130.1, 129.1 
(3J = 8.4 Hz, 2), 127.5, 126.6, 124.2, 115.6 (2J = 21.6 Hz, 2) 114.9, 70.5. GC-MS 









4-fluorobenzyl)(2,4,6-trichlorophenyl)sulfane (3.1.8l).  
 
Utilizing general procedure A, 3.1.8l (21 mg, 0.065 mmol, 95%) was isolated as a 
thick liquid.  
FTIR (neat) 2933, 1600, 1505, 1433, 1323, 1228, 1116, 1058, 837 cm-1. 1H NMR 
(500 MHz, CDCl3): δ 7.49 (s, 1H), 7.31–7.34 (m, 2H), 7.29 (s, 1H), 7.01–7.05 (m, 
2H), 4.13 (s, 2H).  
13C NMR (126 MHz, CDCl3): δ 163.3, (1JC–F = 247.5 Hz) 135.8, 132.3, 131.3, 131.1 
(4JC–F = 3.6 Hz), 130.7, 130.5 (3J = 8.5 Hz, 2) 130.4, 129.9, 115.7 (2J = 22.3 Hz, 2), 
36.9. GC-MS (EI+). C13H8Cl3FS calculated 319.94; found 319.9 (M+ 5), 109 (100). 
2,4-dichloro-1-((3,5-dimethoxybenzyl)oxy)benzene (3.1.8m).  
 
Utilizing general procedure A, 3.1.8m (28 mg) 0.089 mmol, 98%) was isolated as a 
yellow solid. MP: 55 ºC; FTIR (neat): 2935, 2825, 1598, 1483, 1456, 1292, 1157, 
1060 cm-1; 
1H NMR (500 MHz, CDCl3): δ 7.38 (d, J = 2.5 Hz, 1H), 7.14–7.16 (dd, J = 8.7, 2.4 
Hz, 1H), 6.88–6.85 (d, J = 7.8 Hz, 1H), 6.60 (d, J = 2.2 Hz, 2H), 6.42 (t, J = 2.5 Hz, 










13C NMR (126 MHz, CDCl3): δ 161.0 (2C), 152.9, 138.5, 130.0, 127.5, 126.1, 124.0, 
114.8, 104.7 (2C), 99.8, 70.9, 55.3 (2C). GC-MS (EI+). C15H13Cl3O2S, calculated 
312.03; found 312.0 (M+, 3), 151.1 (100). 
(3,5-dimethoxybenzyl)(2,4,6-trichlorophenyl)sulfane (3.1.8n).  
 
Utilizing general procedure A, 3.1.8n (20 mg, 0.055 mmol, 94%) was isolated as a 
white solid. MP: 84 ºC; FTIR (neat): 2956, 2931, 2830, 1610, 1596, 1454, 1431, 
1323, 1205, 1157, 1158 cm-1;  
1H NMR (500 MHz, CDCl3): δ 7.46 (s, 1H), 7.30 (s, 1H), 6.51 (d, J = 2.25 Hz, 2H), 
6.38 (t, J = 2.3, Hz 1H), 4.08 (s, 2H), 3.79 (s, 6H).  
13C NMR (126 MHz, CDCl3): δ 160.1 (2C), 137.5, 136.3, 131.9, 131.3, 130.6, 130.0, 
129.4, 106.9 (2C), 99.8, 55.4 (2C), 37.8. GC-MS (EI+). C15H13Cl3O2S, calculated 
361.97 found 361.9 (M+ 3), 151.1 (100). 
1-benzyl-4-(pyrrolidin-1-ylmethyl)-1H-1,2,3-triazole (3.1.11a).  
 
Utilizing general procedure B, 3.1.11a (48 mg, 0.198 mmol, 84%) was isolated as a 
light brown thick liquid. FTIR (neat): 3307, 2923, 1581, 1448, 1420, 1396, 1238, 
1215, 1121, 1008 cm-1;  
1H NMR (400 MHz, CDCl3): δ 7.59 (s, 1H), 7.41–7.33 (m, 3H), 7.30–7.26 (m, 2H), 











MHz, CDCl3): δ 144.6, 134.6, 129.1 (2C), 128.7, 128.1 (2C), 122.9, 54.2, 53.9 (2C), 
50.5, 23.4 (2C). HRMS calculated for C14H19N4 (M+H)+ 243.1610; found 243.1631 
(TOF MS ES+). 
1-benzyl-4-((3-chlorophenoxy)methyl)-1H-1,2,3-triazole (3.1.11c).  
 
Utilizing general procedure B, 1-benzyl-4-((3-chlorophenoxy)methyl)-1H-1,2,3-
triazole 3.1.11c ( 50 mg, 0.167 mmol, 91%) was isolated as a white solid. MP: 96 ºC; 
FTIR (neat): 2960, 2358, 1610, 1511, 1463, 1250, 1184, 1031 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.53 (s, 1H), 7.43 – 7.35 (m, 3H), 7.29 (dd, J = 4.8, 
2.8 Hz, 2H), 7.20 (t, J = 8.1 Hz, 1H), 6.98 – 6.93 (m, 2H), 6.89 – 6.84 (m, 1H), 5.55 
(s, 2H), 5.17 (s, 2H).  
13C NMR (126 MHz, CDCl3): δ 158.9, 144.1, 134.9, 134.4, 130.3, 129.2 (2C), 128.9, 
128.2 (2C), 122.7, 121.5, 115.4, 113.1, 62.2, 54.3. HRMS calculated for C16H15ClN3O 
(M+H)+ 300.0904; found 300.0906 (TOF MS ES+). 
1-benzyl-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (3.1.11d).  
 
Utilizing general procedure B, 3.1.11d (53 mg, 0.168 mmol, 90%) was isolated as a 









FTIR (neat): 3409, 2918, 1583, 1458, 1390, 1267, 1238, 1155, 1095 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 8.23 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.62 (s, 1H), 
7.54–7.44 (m, 3H), 7.43–7.36 (m, 4H), 7.34 – 7.25 (m, 2H), 6.98 (d, J = 7.6 Hz, 1H), 
5.57 (s, 2H), 5.41 (s, 2H). 
 13C NMR (126 MHz, CDCl3): δ 153.9, 144.8, 134.5, 129.2 (2C), 128.8, 128.1 (2C), 
127.5, 126.5, 125.8, 125.6, 125.3, 122.6, 122.0, 120.9, 105.4, 62.5, 54.3. HRMS 
calculated for C20H18N3O (M+H)+ 316.1450; found 316.1427 (TOF MS ES+). 
1-benzyl-4-(((2,4,6-trichlorophenyl)thio)methyl)-1H-1,2,3-triazole (3.1.11e).  
 
Utilizing general procedure A, 3.1.11e (63 mg, 0.164 mmol, 92%) was isolated as a 
white solid. MP: 137 ºC; FTIR (neat):  3369, 2923, 1699, 1456, 1433, 1363, 1242, 
1116, 1049, 721 cm-1;  
1H NMR (400 MHz, CDCl3): δ 7.44 (s, 1H), 7.41–7.34 (m, 5H), 7.24–7.20 (m, 2H), 
5.52 (s, 2H), 4.25 (s, 2H).  
13C NMR (126 MHz, CDCl3): δ 143.8, 135.1, 134.4, 132.3, 131.5, 130.7, 130.6, 
130.0, 129.2 (2C), 128.9, 128.0 (2C), 122.1, 54.3, 27.8. HRMS calculated for 








1-benzyl-4-(((3,4-dimethoxyphenyl)thio)methyl)-1H-1,2,3-triazole (3.1.11f).  
 
Utilizing general procedure B, 3.1.11f (53 mg, 0.155 mmol, 94%) was isolated as a 
white solid. MP: 101 ºC;  
FTIR (neat): 2952, 1581, 1502, 1438, 1253, 1228, 1135, 1024 cm-1;  
1H NMR (400 MHz, CDCl3): δ 7.58–7.32 (m, 3H), 7.20 (dd, J = 6.7, 2.7 Hz, 2H), 
7.17 (s, 1H), 6.89 (dt, J = 5.1, 2.1 Hz, 2H), 6.72 (d, J = 8.2 Hz, 1H), 5.47 (s, 2H), 4.14 
(s, 2H), 3.86 (s, 3H), 3.79 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 149.0, 148.7, 145.5, 134.6, 129.1 (2C), 128.7, 127.9 
(2C), 125.7, 124.8, 121.9, 115.2, 111.4, 55.9, 55.9, 54.1, 30.8.  
HRMS calculated for C18H19N3O2S (M+Na)+ 364.1096; found 364.1063 (TOF MS 
ES+). 
N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-2-bromo-N-
isopropylbenzenesulfonamide (3.1.11g).   
 
Utilizing general procedure B, 3.1.11g (47 mg, 0.104 mmol, 89%) was isolated as a 
colorless thick liquid. FTIR (neat): 3134, 2923, 2846, 1703, 1604, 1487, 1456, 1411, 













1H NMR (400 MHz, CDCl3): δ 8.14 (dd, J = 7.8, 1.8 Hz, 1H), 7.2923, (dd, J = 7.7, 
1.4 Hz, 1H), 7.65 (s, 1H), 7.48 – 7.32 (m, 5H), 7.27 – 7.20 (m, 2H), 5.52 (d, J = 5.1 
Hz, 2H), 4.71 (s, 2H), 4.03 – 3.82 (m, 1H), 1.09 (d, J = 6.8 Hz, 6H).  
13C NMR (126 MHz, CDCl3): δ 147.1, 139.3, 135.6, 134.7, 133.5, 132.5, 129.1 (2C), 
128.7, 127.9 (2C), 127.5, 123.6, 120.3, 54.2, 49.9, 38.6, 21.1 (2C).  
HRMS calculated for C19H21BrN4NaO2S (M+H)+ 471.0466; found 471.0478 (TOF 
MS ES+) 
4-((4-bromophenoxy)methyl)-1-(4-methylbenzyl)-1H-1,2,3-triazole (3.1.11h).  
 
Utilizing general procedure B, 3.1.11h (52 mg, 0.145 mmol, 85%) was isolated as a 
white solid. MP: 103 ºC; FTIR (neat): 3087, 2920, 1589, 1490, 1384, 1282, 1242, 
1022, 825, 757 cm-1.  
1H NMR (400 MHz, CDCl3): δ 7.49 (s, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.19 (m, 4H), 
6.85 (d, J = 8.8 Hz, 2H), 5.49 (s, 1H), 5.14 (s, 1H), 2.36 (s, 1H).  
13C NMR (126 MHz, CDCl3): δ 157.3, 144.1, 138.8, 132.3 (2C), 131.3, 129.8 (2C), 
128.2 (2C), 122.6, 116.6 (2C), 113.5, 62.2, 54.1, 21.2.  












Utilizing general procedure B, 3.1.11i (48 mg, 0.120 mmol, 87%) was isolated as a 
white solid. MP: 136 ºC; FTIR (neat): 3083, 2920, 1515, 1434, 1323, 1151, 1116, 
1058, 871 cm-1. 
1H NMR (400 MHz, CDCl3): δ 7.43 (s, 1H), 7.38 (s, 1H), 7.31 (s, 1H), 7.18 (d, J = 
7.9 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 5.45 (s, 2H), 4.23 (s, 2H), 2.36 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 143.7, 138.2, 135.1, 132.3, 131.5, 131.3, 130.7, 
130.5, 130.0, 129.8 (2C), 128.0 (2C), 122.0, 54.1, 27.9, 21.2.  
HRMS calculated for C17H15Cl3N3S (M+H)+ 398.0052; found 398.0063 (TOF MS 
ES+). 
4-((4-bromophenoxy)methyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazole (3.1.11j).  
 
Utilizing general procedure B, 3.1.11j (67 mg, 0.179 mmol, 89%) was isolated as a 
white solid. MP: 98 ºC  













1H NMR (400 MHz, CDCl3): δ 7.48 (s, 1H), 7.36 (dd, J = 9.6, 2.5 Hz, 2H), 7.23 (d, J 
= 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.9 Hz, 2H), 5.47 (s, 2H), 5.14 (s, 
2H), 3.82 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 160.0, 157.3, 144.1, 132.3 (2C), 129.8 (2C), 126.3, 
122.4, 116.6 (2C), 114.5 (2C), 113.5, 62.2, 55.4, 53.9.  





Utilizing general procedure B, 3.1.11k (50 mg, 0.120 mmol, 86%) was isolated as a 
yellow solid.  
FTIR (neat): 3082, 2931, 1612, 1514, 1434, 1323, 1249, 1176, 1118, 1058 cm-1; MP: 
88 ºC 1H NMR (400 MHz, CDCl3): δ 7.35 (m, 1H), 7.31 (m, 1H), 7.22 (s, 1H), 7.20–
7.17 (m, 1H), 7.09 (dd, J = 8.5, 1.8 Hz, 2H), 6.82 (dd, J = 8.4, 2.1 Hz, 2H), 5.34 (s, 
2H), 4.14 (s, 2 H), 3.74 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 160.0, 143.6, 135.2, 132.3, 131.5, 130.7, 130.5, 
130.0, 129.6 (2C), 126.3, 121.9, 114.5 (2C), 55.4, 53.8, 27.9. 











Utilizing general procedure B, 3.1.11l (52 mg, 0.148 mmol, 86%) was isolated as a 
white solid. FTIR (neat): 2921, 2852, 1488, 1446, 1384, 1244, 1224, 1112, 1054 cm-
1; MP: 90 ºC;  
1H NMR (400 MHz, CDCl3): 7.54 (s, 1H), 7.41–7.35 (ddd, J = 10.2, 3.4, 2.2, 2H), 
6.91–6.85 (ddd, J = 10.2, 3.4, 2.2, 2H), 5.19 (s, 2H), 4.18 (d, J = 7.2 Hz, 2H), 1.94–
1.83 (m, 1H), 1.76–1.61 (m, 5H), 1.29–1.14 (m, 3H), 1.04–0.94 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ 157.3, 143.5, 132.3, 123.1, 116.7, 113.5, 62.3, 56.6, 
38.7, 30.5 (2C), 26.0, 25.5 (2C).  





Utilizing general procedure B, 3.1.11m (48 mg, 0.122 mmol, 88%) was isolated as a 
white solid.  











1H NMR (500 MHz, CDCl3): δ 7.46 (s, 1H), 7.39 (d, J = 5.3 Hz, 2H), 4.27 (s, 2H), 
4.14 (d, J = 7.2 Hz, 2H), 1.89–1.79 (m, 1H), 1.76–1.61 (m, 4H), 1.58–1.50 (m, 2H), 
1.28–1.09 (m, 4H), 0.95 (qd, J = 12.2, 3.2 Hz, 2H).  
13C NMR (126 MHz, CDCl3): δ 143.1, 135.2, 132.3, 131.5, 130.7, 130.5, 130.0, 
122.6, 56.6, 38.7, 30.4 (2C), 27.8, 26.0, 25.5 (2C).  
HRMS calculated for C16H19Cl3N3S (M+H)+ 390.0365; found 390.0377 (TOF MS 
ES+). 
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5.8 Experimental for Chapter 3.2. 
Application of Silica-supported Alkylating Reagents in a One-Pot, Sequential 
Protocol to Diverse Benzoxathiazepine 1,1-Dioxides. 
Experimental Section and Characterization data        (SI-295–SI-310) 
1H, 13C, Spectra for all Relevant Compounds         (SI-311–SI-325) 
 
Procedure A: General procedure for the synthesis of benzoxathiazepine 1,1-
dioxides in one pot sequential protocol. 
 
 To a microwave vial (0.5–2.0 mL) vial w/ teflon cap was added 2,4-
difluorobenzenesulfonyl chloride 3.2.4 (1.0 equiv.) in solvent DMF (0.2 M) followed 
by addition of chiral amino alcohol 3.2.5 (1.1 equiv.) and Et3N (1.2 equiv.). The 
reaction was sealed under argon and stirred for 4–5 hours at RT. Next, Cs2CO3 (2.5 
equiv.) was added and the reaction mixture was heated to 140 ºC under microwave 
conditions for 30 min to generate compound 3.2.7.  The reaction was monitored by 
TLC, and upon disappearance of SM, the corresponding Si-Reagent [Si-ROMP 
benzylating Si-OBPn 3.2.3a–c (n ~ 50) and triazolating Si-OTPn 3.2.3d–e (n ~ 50)] 
was added to the resulting mixture, followed by the addition of NaI (0.2 equiv.) and 
the mixture was heated to 80 ºC for 12–14 hrs.  Then the amine component (2.5 
equiv.) was added neat, and the final intermolecular SNAr reaction was achieved at 
150 ºC under microwave irradiations in the same pot. The mixture was concentrated 
in vacuo and purified by flash chromatography.  The resulting final products (3.2.10–






FF ii) SNAr, µW,















    NaI (0.2 equiv.)













benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10a) 
 
 
Utilizing general procedure A, 3.2.10a (34 mg, 0.082 mmol, 71%) was isolated after 
chromatography (5% MeOH in EtOAc) as a yellow solid. 
MP: 131 ºC. 
FTIR (neat, cm-1): 2975, 2929, 2864, 2773, 1600, 1514, 1481, 1330, 1143, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 7.1 Hz, 2H), 
7.36–7.30 (m, 2H), 7.30–7.24 (m, 1H), 6.29 (dd, J = 8.9, 2.4 Hz, 1H), 6.17 (d, J = 2.4 
Hz, 1H), 4.40 (dd, J = 13.1, 10.5 Hz, 1H), 4.28 (d, J = 15.4 Hz, 1H), 4.20 (dd, J = 
13.1, 3.8 Hz, 1H), 4.08 (d, J = 15.4 Hz, 1H), 3.57–3.44 (m, 2H), 3.34 (td, J = 9.8, 6.7 
Hz, 1H), 3.19 (t, J = 8.8 Hz, 1H), 2.94–2.82 (m, 1H), 2.33 (s, 6H), 2.25 (dd, J = 12.1, 
5.8 Hz, 1H), 2.05–1.91 (m, 1H), 1.28–1.21 (m, 1H), 1.10 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.2, 151.4, 137.5, 130.5, 128.5 (2C), 127.9, 127.9, 
127.5, 118.6, 106.5, 103.1, 77.3, 73.9, 65.3, 56.5, 52.0, 46.9, 44.2, 44.1, 29.9, 16.2. 










benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10b)  
 
Utilizing general procedure A, 3.2.10b (33 mg, 0.085 mmol, 90%) was isolated after 
chromatography (2:8 Hex/EtOAc) as a light brown solid. 
MP: 95 ºC. 
FTIR (neat, cm-1): 2929, 2854, 1600, 1504, 1388, 1325, 1139, 1080. 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.8 Hz, 1H), 7.44–7.38 (m, 2H), 7.36–
7.31 (m, 2H), 7.31–7.22 (m, 1H), 6.29 (dd, J = 8.8, 2.4 Hz, 1H), 6.18 (d, J = 2.3 Hz, 
1H), 4.63 (m, 1H), 4.37 (dd, J = 13.2, 10.4 Hz, 1H), 4.30–4.24 (m, 1H), 4.21 (dd, J = 
13.1, 3.7 Hz, 1H), 4.15–4.04 (m, 2H), 3.58–3.49 (m, 2H), 3.40 (td, J = 9.1, 3.1 Hz, 
1H), 3.29 (dt, J = 10.8, 1.6 Hz, 1H), 2.16 (m, 1H), 2.10 (m, 1H), 1.27 (t, J = 7.2 Hz, 
1H), 1.10 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 151.6, 137.5, 130.5, 128.5 (2C), 127.9 (2C), 
127.5, 118.4, 106.8, 103.4, 73.9, 70.8, 56.5, 56.1, 51.7, 45.6, 34.0, 16.2. 










benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10c) 
 
Utilizing general procedure A, 3.2.10c (30 mg, 0.076 mmol, 79%) was isolated after 
chromatography (5% MeOH in EtOAc) as a yellow solid. 
MP: 136 ºC. 
FTIR (neat, cm-1): 2935, 2844, 2796, 1596, 1550, 1425, 1330, 1147, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.9 Hz, 1H), 7.40 (d, J = 7.5 Hz, 2H), 
7.37–7.28 (m, 3H), 6.64 (dd, J = 9.0, 2.5 Hz, 1H), 6.50 (d, J = 2.4 Hz, 1H), 4.48 (t, J 
= 12.0 Hz, 1H), 4.36 (d, J = 15.3 Hz, 1H), 4.22 (dd, J = 13.1, 4.0 Hz, 1H), 4.09 (d, J = 
15.3 Hz, 1H), 4.01 (m, 1H), 3.37 – 3.28 (m, 4H), 2.56 (t, J = 5.1 Hz, 4H), 2.37 (s, 
3H), 1.11 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 154.8, 137.2, 130.2 (2C), 128.5 (2C), 128.0, 
127.6, 121.1, 109.3, 106.6, 77.2, 74.2, 56.7, 54.6 (2C), 47.3 (2C), 46.0, 16.2. 












benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10d) 
 
Utilizing general procedure A, 3.2.10d (31.5 mg, 0.085 mmol, 90%) was isolated 
after chromatography (1:1, Hex/EtOAc) as a white solid. 
MP: 149 ºC. 
FTIR (neat, cm-1): 2979, 2923, 1600, 1521, 1334, 1159, 1076. 
1H NMR (500 MHz, CDCl3) δ 7.99–7.96 (m, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.77 (d, J 
= 1.7 Hz, 1H), 7.53–7.48 (m, 2H), 7.41–7.38 (m, 2H), 7.35 (tt, J = 6.3, 1.0 Hz, 2H), 
7.32–7.29 (m, 1H), 6.52 (dd, J = 2.6, 1.7 Hz, 1H), 4.73–4.61 (m, 1H), 4.48 (d, J = 
15.1 Hz, 1H), 4.32 (dd, J = 13.2, 4.4 Hz, 1H), 4.16 (d, J = 15.0 Hz, 1H), 4.06–3.96 
(m, 1H), 1.16 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 156.8, 143.8, 142.9, 136.4, 130.4, 128.6 (2C), 129.5, 
128.2 (2C), 127.9, 126.9, 113.1, 111.7, 108.7, 74.8, 56.9, 53.3, 16.1. 











benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10e) 
 
Utilizing general procedure A, 3.2.10e (32 mg, 0.087 mmol, 91%) was isolated after 
chromatography (1:1, Hex/EtOAc) as a yellow liquid. 
FTIR (neat, cm-1): 2929, 2852, 1602, 1575, 1328, 1498, 1334, 1203, 1161, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.5 Hz, 1H), 7.92 (s, 1H), 7.40–7.29 (m, 
6H), 7.26–7.19 (m, 2H), 7.11–7.07 (m, 1H), 4.75 (t, J = 12.2 Hz, 1H), 4.53 (d, J = 
14.9 Hz, 1H), 4.33 (dd, J = 13.2, 4.5 Hz, 1H), 4.18 (d, J = 14.9 Hz, 1H), 3.98 (m, 
1H), 1.17 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 156.9, 141.1, 136.1, 135.3, 131.2, 130.9, 130.6, 128.6 
(2C), 128.3 (2C), 128.0, 117.7, 115.3, 113.6, 75.1, 57.1, 53.8, 16.1. 











2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10f) 
 
Utilizing general procedure A, 3.2.10f (34.5 mg, 0.085 mmol, 90%) was isolated after 
chromatography (2:8, Hex/EtOAc)  as a yellow liquid.  
FTIR (neat, cm-1): 2975, 2929, 2918, 2854, 1600, 1508, 1388, 1325, 1139, 1078. 
1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.8 Hz, 1H), 7.43–7.32 (m, 2H), 7.09–
6.95 (m, 2H), 6.29 (dd, J = 8.8, 2.4 Hz, 1H), 6.17 (d, J = 2.3 Hz, 1H), 4.68–4.55 (m, 
1H), 4.40–4.29 (m, 1H), 4.20 (dt, J = 14.3, 4.0 Hz, 2H), 4.07 (t, J = 13.4 Hz, 2H), 
3.59–3.48 (m, 2H), 3.39 (ddd, J = 9.4, 8.4, 3.2 Hz, 1H), 3.29 (dt, J = 10.9, 1.6 Hz, 
1H), 2.23–2.03 (m, 3H), 1.09 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.2 (1JC–F = 245.6 Hz), 157.1, 151.6, 133.3 (4JC–F = 
3.1 Hz), 130.5, 129.5 (3JC–F = 8.1 Hz), 118.3, 115.3 (2JC–F = 21.6 Hz, 2C), 106.5, 
103.1, 73.8, 70.8, 60.4, 56.6, 56.1, 50.8, 45.6, 34.0, 16.2. 












dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10g) 
 
Utilizing general procedure A, 3.2.10g (36 mg, 0.083 mmol, 90%) was isolated after 
chromatography (5% MeOH in EtOAc)  
 as a light brown solid. 
MP: 132 ºC. 
FTIR (neat, cm-1): 2975, 2948, 2866, 2773, 1600, 1508, 1330, 1143, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.8 Hz, 1H), 7.41–7.33 (m, 2H), 7.06–
6.92 (m, 2H), 6.29 (dd, J = 8.8, 2.4 Hz, 1H), 6.16 (d, J = 2.4 Hz, 1H), 4.42–4.32 (m, 
1H), 4.26–4.16 (m, 2H), 4.16–4.01 (m, 2H), 3.56–3.43 (m, 2H), 3.34 (td, J = 9.8, 6.8 
Hz, 1H), 3.18 (dd, J = 9.3, 8.2 Hz, 1H), 2.92–2.79 (m, 1H), 2.33 (s, 6H), 2.29–2.21 
(m, 1H), 2.00–1.90 (m, 1H), 1.09 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.2 (1JC–F = 245.6) Hz, 157.1, 151.4, 133.3 (4JC–F = 
3.2 Hz), 130.4, 129.6, 129.5 (3JC–F = 8.1 Hz), 118.4, 115.3 (2JC–F = 21.4 Hz, 2C), 
106.5, 103.1, 73.9, 65.3, 56.5, 52.2, 51.0, 46.9, 44.2 (2C), 30.1, 16.2. 













2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10h)  
 
 
Utilizing general procedure A, 3.2.10h (33 mg, 0.067 mmol, 72%) was isolated after 
chromatography (5% MeOH in EtOAc) as a white solid. 
MP: 158 ºC. 
FTIR (neat, cm-1): 2975, 2947, 2835, 2773, 1600, 1546,, 1485, 1330, 1143, 1074. 
1H NMR (400 MHz, CDCl3) 7.63 (d, J = 8.8 Hz, 1H), 7.47–7.43 (m, 2H), 7.29 (d, J = 
1.9 Hz, 1H), 7.28, (d, J = 1.9 Hz, 1H) 6.29 (dd, J = 8.8, 2.4 Hz, 1H), 6.16 (d, J = 2.4 
Hz, 1H), 4.39–4.29 (m, 1H), 4.20 (dd, J = 13.1, 3.8 Hz, 1H), 4.13 (d, J = 21.3 Hz, 
2H), 4.06 (d, J = 15.7 Hz, 1H), 3.61–3.43 (m, 2H), 3.34 (td, J = 9.9, 6.8 Hz, 1H), 3.18 
(dd, J = 9.3, 8.1 Hz, 1H), 2.93–2.79 (m, 1H), 2.33 (s, 6H), 2.24 (ddt, J = 12.8, 6.6, 2.8 
Hz, 1H), 2.02–1.87 (m, 1H), 1.09 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 151.5, 136.7, 131.6 (2C), 130.5, 129.6 (2C), 
121.4, 118.4, 106.6, 103.2, 73.8, 65.3, 56.7, 52.1, 51.0, 46.9, 44.2 (2C), 30.1, 16.2. 












2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10i) 
 
Utilizing general procedure A, 3.2.10i (37 mg, 0.079 mmol, 84%) was isolated after 
chromatography (100% EtOAc) as a yellow liquid. 
FTIR (neat, cm-1): 2933, 2916, 2848, 1600, 1487,1386, 1326, 1141, 1078. 
1H NMR (400 MHz, CDCl3) δ 7.61 (dd, J = 8.8, 2.1 Hz, 1H), 7.47–7.42 (m, 2H), 
7.31–7.24 (m, 2H), 6.28 (dt, J = 8.9, 2.3 Hz, 1H), 6.17 (t, J = 2.2 Hz, 1H), 4.66–4.58 
(m, 1H), 4.38–4.26 (m, 1H), 4.24–4.00 (m, 4H), 3.57–3.46 (m, 2H), 3.40 (td, J = 8.9, 
3.2 Hz, 1H), 3.29 (dt, J = 10.9, 1.7 Hz, 1H), 2.21–2.07 (m, 1H), 1.95 (bs, 1H), 1.26 
(td, J = 7.2, 2.1 Hz, 1H), 1.09 (dd, J = 7.3, 2.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 151.7, 136.7, 131.6 (2C), 130.5, 129.6, 129.5, 
121.4, 118.3, 106.8, 103.5, 77.3, 73.7, 70.8, 56.6, 56.1, 45.6, 34.0, 16.1. 












benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.10j)  
 
Utilizing general procedure A, 3.2.10j (29.5 mg, 0.066 mmol, 70%) was isolated after 
chromatography (1:1, Hex/EtOAc) as a white solid. 
MP: 192 ºC. 
FTIR (neat, cm-1): 2972, 2848, 1600, 1575, 1487, 1514, 1388, 1334, 1159,1076. 
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 2.5 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.75 
(d, J = 1.7 Hz, 1H), 7.52–7.43 (m, 4H), 7.25–7.16 (m, 2H), 6.53 –6.48 (m, 1H), 4.61 
(dd, J = 13.3, 10.9 Hz, 1H), 4.43–4.25 (m, 2H), 4.11 (d, J = 15.3 Hz, 1H), 4.00 (dt, J 
= 11.8, 5.6 Hz, 1H), 1.15 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 156.8, 143.9, 142.2, 135.7, 131.8 (2C), 130.5, 129.8 
(2C), 129.3, 126.9, 121.8, 113.2, 111.8, 108.8, 74.6, 57.3, 52.5, 16.1. 
















Utilizing general procedure A, 3.2.11a (33 mg, 0.066 mmol, 70%) was isolated after 
chromatography (100% EtOAc) as a brown liquid. 
FTIR (neat, cm-1): 2933, 2916, 2848, 1600, 1514, 1328, 1249, 1078. 
1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.8 Hz, 1H), 7.45 (s, 1H), 7.20–7.16 (m, 
2H), 6.91–6.85 (m, 2H), 6.26 (dd, J = 8.9, 2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 
5.54–5.27 (m, 2H), 4.63 (tt, J = 4.6, 2.0 Hz, 1H), 4.41– 4.29 (m, 1H), 4.24–4.17 (m, 
2H), 4.17–4.08 (m, 2H), 3.85–3.78 (m, 4H), 3.58–3.47 (m, 2H), 3.38 (td, J = 8.9, 3.2 
Hz, 1H), 3.28 (dt, J = 10.8, 1.6 Hz, 1H), 2.15–2.09 (m, 2H), 1.16 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 159.9, 157.1, 151.8, 130.4, 129.8, 129.7, 129.6, 
126.4, 123.1, 118.4, 114.5 (2C), 106.6, 103.9, 73.3, 70.7, 56.5, 56.2, 55.4, 53.7, 45.6, 
42.0, 34.0, 15.7. 



















Utilizing general procedure A, 3.2.11b (35.5 mg, 0.067 mmol, 72%) was isolated 
after chromatography (5% MeOH in EtOAc) as a brown liquid. 
FTIR (neat, cm-1): 2950, 2852, 2773, 1600, 1514, 1330, 1251, 1143, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.8 Hz, 1H), 7.46 (s, 1H), 7.23–7.11 (m, 
2H), 6.92–6.78 (m, 2H), 6.26 (dd, J = 8.8, 2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 
5.46–5.31 (m, 2H), 4.39–4.29 (m, 1H), 4.24–4.17 (m, 4H), 3.81 (s, 3H), 3.58–3.43 
(m, 2H), 3.32 (td, J = 9.8, 6.8 Hz, 1H), 3.18 (dd, J = 9.4, 8.1 Hz, 1H), 2.94–2.82 (m, 
1H), 2.33 (s, 6H), 2.27–2.21 (m, 1H), 1.97 (dt, J = 12.0, 9.3 Hz, 1H), 1.16 (d, J = 7.1 
Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 159.9, 157.2, 151.6, 145.7, 130.4, 129.6 (2C), 126.4, 
123.1, 118.6, 114.5 (2C), 106.4, 103.8, 73.4, 65.2, 56.5, 55.4, 53.7, 52.0, 46.9, 44.1 
(2C), 42.0, 29.9, 15.7. 
















pyrazol-1-yl)-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.2.11c) 
 
 
Utilizing general procedure A, 3.2.11c (33 mg, 0.069 mmol, 73%) was isolated after 
chromatography (1:2, Hex/EtOAc) as a yellow solid. 
MP: 86 ºC. 
FTIR (neat, cm-1): 2954, 2935, 2848, 1600, 1514, 1336, 1159, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 2.6, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.77 
(dd, J = 1.7, 0.6 Hz, 1H), 7.48 (dd, J = 8.6, 2.2 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.28 
(s, 1H), 7.16–7.08 (m, 2H), 6.90–6.78 (m, 2H), 6.53 (dd, J = 2.6, 1.7 Hz, 1H), 5.47–
5.22 (m, 2H), 4.50–4.42 (m, 1H), 4.40 (d, J = 2.7 Hz, 2H), 4.34 (ddd, J = 14.3, 7.6, 
3.8 Hz, 1H), 4.28 (dd, J = 12.8, 3.7 Hz, 1H), 3.80 (s, 3H), 1.25 (dd, J = 7.0, 2.6 Hz, 
3H). 
13C NMR (126 MHz, CDCl3) δ 159.9, 156.7, 144.2, 143.9, 142.3, 130.1, 129.7 (2C), 
129.6, 126.9, 126.1, 122.9, 114.5 (2C), 113.0, 111.8, 108.9, 74.2, 57.0, 55.4, 53.8, 
43.5, 15.8. 


















Utilizing general procedure A, 3.2.11d (45 mg, 0.079 mmol, 80%) was isolated after 
chromatography (1:1, Hex/EtOAc) as a brownish red liquid. 
FTIR (neat, cm-1): 2927, 2848, 1596, 1332, 1153, 1143, 1076. 
1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.9 Hz, 1H), 7.49 (s, 1H), 7.34–7.31 (m, 
2H), 7.30 (dd, J = 7.7, 1.6 Hz, 2H), 7.22–7.20 (m, 2H), 7.19–7.13 (m, 2H), 7.12–7.09 
(m, 1H), 6.59 (dd, J = 9.1, 2.4 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 5.48–5.38 (m, 2H), 
4.30–4.23 (m, 2H), 4.20–4.15 (m, 2H), 3.82–3.75 (m, 2H), 2.82–2.74 (m, 2H), 2.57 
(d, J = 6.7 Hz, 2H), 1.77–1.68 (m, 3H), 1.34–1.22 (m, 3H), 1.19 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 155.1, 145.9, 140.0, 136.4, 135.0,130.4, 130.2, 
129.1 (2C), 129.0, 128.3 (2C), 128.1, 126.1, 126.0, 123.4, 120.1, 109.1, 106.5, 73.4, 
57.0, 56.7, 53.5, 48.0, 47.9, 43.0, 37.9, 31.4, 31.4, 15.8. 
















Utilizing general procedure A, 3.2.11e (43 mg, 0.085 mmol, 92%) was isolated after 
chromatography (1:2, Hex/EtOAc) as a yellow liquid. 
FTIR (neat, cm-1): 3404, 3141, 2939, 2854, 1600, 1388, 1326, 1141, 1078. 
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8.8 Hz, 1H), 7.52 (s, 1H), 7.34–7.28 (m, 
2H), 7.20 (t, J = 1.8 Hz, 1H), 7.10 (dt, J = 7.1, 1.6 Hz, 1H), 6.26 (dd, J = 8.8, 2.4 Hz, 
1H), 6.14 (d, J = 2.3 Hz, 1H), 5.48–5.33 (m, 2H), 4.63 (dt, J = 4.6, 2.6 Hz, 1H), 4.41–
4.30 (m, 1H), 4.27–4.14 (m, 3H), 4.13–4.02 (m, 1H), 3.58–3.45 (m, 2H), 3.37 (ddd, J 
= 9.4, 8.3, 3.2 Hz, 1H), 3.27 (dt, J = 10.9, 1.4 Hz, 1H), 2.32 (bs, 1H) 2.19–2.10 (m, 
2H), 1.17 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.1, 151.9, 136.4, 134.9, 130.5, 130.4, 129.0, 
128.9, 128.0, 126.0, 123.5, 118.3, 106.7, 103.9, 73.3, 70.7, 56.6, 56.5, 53.5, 45.6, 
41.9, 34.0, 15.8. 














5.9 Spectra for Chapter 3.2 
 
(S)-2-benzyl-7-((R)-3-(dimethylamino)pyrrolidin-1-yl)-3-methyl-3,4-dihydro-2H-








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.10 Experimental for Chapter 3.3. 
Synthesis of High-load, Hybrid Silica-immobilized Heterocyclic Benzyl 
Phosphate (Si-OHBP) and Triazolyl Phosphate (Si-OHTP) Alkylating Reagents. 
Experimental Section and Characterization data        (SI-326–SI-337) 
1H, 13C, Spectra for all Relevant Compounds         (SI-338–SI-356) 
 
General procedure for silica oligomeric heterocyclic benzyl phosphate (Si-
OHBPn) and triazole phosphate (Si-OHTPn). 
 
Si-Nb (load ~0.4 mmol/g, 1 equiv.) was heated with C848 (G-II) (0.2 equiv.) 
at 45 ºC in dichloromethane for 2 h under argon.  The OHBP or OHTP monomer was 
added (50 equiv. w/r to cat. G-II) in CH2Cl2 and toluene to the reaction mixture and 
heated at 45 ºC for overnight. The reaction mixture was cooled to room temperature 
and EVE was added, and then stirred for an additional 1 hour at room temperature.  
The reaction mixture was filtered and washed with mixture of toluene:CH2Cl2 (1:1), 

















1. C848 (0.2 equiv)
    CH2Cl2, 45 ºC, 2 h
2. Tol-CH2Cl2, 45 ºC









To a 1-dram vial w/teflon cap was added Si-OHBP 3.1.7a or 3.1.7b (1.5 
equiv.) followed by addition of sodium iodide (0.2 equiv.), Cs2CO3 (3.0 equiv.), and 
solvent THF (0.2 M).  The mixture was stirred rapidly followed by subsequent 
addition of different nucleophiles.  The reaction was sealed under argon and heated to 
80 ºC w/stirring for 12–14 hrs.  After such time the reaction was cooled to rt and 
crude mixture was then filtered via celite packed 6 mL SPE and rinsed several times 
with a mixture of hexanes:EtOAc (1:2).  The resulting eluent was then concentrated 
in vacuo to yield the hetero-benzylated products in good to excellent yields and 
purities. 
 
Procedure B: General procedure for different nucleophilic substitution with Si-
OHTPn 
 
 To a 1-dram vial w/ teflon cap was added Si-OHTP 3.3.7c or 3.3.7d (1.5 
equiv.) followed by addition of sodium iodide (0.2 equiv.), Cs2CO3 (3.0 equiv.), and 
solvent DMF (0.2 M).  To the mixture nucleophile was added and stirred rapidly.  
The reaction was sealed under argon and heated to 80 ºC w/ stirring for 12−14 hrs. 
The resulting eluent was then concentrated in vacuo. The crude mixture of either case 








1) R2–XH, Cs2CO3, NaI





R1 = 3-pyridyl (3.3.7a)















1) R2–XH, Cs2CO3, NaI













The resulting eluent was then concentrated in vacuo to yield the products in good to 
excellent yields and purities. 
(5aR,6R,9S,9aS)-3-(pyridin-3-ylmethoxy)-1,5,5a,6,9,9a-hexahydro-6,9-
methanobenzo[e][1,3,2]dioxaphosphepine 3-oxide (3.3.3a) 
 
Compound 3.3.3a (2.6 g, 8.4 mmol, 66%) was isolated as a light brown solid. 
MP = 101 ºC. FTIR (neat, cm-1): 3446, 3058, 2960, 2850, 1577, 1429, 1284, 1060, 
1035, 1010; 1H NMR (500 MHz, CDCl3) δ 8.69 (d, J = 2.5 Hz, 1H), 8.63, (m, 1H), 
7.82 (dt, J = 8.0, 2.0 Hz, 1H), 7.36 (dd, J = 7.9, 4.8 Hz, 1H), 6.22 (t, J = 1.9 Hz, 2H), 
5.15 (d, J = 8.2 Hz, 2H), 4.17 (ddd, J = 25.5, 12.1, 3.7 Hz, 2H), 4.08–3.94(m, 2H), 
2.54 (s, 2H), 2.15 (m, 2H), 1.34 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 150.9, 
149.3, 137.4, 137.3, 136.2, 123.6, 69.4, 69.3, 66.3, 66.2, 44.8 (2C), 43.6, 41.9 (2C). 




methanobenzo[e][1,3,2]dioxaphosphepine 3-oxide (3.3.3b)  
 
Compound 3.3.3b (1.9 g, 6.1mmol, 60%) was isolated as a brown solid. 
MP = 110 ºC. FTIR (neat, cm-1): 3446, 3058, 2966, 2850, 1604, 1564, 1415, 1288, 
1064, 1035, 1012; 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 5.1 Hz, 2H), 7.31 (m, 
2H), 6.21 (t, J = 2.2 Hz, 2H), 5.11 (d, J = 7.7 Hz, 2H), 4.21(ddd, J = 25.7, 12.0, 3.8 
Hz, 2H), 4.12–3.99 (m, 2H), 2.54 (s, 2H), 2.15 (ddd, J = 8.9, 4.5, 2.2 Hz, 2H), 1.35 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 150.1 (2C), 144.7, 137.4, 137.3 (2C), 121.6, 
69.4, 69.3, 66.5, 44.8 (2C), 43.6, 41.9 (2C). HRMS calculated for C15H19NO4P 













1,5,5a,6,9,9a-hexahydro-6,9 methanobenzo[e][1,3,2]dioxaphosphepine 3-oxide 
(3.3.4a) 
  
Compound 3.3.4a (0.38 g, 0.978 mmol, 83%) was isolated as white solid. 
MP = 154 ºC. FTIR (neat): 2683, 2358, 2104, 1635, 1429, 1340, 1274, 1176, 1120, 
1006 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.58 (brs, 2H), 7.81–7.71 (m, 1H), 7.61–
7.50 (m, 1H), 7.39–7.27 (m, 1H), 6.25–6.18 (m, 2H), 5.64–5.49 (m, 2H), 5.26–5.14 
(m, 2H), 4.18–3.97 (m, 4H), 2.60–2.42 (m, 2H), 2.15–1.92 (m, 2H), 1.38 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ 150.4, 149.2, 143.5, 137.5, 137.3, 135.7, 130.2, 
124.1, 123.9, 69.5, 69.4, 59.7, 51.7, 44.8 (2C), 43.6, 42.0 (2C). 







Compound 3.3.4b (1.81 g, 4.63 mmol, 79%) was isolated as a white solid. 
MP = 149 ºC. FTIR (neat):  2964, 2358, 2341, 1645, 1591, 1488, 1419, 1323, 1249, 
1207, 1093 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.62 (d, J = 5.3 Hz, 2H), 7.83 (s, 
1H), 7.12 (d, J = 5.3 Hz, 2H), 6.25–6.19 (m, 2H), 5.58 (s, 2H), 5.23 (d, J = 10.4 Hz, 
2H), 4.09 (dd, J = 20.6, 6.4 Hz, 4H), 2.52 (s, 2H), 2.12–2.03 (m, 2H), 1.40–1.32 (m, 
2H). 13C NMR (126 MHz, CDCl3): δ 150.6, 143.8, 143.3, 137.3 (2C), 124.7, 122.2 
(2C), 122.1, 69.5, 69.4, 59.7, 52.8, 44.8, 44.7, 43.5, 42.3, 41.9. 



















Utilizing general procedure A, 3.3.8a (19.5 mg, 0.08mmol, 97%) was isolated as a 
light brown solid. 
MP = 53 ºC. FTIR (neat, cm-1): 2958, 1605, 1585, 1518, 1294, 1242, 1182, 827; 
1H NMR (400 MHz, CDCl3) δ 8.72 (s, 1 H), 8.61 (s, 1H), 7.84 (dd, J = 7.9, 4.9 Hz, 
1H), 7.38 (dd, J = 7.9, 4.9 Hz, 1H), 7.35–7.31 (m, 2H), 6.92 (d, J = 8.8 Hz, 2H), 5.10 
(m, 2H), 1.31 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.1, 148.7, 148.3, 144.2, 
135.9, 133.2, 126.4 (2C), 123.8, 114.3 (2C), 67.4, 34.1, 31.5 (3C). 




Utilizing general procedure A, 3.3.8b (16.5 mg, 0.065mmol, 72%) was isolated as a 
yellow solid 
MP = 105 ºC. FTIR (neat, cm-1): 2918, 1595, 1490, 1461, 1431, 1298, 1066, 802; 
1H NMR (400 MHz, CDCl3) δ 8.74 (s, 1 H), 8.64 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 
7.42–7.36 (m, 2H), 7.20 (dt, J = 8.8, 2.4 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 5.17 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 152.6, 149.1, 148.1, 135.6, 132.1, 130.3, 127.7, 
126.8, 124.3, 123.8, 114.9, 68.7. HRMS calculated for C12H10Cl2NO (M+H)+ 











Utilizing general procedure A, 3.3.8c (16 mg, 0.061 mmol, 70%) was isolated as a 
yellow thick liquid. 
FTIR (neat, cm-1): 2997, 2954, 2848, 1581, 1504, 1461, 1253, 1135, 1024, 1035; 
1H NMR (500 MHz, CDCl3): δ 8.49 (s, 1H), 8.39 (s, 1H), 7.51(d, J = 8.0 Hz, 1H), 
7.24 (m, 1H), 6.90 (dd, J = 8.3 Hz, 2.1 Hz, 1H), 6.77 (dd, J = 5.2, 3.1 Hz, 2H), 3.98 
(s, 2H), 3.87 (s, 3H), 3.79 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 149.6, 149.2, 148.9, 147.8, 136.8, 134.4, 126.2, 124.7, 
123.5, 116.3, 111.4, 55.9 (2C), 38.4. 
HRMS calculated for C14H16NO2S (M+H)+ 262.0902; found 262.0890 (TOF MS 
ES+). 
 
4-((4-(tert-butyl)phenoxy)methyl)pyridine (3.3.8d)  
 
Utilizing general procedure A, 3.3.8d (19 mg, 0.078 mmol, 98%) was isolated as a 
brown liquid. 
FTIR (neat, cm-1): 2958, 2904, 2866, 1606, 1502, 1413, 1244, 1182, 827; 
1H NMR (400 MHz, CDCl3) δ 8.63–8.64 (m, 2H), 7.42 (d, J = 5.3 Hz, 2H), 7.34–7.32 
(m, 2H), 6.91–689 (m, 2H), 5.12 (s, 2H), 1.31 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 155.8, 149.3 (2C), 147.4, 144.3, 126.4 (2C), 121.7, 
114.9, 114.2 (2C), 68.1, 34.1, 31.5 (3C). 









4-(((2,4,6-trichlorophenyl)thio)methyl)pyridine (3.3.8e)  
 
Utilizing general procedure A, 3.3.8e (16.5 mg, 0.054 mmol, 97%) was isolated as a 
white solid  
MP =  86 ºC. FTIR (neat, cm-1): 3070, 3028, 2956, 2921, 1598, 1560, 1433, 1413, 
1323, 1116, 1018; 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 54.1 Hz, 2H), 7.49 (s, 
1H), 7.29 (d, J = 5.8 Hz, 2H), 7.26 (s, 1H), 4.12(s, 2H). 13C NMR (126 MHz, CDCl3) 
δ 149.7 (2C), 145.6, 134.4, 133.1, 131.5, 131.3, 130.9 (2C), 130.7, 123.9, 36.7. 
HRMS calculated for C12H9Cl3NS (M+H)+ 383.9521; found 383.9430 (TOF MS 
ES+). 
(S)-3-benzyl-7-bromo-2-(pyridin-3-ylmethyl)-3,4-dihydro-2H-
benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.3.8f)  
 
Utilizing general procedure A, 3.3.8f (25mg, 0.054 mmol, 99%) was isolated as a 
white solid.  
MP = 175 ºC. FTIR (neat, cm-1):  3085, 3026, 2954, 2921, 1579, 1550, 1452, 1326, 
1155, 1027; 1H NMR (500 MHz, CDCl3) δ 8.48 (d, J = 4.1 Hz, 1H), 8.37 (s, 1H), 
7.72 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.33 (dd, J = 8.5, 1.8 Hz, 1H), 
7.23–7.17 (m, 4H), 7.11 (dd, J = 7.9, 4.8 Hz, 1H), 7.01 (m, J = 7.3, 1.9 Hz, 2H), 4.85 
(t, J = 12.2 Hz, 1H), 4.37 (dd, J = 13.3, 4.8 Hz, 1H), 4.29 (d, J = 15.1 Hz, 1H), 4.15–
4.07 (m, 1H), 3.89 (m, 1H), 3.00 (dd, J = 14.1, 8.0 Hz, 1H), 2.81 (dd, J = 13.8, 7.0 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 156.0, 148.7, 148.6, 137.2, 136.8, 131.4, 
129.9, 129.3 (2C), 129.1, 128.8 (2C), 127.6, 126.9, 126.7, 124.7, 123.8, 74.2, 63.5, 
52.5, 37.0. HRMS calculated for C21H19BrN2OS (M+H)+ 459.0378; found 459.0282 












benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.3.8g) 
 
Utilizing general procedure A, 3.3.8g (21.5 mg, 0.050 mmol, 84%) was isolated as a 
white solid. MP: 173 ºC.  FTIR (neat, cm-1):  2954, 2923, 2958, 2875, 1579, 1550, 
11471, 1325, 1153, 1024; 1H NMR (500 MHz, CDCl3) δ 8.59 (s, 2H), 7.89 (d, J = 7.8 
Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.39–7.31 (m, 2H), 7.26 (d, J = 1.9 Hz, 1H), 4.56 
(t, J = 11.9 Hz, 1H), 4.46–4.28 (m, 2H), 4.25–4.08 (m, 1H), 3.89 (s, 1H), 1.37 (m, 
1H), 1.31–1.19 (m, 2H), 0.70 (d, J = 6.5 Hz, 3H), 0.67 (d, J = 6.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 156.1, 148.8 (2C), 137.5, 130.9, 130.2 (2C), 127.7, 126.9, 
125.2, 123.3, 74.2, 60.2, 39.5, 29.7, 24.7, 22.9, 22.0. HRMS calculated for 
C18H22BrN2O3S (M+H)+ 425.0535; found 425.0536 (TOF MS ES+). 
(S)-3-benzyl-7-bromo-2-(pyridin-4-ylmethyl)-3,4-dihydro-2H-
benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.3.8h) 
 
Utilizing general procedure A, 3.3.8h (18 mg, 0.039 mmol, 97%) was isolated as a 
yellow solid. MP = 179 ºC. FTIR (neat, cm-1):  3085, 3026, 2958, 2921, 1602, 1579, 
1538, 1323, 1153, 1018; 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 2H), 7.71 (d, J = 8.5 
Hz, 1H), 7.35 (dd, J = 8.5, 2.0 Hz, 1H), 7.25 (d, J = 1.9 Hz, 1H), 7.24–7.19 (m, 3H), 
7.09 (m, 2H), 7.04–6.99 (m, 2H), 4.79 (t, J = 12.2 Hz, 1H), 4.44–4.28 (m, 2H), 4.07 
(d, J = 15.6 Hz, 1H), 3.95–3.88 (m, 1H), 3.06 (dd, J = 14.0, 8.2 Hz, 1H), 2.85 (dd, J = 
13.9, 7.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 155.9, 148.3 (2C), 146.4, 136.7, 
130.1, 129.2 (2C), 129.1, 128.9, 128.8, 127.8, 127.3, 127.1, 126.9, 124.9, 123.5, 74.2, 
64.3, 53.9, 36.9. HRMS calculated for C21H20BrN2O3S (M+H)+ 459.0378; found 















Utilizing general procedure A, 3.3.8i (14 mg, 0.036 mmol, 72%) was isolated as a 
yellow solid MP = 164 ºC. FTIR (neat, cm-1):  2960, 2852, 2358, 1600, 1577, 1538, 
1460, 1340, 1161, 1024, 1006; 1H NMR (500 MHz, CDCl3) δ 8.67–8.58 (m, 2H), 
7.70 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 5.1 Hz, 2H), 7.36 (dd, J = 8.4, 1.9 Hz, 1H), 7.31 
(d, J = 1.9 Hz, 1H), 4.47 (t, J = 12.0 Hz, 1H), 4.40–4.29 (m, 2H), 4.21 (d, J = 16.4 
Hz, 1H), 4.15–4.04 (m, 1H), 1.19 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
156.0, 148.9, 147.6, 131.1, 130.1 (2C), 127.9, 127.1 (2C), 125.5, 122.9, 74.5, 51.4, 
57.7, 15.9. HRMS calculated for C16H15BrN2O3S (M+H)+ 383.0065; found 382.0039 







Utilizing general procedure B, 3.3.9a (47 mg, 0.121 mmol, 88%) was isolated as a 
brown thick liquid. FTIR (neat):  2358, 2341, 1629, 1473, 1321, 1274, 1259, 1116, 
1058 cm-1; 1H NMR (500 MHz, CDCl3): δ 8.63 (dd, J = 4.8, 1.5 Hz, 1H), 8.60 (d, J = 
2.1 Hz, 1H), 7.55–7.50 (m, 1H), 7.45(s, 1H), 7.41 (s, 1H), 7.39 (s, 1H), 7.34–7.31 (m, 
1H), 5.53 (s, 2H), 4.25 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 150.4, 149.1, 144.3, 
135.6, 134.9, 132.4, 131.5, 130.7, 130.7, 130.3, 129.9, 124.0, 122.1, 51.7, 27.7. 



















Utilizing general procedure B, 3.3.9b (57 mg, 0.170 mmol, 93%) was isolated as a 
colorless thick liquid. FTIR (neat): 2925, 2358, 2341, 1635, 1375, 1261, 1118, 1026 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.65 (brs, 2H), 7.65 (s, 1H), 7.61 (d, J = 7.9 Hz, 
1H), 7.37 (d, J = 2.5 Hz, 1H), 7.35 – 7.32 (m, 1H), 7.19 (dd, J = 8.8, 2.5 Hz, 1H), 
7.05 (d, J = 8.8 Hz, 1H), 5.59 (s, 2H), 5.27 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 
152.5, 150.4, 149.1, 144.3, 135.7, 130.3, 130.1, 127.7, 126.6, 124.1, 124.0, 122.8, 
115.1, 63.5, 51.7. HRMS calculated for C15H13Cl2N4O (M+H)+ 335.0466; found 
335.0421 (TOF MS ES+). 
 
(S)-7-bromo-3-isobutyl-2-((1-(pyridin-3-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-
3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.3.9c) 
 
 
Utilizing general procedure B, 3.3.9c (36 mg, 0.071 mmol, 81%) was isolated as a 
thick liquid. 
FTIR (neat): 2958, 2358, 2341, 1579, 1558, 1458, 1423, 1373, 1323, 1164, 1081 cm-
1; 1H NMR (400 MHz, CDCl3): δ 8.64 (d, J = 8.4 Hz, 1H), 8.58 (s, 1H), 7.64 (d, J = 
8.4 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.38 (s, 1H), 7.35–7.31 (m, 1H), 7.30–7.27 (m, 
1H), 7.16 (s, 1H), 5.47 (dd, J = 34.4, 15.1 Hz, 2H), 4.45–4.29 (m, 3H), 4.28– 4.20 (m, 
2H), 1.75 – 1.64 (m, 1H), 1.49–1.38 (m, 1H), 1.26–1.20 (m, 1H), 0.82 (dd, J = 6.4, 
3.5 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 156.1, 150.4, 149.2, 144.3, 135.6, 131.6, 














22.8, 22.0. HRMS calculated for C21H25BrN5O3S (M+H)+ 506.0861; found 506.0868 





Utilizing general procedure B, 3.3.9d (45 mg, 0.116 mmol, 84%) was isolated as a 
brown thick liquid. FTIR (neat):  2923, 2850, 2283, 1635, 1473, 1274, 1259, 1110, 
1024 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.51 (d, J = 4.7 Hz, 1H), 7.61 (t, J = 7.7 
Hz, 1H), 7.54 (s, 1H), 7.36 (s, 1H), 7.31 (s, 1H), 7.20 (t, J = 6.2 Hz, 1H), 7.05 (d, J = 
7.8 Hz, 1H), 5.54 (s, 2H), 4.19 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 154.2, 149.8, 
143.8, 137.4, 135.1, 132.4, 131.5, 130.7, 130.5, 129.9, 123.5, 122.9, 122.3, 55.7, 27.8. 






Utilizing general procedure B, 3.3.9e (53 mg, 0.155 mmol, 89%) was isolated as a 
white solid. 
FTIR (neat): 2952, 1581, 1502, 1438, 1253, 1228, 1135, 1024 cm-1. 
1H NMR (400 MHz, CDCl3): δ 7.58–7.32 (m, 2H), 7.26–7.18 (m, 2H), 7.17 (s, 1H), 
6.92–6.85 (m, 2H), 6.72 (d, J = 8.2 Hz, 1H), 5.47 (s, 2H), 4.14 (s, 2H), 3.86 (s, 3H), 
3.79 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 149.4, 148.6, 145.2, 134.9, 129.1, 128.7, 
127.6 (2C), 125.6, 124.7, 121.4, 115.8, 111.7, 55.9, 55.8, 54.2, 30.6. 




















Utilizing general procedure B, 3.3.9f (53 mg, 0.158 mmol, 87%) was isolated as a 
colorless thick liquid. 
FTIR (neat): 2929, 2850, 2358, 2088, 1639, 1448, 1274, 1259, 1135, 1105, 1049 cm-
1; 1H NMR (400 MHz, CDCl3): δ 8.52 (d, J = 4.6 Hz, 1H), 7.76 (s, 1H), 7.62 (t, J = 
7.7 Hz, 1H), 7.28 (s, 1H), 7.21–7.18 (m, 1H), 7.13–7.09 (m, 2H), 6.98 (d, J = 8.8 Hz, 
1H), 5.59 (s, 2H), 5.20 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 154.2, 152.6, 149.9, 
143.9, 137.4, 130.1, 127.7, 126.5, 124.0, 123.6, 123.6, 122.5, 115.2, 63.5, 55.7. 









5.11 Spectra for Chapter 3.3 
(5aR,6R,9S,9aS)-3-(pyridin-3-ylmethoxy)-1,5,5a,6,9,9a-hexahydro-6,9-































































































































































































































































































































































































































































































































































































































































































































































5.12 Experimental for Chapter 4.1. 
Recyclable Magnetic Co/C Hybrid ROMP Benzene Sulfonate Ester (Co/C-
OBSE) and Sulfonyl Chloride (Co/C-OBSC) Nanoparticles (NPs) as Facile 
Methylating/Alkylating Reagents: Development and Applications. 
Experimental Section and Characterization data        (SI-357–SI-362) 
1H, 13C, Spectra for all Relevant Compounds         (SI-363–SI-372) 
 
Procedure A: General procedure for the synthesis of Nb-tagged 
Benzenesulfonate Ester. 
 
 To a dry Mortar Nb-tagged benzenesulfonyl chloride 4.1.2 and K2CO3 (2.5 
equiv.) was added and mechanically grinded in wet methanol for 3-5 min. The 
resulting product is monitored by TLC analysis, and upon disappearance of SM, the 
resulting mixture was extracted with CH2Cl2/H2O. The combined organic layer was 
washed with brine, dried (Na2SO4) and concentrated in vacuo, which afforded the 
desired norbornenyl-tagged benzene sulfonate ester 4.1.7 (90% yield) as a white solid 
in high purity without any flash chromatography. 
Procedure B: General procedure for synthesis Co/C Hybrid ROMP 























Co R = OMe = Co/C-OBSEn 4.1.8






R = OMe, Cl
4.1.6
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 To initiate ROMP on the surface of the nanobeads, Nb-tagged Co/C 
nanobeads linker 4.1.6 were dispersed in degassed toluene/CH2Cl2 in a sealed 
pressure tube under argon atmosphere using sonicator. A solution of Grubbs-II 
catalyst (1.0 equiv. with respect to the loading of Co/C-Nb 4.1.6) was sonicated at 45 
ºC to generate an active ruthenium carbene species on the surface of the nano-beads. 
Then Nb-tagged sulfonate or sulfonyl chloride (50 equiv.) monomer was added in 
solution and heated further 6-8 hours under sonication, which afforded a ROMPgel 
grafted onto the nano-beads. After quenching with ethyl vinyl ether EVE, the solvent 
was decanted with the help of neodymium magnet, washed with CH2Cl2 and the lump 
was dried well under vacuum and crushed for further use. Based on the gain in mass 
of magnetic polymers 4.1.8 or 4.1.10, greater than 95% of monomer was incorporated 
into the hybrid material. 
Procedure C: General procedure for methylation/alkylation of various 
carboxylic acids. 
  To a Pyrex pressure tube (5.0 mL) w/teflon cap was added carboxylic acid 
(1.0 equiv.) in CH3CN (0.5 M) followed by addition of K2CO3 (2.0 equiv.), MeOH 
(5.0 equiv.) and Co/C-OBSE or Co/C-OBSC (1.5 equiv.). The reaction was sealed 
under argon and sonicated for 4–6 hours at 50 ºC. Further it was monitored by TLC, 
and upon disappearance of SM, the reaction mixture was decanted with the help of 
neodymium magnet, and filtered with celite to remove K2CO3 and concentrated in 
vacuo.  The resulting methylated/alkylated products were isolated in 70–99% overall 
yields. 
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Procedure D: Regeneration of Co/C ROMP Benzenesulfonic Acid (Co/C-OBSAn) 
to Benzenesulfonyl Chloride (Co/C-OBSCn) 
 To a Pyrex pressure tube (5.0 mL) w/ Teflon cap was added Co/C-OBSA (1.0 
equiv.) in toluene (0.5 M) followed by addition of SOCl2 (5.0 equiv.), and sonicated 
for 30 minutes. After such time catalytic DMF (0.1 equiv.) was added and the 
reaction was sonicated additional for 8–10 hours at 40 ºC. The reaction mixture is 
cooled to room temperature and washed with toluene. Then subsequently washed 
with water and acetone with the help of neodymium magnet, dried in vacuo, and re-
used for next reactions. 
Procedure E: Acid Catalyzed reactions using Co/C Benzene Sulfonic acid NPs 
(Co/C-OBSAn). 
Coupling Reaction: To a 1-dram vial w/teflon cap was added indole (1.0 equiv.) 
followed by addition of methyl vinyl ketone (3 equiv.), Co/C-OBSA 4.1.13 (20 
mol%), and solvent CH3CN (0.5 M). The mixture was stirred at room temperature for 
12–14 hrs.  After such time the reaction mixture was decanted to R.B.F with the help 
of neodymium magnet and the solvent is evaporated in vacuo. Further crude product 
is filtered via celite SPE and rinsed with a mixture of Hexane:EtOAc (1:1).  The 
resulting eluent was then concentrated in vacuo to yield the desired Michael adduct in 
90% yield. 
Alcoholysis: To a 1-dram vial w/teflon cap was added carbic anhydride (1.0 equiv.) 
followed by addition of EtOH (5 equiv.), Co/C-OBSA 4.1.13 (20 mol%), and solvent 
CH3CN (0.5 M). The mixture was stirred at room temperature for 12–14 hrs.  After 
such time the reaction mixture was decanted to R.B.F with the help of neodymium 
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magnet and the solvent is evaporated in vacuo. Further the crude product is filtered 
via celite SPE and rinsed with a mixture of Hexane:EtOAc (1:1).  The resulting eluent 
was then concentrated in vacuo and afforded alcoholysis product in 85% yield. 
 
Methyl 4-((1R,2R,4R)-bicyclo[2.2.1]hept-5-en-2-yl)benzenesulfonate 4.1.7. 
 
Utilizing general procedure A, 7 (200 mg, 0.758 mmol, 98%) was isolated as a yellow 
solid. 
MP: 51-53 ºC. 
FTIR (neat, cm-1): 3058, 2958, 2877, 1693, 1595, 1454, 1402, 1359, 1178, 1095, 989. 
1H NMR (400 MHz, CDCl3) δ 7.78–7.74 (m, 2H), 7.34–7.30 (m, 2H), 6.31 (dd, J = 
5.6, 3.1 Hz, 1H), 5.76 (dd, J = 5.7, 2.9 Hz, 1H), 3.75 (s, 3H), 3.52–3.43 (m, 1H), 3.12 
(q, J = 2.2, 1.8 Hz, 1H), 3.02 (s, 1H), 2.25 (ddd, J = 12.0, 9.3, 3.8 Hz, 1H), 1.59–1.47 
(m, 2H), 1.33 (ddd, J = 12.0, 4.8, 2.5 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 152.1, 137.8, 132.3, 132.2, 128.9 (2C), 127.5 (2C), 
56.2, 50.4, 48.8, 43.8, 43.3, 33.1. 







Table 5.3. Alkylation of Carboxylic Acids Utilizing Magnetic (Co/C-OBSCn. 
Compd. # Product  1H-NMR  
4.1.9a 
4.1.11a  
(400 MHz, CDCl3) δ 7.20 (d, J = 2.4 Hz, 2H), 6.66 (t, J 
= 2.4 Hz, 1H), 3.92 (s, 3H), 3.84 (s, 6H). 
4.1.9b 
4.1.11c  
(400 MHz, CDCl3) δ 8.01 (dd, J = 8.0, 1.2 Hz, 1H), 7.81 
(dd, J = 7.8, 1.7 Hz, 1H), 7.41 (td, J = 7.6, 1.2 Hz, 1H), 
7.16 (td, J = 7.7, 1.7 Hz, 1H), 3.94 (s, 3H). 
4.1.9c 
 
(400 MHz, CDCl3) δ 7.82 (d, J = 8.4 Hz, 1H), 7.49 (d, J 




(400 MHz, CDCl3) δ 8.34–8.26 (m, 1H), 8.26–8.20 (m, 
1H), 3.99 (d, J = 1.0 Hz, 2H). 
4.1.11d  
(400 MHz, CDCl3) δ 8.00–7.91 (m, 2H), 6.90–6.82 (m, 
2H), 5.32 (s, 1H), 3.90 (s, 3H). 
4.1.9e 
4.1.11e  
(400 MHz, CDCl3) δ 8.09 (s, 1H), 7.70–7.60 (m, 1H), 
7.41–7.35 (m, 1H), 7.25–7.12 (m, 2H), 3.80 (d, J = 0.9 
Hz, 1H), 3.71 (s, 2H). 
4.1.11f  
(400 MHz, CDCl3) δ 7.32–7.27 (m, 2H), 7.18–7.22 (m, 
3H), 3.68 (s, 3H), 2.66 (t, J = 7.6 Hz, 2H), 2.35 (t, J = 
7.5 Hz, 2H), 2.02–1.92 (m, 2H). 
4.1.11g  
(400 MHz, CDCl3) δ 3.68 (s, 3H), 2.31 (t, J = 7.6 Hz, 
2H), 1.62 (m, 2H), 1.28 (m, 16H), 0.89 (t, J = 6.8 Hz, 
3H). 
4.1.11h  
(400 MHz, CDCl3) δ 3.68 (s, 3H), 2.31 (t, J = 7.6 Hz, 
























400 MHz, CDCl3 δ 7.21–7.17 (m, 2H), 6.66 (td, J = 2.5, 
1.0 Hz, 1H), 3.83 (dd, J = 5.4, 2.3 Hz, 6H). 
4.1.12b  400 MHz, CDCl3 δ 8.33–8.28 (m, 2H), 8.25–8.20 (m, 2H). 
4.1.12c 
 
(400 MHz, CDCl3) δ 7.47–7.43 (m, 2H), 7.42–7.35 (m, 
3H), 7.23 (d, J = 2.3 Hz, 2H), 6.66 (t, J = 2.4 Hz, 1H), 
5.37 (s, 2H), 3.83 (s, 6H). 
4.1.12d  
 (400 MHz, CDCl3) δ 8.27 (q, J = 8.9 Hz, 4H), 7.50–
7.38 (m, 5H), 5.42 (s, 2H). 
4.1.12e 
 
(400 MHz, CDCl3) δ 8.09 (bs, 1H), 7.64 (d, J = 7.8 Hz, 
1H), 7.38 (d, J = 8.0 Hz, 1H), 7.24–7.10 (m, 3H), 4.18 




(400 MHz, CDCl3) δ 8.09 (bs, 1H), 7.41–7.34 (m, 1H), 
7.25–7.12 (m, 3H), 5.93 (ddt, J = 16.4, 10.9, 5.7 Hz, 




 (400 MHz, CDCl3) δ 8.09 (bs, 1H), 7.64 (d, J = 7.8 Hz, 
1H), 7.40–7.33 (m, 1H), 7.25–7.10 (m, 3H), 4.12 (dd, J 
= 7.2, 6.2 Hz, 2H), 3.79 (d, J = 1.1 Hz, 2H), 1.68–1.58 






















5.13 Spectra for Chapter 4.1 
















































Methyl 3,5-dimethoxybenzoate 4.1.9a 
 


















































Methyl 2,4-dichlorobenzoate 4.1.9c 
 



















































Methyl 4-hydroxybenzoate 4.1.11d 
 
































































Methyl 4-phenylbutanoate 4.1.11f 
 



























































































Deuterated methyl 4-nitrobenzoate 4.1.12b
 


















































Benzyl 4-nitrobenzoate 4.1.12d 
 
























































































Butyl 2-(1H-indol-3-yl)acetate 4.1.12f 
 

















































































































































































































































5.14 Experimental for Chapter 4.2 
Synthesis of High-load, Hybrid Co/C-Oligomeric Phosphonyl Dichloride: 
Application to Scavenging Amines. 
Experimental Section and Characterization data        (SI-373–SI-377) 
1H, 13C, Spectra for all Relevant Compounds         (SI-378–SI-386) 
General Procedure:  
Sulfonamide Reaction: In a sealed pressure tube was added sulfonyl chloride (1 
equiv.) in CH2Cl2 (0.1M), followed by addition of amine (1.5 equiv.) and Et3N (2.0 
equiv.). The mixture was stirred rapidly at room temperature for 6–8 h. After 
completion of reaction, Co/C-OPC (0.6 equiv.) was added and stirred for another 4 h 
to scavenge the excess amine. Then the reaction mixture was decanted using external 
magnet and filtered via Celite-packed SPE. The resulting eluent was concentrated in 
vacuo which afforded the desired sulfonylated products in good to excellent yields 
and purities. 
Urea formation Reaction: In a sealed pressure tube was taken isocyanate (1 equiv.) 
in CH2Cl2 (0.1M), followed by addition of amino alcohol (1.5 equiv.) and Et3N (2.0 
equiv.). The mixture was stirred rapidly at room temperature for 8-10 h. After such 
time, Co/C-OPC (0.8 equiv) was added and stirred for another 4 h to scavenge the 
excess amino alcohol. Then the reaction mixture was decanted using external magnet 
and filtered via Celite SPE. The resulting eluent was concentrated in vacuo to yield 






Utilizing general procedure B, 2-bromo-N-isopropylbenzenesulfonamide 4.2.11a (28 







1H NMR (500 MHz, CDCl3): δ 8.21–8.14 (m, 1H), 7.77–7.69 (m, 1H), 7.50–7.46 (m, 
1H), 7.42–7.38 (m, 1H), 5.03 (d, J = 7.1 Hz, 1H), 3.47–3.38 (m, 1H), 1.12 (s, 3H), 
1.10 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 139.8, 135.1, 133.6, 131.4, 127.9, 119.8, 46.6, 23.5. 






Utilizing general procedure B, 2-bromo-4-fluoro-N-isobutylbenzenesulfonamide 
4.2.11a (26 mg, 0.083 mmol, 93%) was isolated as a white solid. 
1H NMR (500 MHz, CDCl3): δ 8.17 (dd, J = 8.8, 5.8 Hz, 1H), 7.50 (dd, J = 7.9, 2.5 
Hz, 1H), 7.20 (ddd, J = 8.9, 7.6, 2.5 Hz, 1H), 5.14 (t, J = 6.2 Hz, 1H), 2.72 (t, J = 6.6 
Hz, 2H), 1.77–1.71 (m, 1H), 0.91 (d, J = 6.7 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ 164.2 (d, J = 258.8 Hz), 135.1 (d, J = 3.6 Hz), 133.6 
(d, J = 9.2 Hz), 122.5 (d, J = 25.1 Hz), 120.8 (d, J = 10.0 Hz), 115.0 (d, J = 21.1 Hz), 
50.7, 28.4, 19.9. 






Utilizing general procedure B, N-cyclopropyl-2,6 difluorobenzenesulfonamide 
4.2.11a (32 mg, 0.137 mmol, 91%) was isolated as a white solid. 
1H NMR (500 MHz, CDCl3):  δ 7.60–7.51 (m, 1H), 7.10–7.01 (m, 2H), 5.42 (brs, 













13C NMR (126 MHz, CDCl3): δ 160.7 (d, J = 3.8 Hz), 158.7 (d, J = 4.0 Hz), 134.6 (t, 
J = 11.2 Hz), 117.6 (t, J = 15.8 Hz), 113.3 (d, J = 3.7 Hz), 113.1 (d, J = 3.9 Hz), 24.4, 
6.9. 






Utilizing general procedure B, 4-benzyl-1-((4-nitrophenyl)sulfonyl)piperidine 4.2.11d 
(37 mg, 0.102 mmol, 95%) was isolated as a light yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.37 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 
7.30–7.24 (m, 2H), 7.22–7.18 (m, 1H), 7.09 (d, J = 7.1 Hz, 2H), 3.85 (d, J = 11.7 Hz, 
2H), 2.54 (d, J = 7.0 Hz, 2H), 2.30 (td, J = 11.9, 2.0 Hz, 2H), 1.72 (d, J = 13.2 Hz, 
2H), 1.54–1.45 (m, 1H), 1.41–1.31 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ 150.1, 142.6, 139.4, 129.0 (2C), 128.7 (2C), 128.4 
(2C), 126.2, 124.3 (2C), 46.5 (2C), 42.5, 37.2, 31.2 (2C). 






Utilizing general procedure B, 4-benzyl-1-((4-chlorophenyl)sulfonyl)piperidine 
4.2.11a (33 mg, 0.094 mmol, 94%) was isolated as a white solid. 
1H NMR (400 MHz, CDCl3): δ 7.69 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 
7.34–7.25 (m, 2H), 7.22–7.15 (m, 1H), 7.10 (d, J = 7.1 Hz, 2H), 3.78 (d, J = 11.7 Hz, 
2H), 2.54 (d, J = 6.9 Hz, 2H), 2.29–2.05 (m, 2H), 1.71 (d, J = 12.7 Hz, 2H), 1.52–










13C NMR (126 MHz, CDCl3): δ 139.7, 139.2, 134.7, 129.3 (2C), 129.1 (2C), 129.0 
(2C), 128.3 (2C), 126.1, 46.5 (2C), 42.6, 37.3, 31.2 (2C).  







Utilizing general procedure B, (S)-2-(hydroxymethyl)-N-phenylpyrrolidine-1-
carboxamide 4.2.11f (28 mg, 0.127 mmol, 91%) was isolated as a thick liquid. 
FTIR (neat): cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.37–7.33 (m, 2H), 7.29–2.25 (m, 2H), 7.03 (t, J = 7.3 
Hz, 1H), 4.53 (brs, 1H), 4.13 (t, J = 8.4 Hz, 1H), 3.74–3.68 (m, 1H), 3.66–3.58 (m, 
2H), 3.49–3.39 (m, 1H), 2.11–2.02 (m, 1H), 1.99–1.88 (m, 2H), 1.67–1.58 (m, 2H). 
13C NMR (126 MHz, DMSO-d6): δ 155.2, 140.9, 128.8 (2C), 121.9, 119.6 (2C), 64.1, 
59.3, 47.0, 28.2, 23.8. 







Utilizing general procedure B, (R)-3-hydroxy-N-phenylpyrrolidine-1-carboxamide 
4.2.11g (25 mg, 0.121 mmol, 93%) was isolated as a brown thick liquid. 
1H NMR (400 MHz, CDCl3): δ 7.38–7.32 (m, 2H), 7.20–7.13 (m, 2H), 6.93–6.86 (m, 
1H), 6.66 (brs, 1H), 4.38 (brs, 1H), 4.16 (brs, 1H), 3.59–3.35 (m, 4H), 1.99–1.86 (m, 
2H). 
13C NMR (126 MHz, DMSO-d6): δ 159.1, 144.3, 133.4 (2C), 127.2, 124.4 (2C), 74.8, 















Utilizing general procedure B, 1-(1-hydroxypropan-2-yl)-3-phenylurea 11a (21 mg, 
0.108 mmol, 89%) was isolated as a colorless thick liquid. 
1H NMR (400 MHz, DMSO-d6): δ 8.00 (s, 1H), 7.51 (d, J = 7.9 Hz, 2H), 7.25 (t, J = 
7.8 Hz, 2H), 6.94 (t, J = 7.3 Hz, 1H), 5.79 (brs, 1H), 4.11 (brs, 1H), 3.96–3.86 (m, 
1H), 3.56 (d, J = 4.6 Hz, 2H), 1.19 (d, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ 155.3, 140.9, 129.1 (2C), 121.5, 117.9 (2C), 65.1, 
47.1, 18.3. 







Utilizing general procedure B, 1-((1R,4R)-4-hydroxycyclohexyl)-3-phenylurea 
4.2.11i (35mg, 0.149 mmol, 92%) was isolated as a brown thick solid. 
1H NMR (400 MHz, DMSO-d6): δ 8.00 (s, 1H), 7.51 (d, J = 7.9 Hz, 2H), 7.25 (t, J = 
7.8 Hz, 2H), 6.94 (t, J = 7.3 Hz, 1H), 5.79 (brs, 1H), 4.11 (brs, 1H), 3.96 – 3.86 (m, 
1H), 3.56 (d, J = 4.6 Hz, 2H), 1.19 (d, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ 155.1, 140.8, 129.1 (2C), 121.5, 118.0 (2C), 68.5, 
48.0, 34.2, 31.2. 

















































N-cyclopropyl-2,6-difluorobenzenesulfonamide (4.2.11c)  
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 381 
4-benzyl-1-((4-nitrophenyl)sulfonyl)piperidine (4.2.11d) 
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4-benzyl-1-((4-chlorophenyl)sulfonyl)piperidine (4.2.11e) 
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(S)-2-(hydroxymethyl)-N-phenylpyrrolidine-1-carboxamide (4.2.11f) 
 
 
 
 
  
H
N N
O OH
H
N N
O OH
 384 
(R)-3-hydroxy-N-phenylpyrrolidine-1-carboxamide (4.2.11g) 
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 385 
1-(1-hydroxypropan-2-yl)-3-phenylurea (4.2.11h) 
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 386 
1-((1R,4R)-4-hydroxycyclohexyl)-3-phenylurea (4.2.11i) 
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